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Abstract 
Cellular differentiation is a process directed by a wide range of controlling 
signaling molecules and pathways. All-trans-retinoic acid (ATRA) is one such 
compound that shows a wide range of biological activity. The endogenous 
effects of ATRA have the potential to be translated into many in vitro and in 
vivo applications; however, its administration is associated with many 
drawbacks. Consequently, a large group of synthetic analogues known as 
synthetic retinoids - that are structurally similar to ATRA have been prepared 
and tested in vitro in the search for higher stability and more potency. 
A small library of stable synthetic retinoids known as EC and GZ derivatives 
were prepared and their biological activity investigated using TERA2.cl.SP12 
human embryonal carcinoma (EC) stem cells and SHSY5Y neuroblastoma cells. 
Two compounds, EC23 and GZ25 were found to inhibit cellular proliferation 
and induce neural differentiation in both cell lines. EC50s showed higher binding 
affinity of these two analogues to all RAR types and was confirmed by how they 
fit into the binding pocket of the different RARs. They bind into the binding 
pocket through a hydrophilic network of carboxylate group with Arg (salt bridge) 
and Ser (two hydrogen bonds) residues similar to ATRA. 
These effects were thoroughly characterized and quantified by monitoring the 
phenotypic changes of both cell lines and the gene expression markers such as 
RAR-β, PAX6, NeuroD1 which showed higher order of efficacy for induction of 
neuronal differentiation.In this study, the combined use of calculated chemical 
structures, molecular docking tools with receptor binding assays and biological 
characterization was useful to probe, and hence, understand the biological 
activity of certain synthetic retinoids with the ultimate goal of designing more 
specific synthetic retinoic acid derivatives.  
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Molecular, cellular and binding activity of retinoids 
 Molecular activity of retinoids 
1.1 Molecular docking 
All pharmaceutical and biotech companies are facing enormous pressure from the 
market to apply all available techniques in the field of drug discovery in lower attrition 
rates and costs. Currently, one of the most widely applied techniques in drug discovery 
is computational chemistry and molecular modelling, which is centred on applying the 
fundamental laws of physics and chemistry to the study of molecules with the potential 
to be drugs. The ultimate aim for molecular modelling is to create models and 
simulations, which can help in the different stages of a discovery pipeline by predicting, 
rationalizing and estimating the properties of molecules and their interactions, thereby 
allowing a more rational approach to drug development. In this piece of research work, 
there is a combination between the molecular docking, receptor binding assay and 
biological evaluation of retinoids in a parallel way to understand the molecular binding 
interaction of retinoids with their cognate target. 
 
The model building can be either simple or sophisticated, depending on the main 
purpose of construction. In practice, the molecular modelling of biomolecular 
interactions and binding processes has some limitations including the large amount of 
CPU time required and limitations in force field accuracy. However, modelling can fit 
in conjunction with other techniques, such as crystallography, to refine biomolecular 
modelling to provide accurate geometries, bond lengths and an insight into actual 
interactions and structure. Molecular modelling techniques are generally divided into 
two broad categories: 1) Ligand-based modelling which consists of a series of 
techniques, used for creating models and predictions based solely on the structure of the 
small organic compounds; 2) Structure-based drug design exploits the knowledge of the 
3D structure of one or more biological receptors (targets, the ones sought to modulate 
and anti-targets, the ones sought not to interfere with) and or their macromolecular 
ligands.1 
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1.2 Receptor-ligand docking 
To carry out receptor-ligand docking, it is assumed that a rigid molecule is used. The 
rigid protein representation greatly reduces the number of degrees of freedom sampled, 
enabling the development of algorithms for the rapid docking of large numbers of 
ligands. The problem with this approximation is that it ignores induced-fit effects.2 
Many docking programs work on this basic principle like that of DOCK, AutoDock,3 
ICM,4 LigandFit5 and Surflex.6 On the other hand, a flexible docking theory was shown 
to be more efficient and convenient approach, generating many initial orientations 
(binding sites), for which at least one should be close to the correct structure. Many new 
programs work using this flexible principle such as FlexX,7 GOLD8 and Glide.9 
 
1.3 Docking accuracy (Validation methods) 
1.3.1 Self-Docking 
The accuracy of a docking program can be assessed by comparing the predicted 
structures of protein-ligand complexes with crystallographic data. For rigid docking, the 
simplest comparisons are made by docking each ligand into its own cognate receptor 
conformation. This is referred to as self-docking.10 It should be noted that these results 
are dependent on a few factors, including the experience of the individual performing 
the experiment, preparation of the individual protein and ligand structures prior to 
docking and average RMSD used as a measure of a docking accuracy. Hence, most data 
raised by self-docking was a round 1.5 Å according to Cambridge Database 
recommendations. In some cases, the polarized charges on the ligand have effect on the 
docking results with low RMSD orientations suggesting incorrect ligand orientation 
inside the binding site and the wrong hydrogen-bonding system and so it is 
recommended to use quantum calculations that apply a total ligand charge is zero.11 
1.3.2 Cross-docking 
Cross-Docking is a more complex and demanding test than self-docking and involves 
docking a ligand into a confirmation of the receptor that is not its cognate, but rather 
either the apo-structure of the receptor or one from co-crystallization with a different 
ligand.12  
 
 
Chapter I 
3 
 
 
Cross-docking can generate reasonable ligand orientations, albeit usually not quite as 
accurate in details as obtained from self-docking. It can also introduce noise into the 
calculations with the effect of creating smaller energy gaps between experimentally 
observed and incorrect docking solutions, introducing an energetic preference for an 
incorrect solution.13 This method is usually carried out by setting up rigid receptor 
docking. Given a setup of superimposed co-crystallized complexes of a given receptor, 
one simply takes all of the ligands and attempt to dock them into all, or some fraction, 
of the receptor conformations and records the ligand RMSDs. Some studies have used 
this procedure and referred to it as "ensemble docking".14,15 
 
1.4  Nuclear receptors as a biological target 
The nuclear hormone receptor super family includes receptors for thyroid and steroid 
hormones, retinoids, vitamin D as well as different “orphan” receptors of unknown 
ligand. Ligands for some of these receptors have been recently identified, showing that 
products of lipid metabolism such as fatty acids, prostaglandins, or cholesterol 
derivatives can regulate gene expression by binding to nuclear receptors. Nuclear 
receptors act as ligand-inducible transcription factors by directly interacting as 
monomers, homodimers, or heterodimers with the retinoid X receptor with DNA 
response elements of target genes, as well as by “cross-talking” to other signalling 
pathways. Most of these receptors bind co repressor factors and actively represses target 
gene expression in the absence of ligand16 and once ligand activation happens, the 
transcription activity occurs through recruitment of coregulators. Since this initial 
finding, it has been shown that the RA signal can be transduced in cultured cells through 
two families of retinoid receptors. The RAR family (RAR-α, -β and -γ and their 
isoforms) are activated by both all-trans-RA and 9-cis-RA, whereas the RXR family 
(RXR-α, -β and -γ) are activated only by 9-cis-RA.17, 18, 19, 20 
 
1.4.1 Retinoic Acid Receptors (RARs) 
The biological effects of retinoids come through retinoic cid receptors. They were first 
identified in 1987 as three major types originated from three different genes; RAR-α 
(NR1B1), RAR-β (NR1B2) and RAR-γ (NR1B3).21,22,23  
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There are various isoforms for each RAR types which differ in the alternative splicing 
of the two promoters in their N-terminal region with P2 as the downstream promoter 
found in the retinoic acid response element (RARE).24 The isomers of RARs are RAR-
(α1 and α2), RAR-(β1 and β2) and RAR-(γ1 and γ3 initiated at the P1 promoter and γ2 
and γ4 initiated at the P2 promoter).25 The biologoical effect of RAR is driven through 
heterodimerization with other different nuclear receptors such as RXRs.26 The resultant 
RXR-RAR heterodimers can bind to RARE DNA region found in many target genes 
responsible for cellular differentiation.27,28 Examples of these target genes are Hox 
genes29,30 which are responsible for cellular development especially in anteroposterior 
axis in embryo. Also, CYP26 genes especially CYP26A1 has this RARE region and 
responsible for the cellular metabolism of ATRA. 31 And finally, retinol binding protein 
I and CRABPII are the two genes which play key role in cellular transport and 
biological activity of retinoids inside the cells. 
 
1.4.2 Retinoic X Receptors (RXRs) 
Retinoid X receptors are the second class of retinoic acid receptor that discovered in 
1990.32 There are three RXR subtypes; RXR-α (NR2B1), RXR-β (NR2B2) and RXR-γ 
(NR2B3) and they originated from different genes.33,34 Also there are two isoforms for 
each subtype; RXR-α (α1 and α2), RXR-β (β1 and β2), and RXR-γ (γ1 and γ2) which 
are different from each other in N-terminal and A/B domain.35 9-CRA, the isomer of 
retinoic acid was known to be the principle ligand acting on these receptors with higher 
binding affinity compared to ATRA.36 In addition, these receptors can also 
heterodimerize with other different nuclear receptors such as vitamin D receptor (VDR), 
farnesoid X receptor (FXR) and constitutively activated receptors (CARs). 
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1.5  Impact of RAR-RXR complex on biological activity of retinoids 
RAR and RXR actively involved in the retinoic acid mediated transcription37, however 
they are not active in their monomeric forms. Also, RAR does not dimerize with itself 
but forms heterodimeric proteins with RXR (RAR-RXR). This RAR-RXR protein 
complex is the predominant receptor complex for retinoic acid signalling.  In addition to 
forming heterodimers with RAR, RXR is able to homodimerize and also dimerize with 
other receptor proteins, including PPAR. The RAR-RXR protein complex binds to 
retinoic acid response elements (RAREs) or retinoid X response elements (RXREs), 
each of which are well-defined DNA sequences.38 RXR enhances the binding of the 
RAR protein to the RARE sequences.5 In the absence of ligands at the ligand receptor 
binding sites, the apo-RAR:RXR heterodimer recruits corepressors, proteins and 
enzymes that interfere with the transcription process.39 Many genes were strongly 
identified as being regulated by this classical pathway (either up-regulated or down-
regulated).40 
Another downstream biological processes occur in parallel to the activation mechanism 
of RAR-RXR, which is ubiquitination and phosphorylation as that are crucial for gene 
regulation and transcription.38,39,41 This includes the degradation of RAR-RXR by the 
proteosome for the termination of retinoid signalling. Phosphorylation may also 
participate in proteosome degradation and affect the ability of the holo- RAR-RXR 
complex to associate with coregulators and general transcription factors.39 
Phosphorylation of the serine residues of RARγ has been shown to control both the 
RARγ transactivation function and the degradation of RARγ by the proteosome.40 
 
1.6 Repression /derepression mechanism 
The mechanism of depression and activation of retinoic acid receptors was suggested in 
absence of retinoic acid agonist, as the corepressor proteins NCoR or SMRT with 
histone deacetylases (HDACs) or DNA-methyl transferases binds to the RAR-RXR 
heterodimers. This complex induces the depression mechanism and hence, the 
condensed chromatin structure and transcription is inhibited.42 
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Upon activation, retinoic acid binds to the RAR type which induces some 
conformational change in the LBD which allows the coactivator binding and 
corepressor release. This is followed by activation of other different enzymes such as 
histone acetyltransferases or histone arginine methyltransferases which are responsible 
for actiation of gene transcription.43,44 The process of binding of retinoic acid to RAR is 
key step in activation of these cascade reactions as RXR- ligands (rexinoids) can not 
activate the previousely mentioned complex formation without RAR- agonist. However, 
the activation of both RAR and RXR by binding to agonists at the same time was shown 
to have synergistic effect on the activation process which might suggest the co-
transcriptional role of RXR as a partner in RAR-RXR heterodimers.45 
Another mechanism is proposed in the absence of agonists, where corepressor links the 
receptor complex to histone deacetylases (HDACs) through SIN3, resulting in 
chromatin condensation and gene silencing. Upon agonist binding to the receptors, a 
conformational change is induced, destabilizing the corepressor complex and allowing 
co-activators to bind. Co-activators recruit histone acetyltransferases (HAT) resulting in 
acetylation of histone amino‐terminal tails, thus, inducing chromatin decondensation.  
Finally, a third multi‐subunit complex, termed Srb and mediator protein‐containing 
complex (SMCC), or thyroid‐hormone‐receptor‐associated protein (TRAP), or 
D‐receptor interacting protein (DRIP) establishes contact with the basal transcriptional 
machinery, leading to increased transcription46 (Fig. 1.1). 
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Figure 1.1: Mechanisms of repression, depression and activated transcription. In the repression state, 
ligand is absent and hence, co repressor (CoR) binds with histone deacetylases (HDACs) through another 
transcription protein, SIN3 resulting in silencing of gene transcription. Once retinoid ligand binds, CoR is 
removed due to conformational changes in the ligand binding pocket to allow co activator (CoA) binds. 
This will activate the recruitment of histone acetyltransferases (HAT) and acetylation of amino terminal 
occurs and hence, the induction of chromatin condensation. Another possibility for the activation 
mechanism is through the formation of multi-subunit complex co activators, SMCC or TRAP with DRIP 
complex to activate the basal transcriptional machinery and gene transcription.46,47 
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1.7 Crystal structure of RARs 
Like other transcriptional regulators, nuclear receptors exhibit a modular structure with 
different regions corresponding to autonomous functional domains that can be 
interchanged between related receptors without loss of function. A typical nuclear 
receptor consists of a variable NH2-terminal region (A/B), a conserved DNA binding 
domain (DBD) or region C, a linker region D; and a conserved E region that contains 
the ligand-binding domain (LBD). Some receptors contain also a COOH terminal region 
(F) of unknown function. All RARs have two activation domains, N-terminal AF-1 
which contributes to constitutive ligand independent transcriptional activation function 
and C-terminal AF-2 which is strictly ligand dependent and conserved among all 
members of the nuclear receptor superfamily48 (Fig. 1.2). 
 
 
 
 
 
 
Figure 1.2: Structural and Functional domains of a retinoid receptor. There are 5 main domains; ligand-
independent, DNA binding, hing, ligand dependent and F domains. Ligand binding domain (LBD) is the 
most important part for binding of RARs with its retinoid ligands. LBD contains AF-2 region which is 
reposnible for co activator binding and active transactivation process.47 
 
Also, it was observed in a study using LSQ options with a RMS deviation 1.5Å that 
human RAR holo-LBD topology (Fig. 1.3) consists of twelve α-helices (H1 to H12), 
which are organized in a three-layer structure with H4, H5, H6, H8 and H9 sandwiched 
between H1 and H3 on one side, and H7, H10 and H11 on the other side. Two 
topologically conserved β-strands (S1-S2) form a β-turn inserted between loop 1-3 
(connecting H1 to H3) and H3.49 In addition, it is noted that H12 helix position is 
essential to seal the ligand binding pocket of the receptor. Also, this conformation 
generates a recognisition surface constituted of mostly hydrophobic residues from 
helices H3, H4 and H12 of RAR-β and RXR-α which allow, after the 
heterodimerization of the two receptors for the binding of coactivator peptide per 
protomer.50  
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Also amino acid sequence alignment of RAR-α, -β and –γ (Fig. 1.4) reveals that among 
all of these residues, only three positions were variable (marked with blue arrows): 
serine 232, alanine 225, and alanine 234 in H3, isoleucine 270, isoleucine 263 and 
methionine 272 in H5 and valine 395, valine 388 and alanine 397 in H11. These amino 
acid residues therefore became obvious candidates as key amino acids responsible for 
RAR-ligand selectivity.51 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Schematic representation to RAR helices arrangement. RAR-γ LBD consists of twelve α-
helices (H1 to H12) and two β-strands (S1-S2). The ligand binding pocket is buried between of H1, H3, 
H5, H7, H11 and H12.47 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Amino acid alignment of RAR-α, -β and –γ LBD. Amino acid regions indicated by blue 
arrows represent residues that are different in RAR LBD and have direct effect on receptor-ligand 
interactions. In H3, serine amino acid in RAR-α is different than alanine in RAR-β and RAR-γ.  In H5, 
methionine amino acid in RAR-γ is different than isoleucine in RAR-α and RAR-β. In H11, alanine 
amino acid in RAR-γ is different than valine in RAR-α and RAR-β.52 
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1.8 The retinoic acid-binding pocket 
The studies showed that the ligand is completely buried within the ligand-binding 
pocket formed by residues located on helices H3, H5, H7, H11 and the β-turn. The 
majority of the contacts are van der Waals interactions except for the carboxylate group 
of the ligand that forms a salt bridge with the conserved Arg residue in helix H5, which 
participates in a network of hydrogen bonds with Ser (β-turn) and Lys or Leu 
residues.53,54 Also sequence alignment of RAR-α,-β, and-γ shows that only three 
residues in the ligand-binding pocket are variable: Ala234 (Ser232 in -α and Ala225 in -
β), Met272 (Ile270 in -α and Ile263 in -β), and Ala397 (Val395 in -α and Val388 in -β). 
These divergent residues are obvious candidates to account for the RAR selectivity of 
certain synthetic retinoids (Fig. 1.5). In RAR-γ, Ala234 and Met272 interact with the 
isoprene tail and Ala397 with the β-ionone ring. RAR-α and RAR-β differ only by one 
residue in the pocket [Ser232 (RAR-α) versus Ala225 (RAR-β) in H3].55,56, 57 The 
orientation of H12 helix is vibrant and movable with changing the binding mode of 
LBD. In the unbound receptor, Phe282 (H3), Phe442 (H11) and Phe455 (H12) are 
almost completely solvent exposed and make very little or no contact at all with other 
LBD residues. Upon binding interaction with ligand, a concerted reorientation of these 
three phenylalanine side-chains occurred that become in close contact to H12 helix and 
the co-activator peptide.58 This is consequently followed by forced rotation of Phe282 
around the Cα-Cβ bond by 110° due to steric restrictions applied by Leu648 of the co 
activator peptide which consequently forces Phe455 from H12 to pivot by 104°.  
 
 
 
 
 
 
 
 
 
Figure 1.5: RAR ligand binding pocket with the main different active residues in LBD. In H3, S232 is 
thought to be responsible for the selectivity of RAR-α and makes the binding pocket more polar; While 
M272 and A397 in RAR-γ are thought to be responsible for preference of the pocket to the retinoid 
ligands with more hydrophobic side chains.58  
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A rigid-body translation of helix H12 towards H3 and the coactivator’s peptide of 
almost 2.0Å allows Phe445 to be accommodated in a small hydrophobic pocket of 
residues composed from helices H3 (Phe282, Leu281, Leu285), H12 (Met459) and the 
peptide (Leu645, Met644, Leu648). Consequently, Phe442 (H11) flips by 112° to 
contact Leu460 (H12) and forms together with Phe282 of H3 an “aromatic clamp” that 
locks H12 in the optimal conformation.59 The more compact structure of RAR-γ and 
other holo-LBDs which are different from the apo-structure in two major ways: (i) three 
helices, H3, H11 and the transactivation helix H12, undergo large conformational 
changes; and (ii) helix H12 of hRARapo-LBD is replaced by a disordered connecting 
peptide in an extended conformation that may be necessary to allow the N-terminal part 
of helix H3 to reach its new position60 (Fig. 1.6). Upon ligand binding, H11 is 
repositioned in continuity with H10, and the concomitant hinging of H12 is 
accompanied by additional structural changes such as bending of H3 and folding of the 
H6-H7 loop. These conformational changes lead finally to the formation of specific 
ligand binding domain interface with coactivators.61 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: Schematic representation of hRXR-α apo-LBD (left) and hRAR-γ holo-LBD (right). RAR-γ 
is bound with ATRA (left) and H12 is able to move in apposition for binding with co activator and lock 
the ligand binding pocket. RXR-α is in the silence state (right) -without binding to the ligand- with H12 is 
flipping in the space.60 
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It was observed also that Lys236 in RAR-γ displays two equivalent possible 
conformations. This can help to coordinate since NH3
+ of Lys236 interacts with the 
carboxyl group of ATRA and other retinoids when possible.61 Furthermore, Leu266 can 
provide some information about the inside of the ligand binding pocket as it was found 
it plays important role for hydrophobic interaction with the 7-methyl-group of ATRA.62 
Also among the numerous residues that have important role inside RAR binding 
pockets are Phe302, which is in close contact with the adjacent C7 methenyl group 
(4.5Å cut-off).62 Also Gly301 and Gly303 were shown to be critical for RAR-α specific 
van der Waal’s interactions with ATRA.63,64 In addition, studies emphasise that some 
amino acid residues from the N-terminal region of the LBD, such as Ser232 and Thr239 
in RAR-α play a role in selectivity for polar retinoids by participating in a hydrogen 
bond with the amide linker of retinoids.65 Also, Al225 and Ile232 in RAR-β inhert 
through different hydrophobic interactions and Met272 in RAR-γ, through the presence 
of a sulphur atom in the side-chain, which could account for weak hydrogen bonding 
with the hydroxyl group of some retinoid agonists and antagonists.66 Finally, it should 
be noted that the interactions between RAR and RXR within the heterodimer work 
independently from each other, like their monomers, which is in agreement with many 
studies that showed that dimerization does not affect the structure of RAR and RXR 
LBDs or their affinities for different retinoids.67 
 
1.9 Endogenous retinoids 
The endogenous ligands for RAR and RXR receptors are ATRA, 9-CRA and 13-CRA. 
ATRA binds and activates only RARs, while 9-CRA acts as an agonist for both RARs 
and RXRs. 13-CRA has no approved significant biological activity as with its isomer 9-
CRA. Crystallographic studies of the LBDs of both types of retinoic receptors showed 
that the shape of the LBP differs markedly between RARs and RXRs. RARs possess 
linear "I" shaped LBPs, whereas those of RXRs are a shorter and more restrictive "L" 
shape. As a result, the linear retinoid ATRA can act as a ligand only for RARs while the 
flexible 9-CRA can adopt both the linear and twisted conformations required for 
binding to both RARs and RXRs respectively68, 69 (Fig.1.7). Also, the superposition of 
9-CRA molecules from holohRXR-α (yellow) and hRAR-γ (red) showed a difference in 
binding affinity to different retinoic receptors70, 71 (Fig. 1.8). 
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Figure 1.7: RAR and RXR cavities calculated by VOIDOO and MSMS72 with a probe radius of 1.4 Å in 
white using DINO73occupied by 9-CRA.60 The conformational bending structure of 9-CRA allows it to 
bind both the L-shaped pocket of RXR and the more elongated pocket of RAR.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure1.8: Relative orientation of 9CRA and ATRA molecules after superimposition in both RXR and 
RAR. A) The superimposition of the 9-CRA before binding to the binding pocket of RAR and RX; B) the 
superimposition of 9-CRA and ATRA inside the binding pocket of RAR and RXR 9- CRA is able to 
adapt its conformational structure to bind both RAR and RXR, while ATRA is able only to bid the pocket 
of RAR.60 
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1.10 Synthetic retinoids analogues 
Before talking about the different synthetic retinoid analogues, we should classify them 
according to the level of transcriptional activation of RAR74 into: 
 Complete agonist: they have good binding affinity to the RAR, induce coactivator 
recruitment and trigger the required response mimic to the action of a naturally 
occurring ATRA. 
 Complete antagonist: this class of retinoids binds in the same fashion like agonists, 
however, the orientation of H12 helix is different than with ATRA or agonists and 
hence, cannot bind the co activator and the response would be different. 
 Neutral antagonist has no activity in the absence of an agonist but can block the 
activity of it. 
 Partial agonist: they bind to and activate RAR, but have only partial efficacy at the 
receptor relative to a full agonist. They may also be considered ligands which display 
both agonistic and antagonistic effects - when both a full agonist and partial agonist are 
present; the partial agonist actually acts as a competitive antagonist. 
 Several studies tried to increase stability and activity of retinoids by replacement of 
two C=C double bonds in the conjugated polyene by other groups to decrease photo-
induced isomerisation. Some examples of these classes are stilbene, tolan and biaryl 
arotenoids such as TTNPB,75 EC2376 and TTNN77 respectively (Fig. 1.9). 
 
 
 
 
 
 
 
 
 
Figure 1.9: Different arotenoids with higher stability and activity than ATRA. 
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TTNPB is one example of a potent arotenoid (aromatic retinoid) analogue of ATRA that 
is modified in the 4-position of the hydrophobic ring as well as the polyene chain,50 and 
it binds to all three nuclear retinoic acid receptors (RARs)78,79 with higher binding 
affinity and is biologically more potent than ATRA80,81 due to the higher stability 
profile.  It is 100-times more effective at inhibiting the growth of breast cancer cells and 
250-fold more potent in suppressing the growth of DMBA-induced skin papilloma in 
mice.82 The modification in TTNPB carboxyl group with N-(4-hydroxyphenyl) amido 
(4HPTTNPB) or a 4-hydroxybenzyl (4HBTTNPB) group gave compounds with 
different biological activity, poor binding affinity to RARs but induces apoptosis in 
cancer cells. Even 4HPTTNPB is less toxic to developing embryos than the parent 
TTNPB (Fig. 1.10). 
 
 
 
 
 
 
 
 
 
 
                         Figure 1.10: Two effective retinoids derivatives of TTNPB.83 
 
Other examples of two selective potent RAR-α selective agonists are AM80 and 
AM580 which displayed a marked selectivity towards RAR-α. The Kd values of these 
compounds for RAR were 1 order of magnitude lower than the Kd for RAR-β and 2 
orders of magnitude lower than the Kd for RAR-γ. This could be explained in terms of 
an additional Ser232 residue present inside, the RAR-α LBD pocket which can be 
oriented in a certain position suitable for the formation of additional hydrogen bonding 
to increase the selectivity and affinity of these compounds to RAR-α.84 There is the 
same issue with BMS-185411, which is selectively bound to RAR through Ser232, 
although it is an antagonist which interferes with H12 transactivation.85 
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In contrast, BMS195614 (check the list of retinoid chemical structures) is an example of 
a neutral antagonist with selectivity for RAR-α and this can be explained in two parts: 
1) the agonistic part is due to interaction between three divergent ligand-binding pocket 
residues that determine the RAR-α selectivity (Ser232 [H3], Ile270 [H5], and Val395 
[H11]); 2) looking carefully into the interactions between these residues and BMS614 
which was previously assumed to be responsible for the RAR-α specificity of BMS614, 
these are not observed in the crystal structure. This is the case for the Ser232 OH group, 
which is not hydrogen bonded with either the amide NH or carbonyl groups of 
BMS614, but with the aromatic CH (3.1° A) located in the meta-position (relative to the 
carboxylate moiety) of ring E. The reasons for this change in interaction and shift in 
activity is assumed to be due to BMS614 being a shorter molecule than ATRA, and also 
due to the location of the antagonistic extension of BMS614 between H3 and H11 
which prevents the positioning of helix H12 in the “active” conformation.55 
 
 Ligand–receptor binding interactions  
The transcriptional response mediated by retinoic acid involves a complex series of 
events beginning with ligand recognition by a nuclear receptor. This step is important to 
recognize and see what factors are affecting retinoid binding to RARs, in terms of 
chemical structure modifications. Several studies have discussed the relative binding 
affinity of several retinoid derivatives, either naturally occurring or synthetic, to 
measure EC50, Kd and Bmax, to explain how this chemical difference affects the binding 
affinity. Many other factors such as the relationship between the binding affinities of 
retinoids to RARs is correlated to heat of binding and thermodynamic entropy occurred 
inside ligand binding pocket need to be considered. In addition, there is still a need for 
explanations about the relative difference in binding affinities for different retinoids in 
terms of molecular modelling studies to give an indication about how the geometry of 
the binding pocket has impact on relative binding affinities. 
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1.11 Law of mass action 
Ligand – Receptor binding experiments are usually analyzed according to the simple 
model of law of mass action:86,87,88 
                                           
                                        [R] + [L]                     [RL] 
 
Where [R], [L] and [RL] represent the free concentrations of receptor, ligand, and 
receptor-ligand complex, respectively, and where it is assumed that the reaction 
components can freely diffuse within the medium. kon and koff are the rate constants for 
association and dissociation of the ligand-receptor complex.The reaction is driven by 
the concentration of the reacting agents. Equilibrium is reached when the rate at which 
ligand-receptor complexes are formed and dissociate are equal. At equilibrium, the 
following applies: 
                                [R] [L] kon = [RL] koff 
The equilibrium dissociation constant, Kd, a measure for binding affinity, is defined as: 
 
                                         Kd =              =   
 
These constants have the following units: kon: M
−1∙s−1; koff: s−1; Kd: M, where M stands 
for Molar or mol∙L−1. When a receptor-binding experiment is performed, [LR] usually is 
the parameter needs to be determined.This implies, however, that only a minor fraction 
(<5%) of the total applied ligand should become bound (either by specific binding, 
nonspecific binding or adsorption to tissue and assay container) so that the free 
concentration is not altered. 
 
 
 
 
 
 
 
 
 
kon 
koff 
kon 
koff 
[L] [R] 
 [RL] 
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1.12 Retinoids receptor binding assays 
Retinoids need a specific receptor-binding assay especially when dealing with naturally 
occurring retinoids (ATRA and 9-CRA) to be sure that they are isomerically pure and of 
high specific activity. Some of the popular radio-receptor assays used are competitive 
binding assays which require high specific activity of radiolabelled [H3]-ATRA or 9-
CRA (> 25 Ci/mol), coupled with a co transfection assay to identify the structural 
features of these retinoids and the impact on receptor selectiveness and ability to induce 
co-activators transactivation. The first example is a study carried out89 to compare 
between the binding affinity of ATRA and 9-CRA to RARs in the different organs of 
rainbow trout tissues through inducing reproduction, body pattern formation and normal 
tissue maintenance. The different tissues were isolated, homogenized and the nuclear 
portion was extracted. Several centrifugation was done and The final pellet was 
transferred to a scintillation vial with 5 ml of scintillation cocktail and assayed for 3H 
activity The results are shown in (Table 1.1) as ATRA showed general higher affinity in 
all types of tissues (lower Kd) compared to 9-CRA (higher Kd) while visa versa in terms 
of binding capacities (Bmax). This means ATRA has higher binding affinity and can 
occupy a lot of free receptors available compared to 9-CRA.  
 
Another radio-labelled receptor binding assay story90 is that of receptor selectivity of 
TTNPB, LG100268 and 9-CRA. Table 1.4 shows the comparative abilities (Kd) of the 
RAR-selective retinoid agonist TTNPB, and the pan RAR-RXR agonist 9-CRA, to bind 
the different baculo virus-expressed retinoid receptors. The structures of these 
compounds are shown in (Fig. 1.11), as it was found that using a competitive binding 
assay, LG100268 binds strongly to RXR-α,-β, and-γ but not to RAR-α,-β, and-γ. 
Conversely, TTNPB binds with high affinity to RAR-α,-β, and-γ but not at all to RXR-α, 
-β, and-γ. The pan agonist 9-CRA binds with high affinity to both RARs and RXRs in 
this assay and that matches with the previous observation regarding twisting structure of 
9CRA inside RAR and RXR LBDs91 (Table 1.2). 
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Figure 1.11: Chemical structures of 9-CRA, TTNPB and LG100268. 
 
Table 1.1: Affinity (Kd) and binding capacity (Bmax) of ATRA and 9-CRA in nuclear fraction of adult 
Rainbow Trout tissues.89 
Tissue 
RA isomer Kd(nM) Bmax 
(fmol/mg protein) 
Gill 
ATRA 
9CRA 
1.0±0.1 
7.0±0.2 
175.6±16.8 
214.3±29.1 
Liver 
ATRA 
9CRA 
2.5±0.1 
51.2±2.9 
74.7±5.3 
1076±270 
Eyed embryo 
ATRA 
9CRA 
1.9±0.03 
11.5±0.3 
483.8±3.3 
526.0±10.4 
Post hatch fry 
ATRA 
9CRA 
3.4±0.1 
24.2±1.4 
296.0±4.7 
342.9±10.8 
Swim-up fry 
ATRA 
9CRA 
3.9±0.1 
55.9±13.5 
62.1±1.4 
115.5±21.7 
 
Table 1.2: Kdvalues for receptor selective ligands.92 
Retinoid agonist 
Kd value (nM) for: 
RAR-α RAR-β RAR-γ RXR-α RXR-β RXR-γ 
9C-RA 
93 97 148 8 15 14 
TTNPB 
20 39 51 8113 4093 2566 
LG100268 
10000 10000 10000 3 3 3 
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The comparison between different retinoid structures in terms of radio labelled binding 
affinity did not stop at natural retinoids but was extended to compare between different 
derivatives of the same synthetic retinoid to explore how structural modification has an 
impact on binding activity. This study was issued to compare ATRA, 9-CRA, TTNPB 
with derivatives of 3-methyl, 3-ethyl and 3-isopropyl TTNPB using competitive binding 
assay with [3H]-9-CRA (Fig.1.12). Table 1.5 shows how is ATRA is a good activator of 
RAR-α, -β, and -γ, however, it is less active at RXR-α, -β, and –γ. In contrast, 9-CRA is 
a potent activator of RXR-α, -β, and -γ.  TTNPB functions as a potent activator of RAR-
α,-β, and-γ but does not activate RXR-α, -β, and -γ in this co-transfection assay. 
Examination of 3-alkyl-substituted TTNPB derivatives show a different activation 
profile: in the co-transfection assay, 3-methyl-TTNPB is a (10-200)-fold weaker 
activator of the RARs than is its parent TTNPB. In contrast, 3-methyl- TTNPB activates 
all members of the RXR subfamily but not all members of the RAR subfamily.  
 
 
 
 
 
 
                                                        R= methyl 
                                                        R= Ethyl 
                                                        R= Isopropyl 
Figure 1.12: Chemical structures of TTNBP analogues used in transactivation and competition assay.51 
 
The results for 3-ethyl- and 3-isopropyl-TTNPB showed similar, albeit lower, activation 
profiles across all six receptors as 3-methyl-TTNPB, as was observed in the binding 
studies. It is still more interesting to know the reason in this difference in binding 
activity due to structural modification93 (Table 1.3). 
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Table 1.3: Competitive assay from CV-1 cell.93 
 
The transactivation and competitive coupled transfection assay is used again to illustrate 
the binding activity of AM80, AM580, BMS-185411 and BMS-18535451 (Fig.1.13). 
Retinoid efficacy was measured by the concentration of induced chloramphenicol 
acetyltransferase gene product obtained from transfected cells using the 
chloramphenicol acetyltransferase enzyme-linked immunosorbent assays kit. Activity 
was routinely normalized for transfection efficiency by β-galactosidase activity. Results 
(EC50) are presented as the dose at which chloramphenicol acetyltransferase induction 
was half of the level observed for ATRA at 10-6 M (Table 1.4). 
From Table 1.4, it was found that Am-580 is RAR-α selective agonist, BMS 185411 
showed specific agonist activity for RAR-β while BMS-185354 selectively activated 
RAR-γ. Two sets of residues, serine232 (Ser232)/alanine225 (Ala225) and threonine239 
(Thr239)/isoleucine232 (Ile232) in RAR-α and RAR-β were found to be essential for 
receptor-ligand-specific interactions. Ser232 in RAR-α may participate in a hydrogen 
bond with the amide linker of Am-580 and its analogs, which links the compound to α-
helix H3. In RAR-β and RAR-γ, alanine residues at positions225 and 234, respectively, 
correspond to Ser232 in RAR-α. The presence of a hydrophilic linker, as seen in Am-
580, in close proximity to a hydrophobic amino acid (Ala225 or Ala234) may result in 
negative interactions between the receptor and retinoid manifested as decreased affinity 
of the compound for both RAR-β and -γ. 
 
Retinoid agonist 
EC50 (nM) 
RAR-α RAR-β RAR-γ RXR-α RXR-β RXR-γ 
ATRA 
350 ± 31 80 ± 9.0 10 ± 2.0 900 ± 70 1400 ± 130 1100 ± 85 
9C-RA 
191 ± 20 50 ± 17 45 ± 5.0 100 ± 25 200 ± 30 140 ± 13 
TTNPB 
30 ± 6.0 3 ± 2.0 2 ± 1.0 >10000 >10000 >10000 
3-Methyl- TTNPB 
340 ± 30 230 ± 28 180 ± 15 1200 ± 120 1175 ± 150 1500 ± 111 
3-Ethyl- TTNPB 
1700 ± 118 310 ± 29 23 ± 4.0 2900 ± 250 2000 ± 150 2600 ± 160 
3-Isopropyl- TTNPB 
>10000 >10000 270 ± 35 300 ± 32 >10000 2700 ± 240 
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Figure 1.13: Chemical structures of the ligands used in transactivation and competition assay.51 
 
Table 1.4: Competitive-transfection assay from Hela cells.51 
Receptor EC50 (nM) 
ATRA AM-580 BMS-185411 BMS-185354 
 
Wild type RAR-α  
 
17 ± 5 
 
3.2 ± 1 
 
NA 
 
NA 
 
 
Wild type RAR-β 
 
23 ± 6 
 
200 ± 90 
 
34 ± 13 
 
280 ± 84 
 
 
Wild type RAR-γ 
 
12 ± 6 
 
400 ± 120 
 
>10000 
 
28 ± 7.5 
 
 
 Cellular activity of retinoids 
1.13 Introduction 
Developing systems exhibit a dynamic balance between cell proliferation and 
differentiation, and although this equilibrium is important, it is a poorly understanding 
question in development. This model holds interactions between proliferation factors, 
and those promoting differentiation to regulate the developmental patterning 
processes.94 Two important terminologies related to developmental potential are related 
here, determination (cell fate) and differentiation.  
 
ATRA 
AM-580 
BMS-185354 
BMS-185411 
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When a cell “chooses” a particular fate, it is said to be determined, although it still 
"looks" just like its undetermined neighbours, however this process is irreversible. 
Determination implies a stable change while the fate of determined cells does not 
change. While differentiation follows determination, as the cell elaborates a cell-specific 
developmental program results in the presence of cell types that have clear-cut identities, 
such as muscle cells, nerve cells and skin cells95 etc. Once differentiation occurs, cell 
size and shape change dramatically, as does its ability to respond to signalling 
molecules through specific combination of genes that are turned on or off 
(expressed or repressed), and this is what dictates how cells function.96 
 
1.14 Retinoids are biologically active molecules 
Vitamin A (retinol) and its naturally occurring and synthetic derivatives collectively are 
referred to as retinoids, a family which consists of poly-isoprenoid lipids with variety of 
profound effects in cell proliferation, cell differentiation and embryonic development.97  
These observations were followed by numerous studies focused on the metabolism and 
pharmacological action of these retinoids in the skin, leading to the establishment of 
retinoic acid treatment for some of the skin diseases.98,99 Also, they are useful therapy 
for someof the  precancerous lesions, including the treatment of acute promyelocytic 
leukemia (APL) through its agonist activity on RARs which consequently 
induces  myeloid differentiation at the promyelocytic stage.100 ATRA also had useful 
clinical use with other therapy for treatment of malignancies in high-risk cancer 
groups.101,102,103 These biological functions of retinoids based on its own profile and 
pharmacological properties that determine its usefulness in clinical dermatology or 
oncology since their biological activities are usually associated with clinical 
disadvantages such as toxicity and teratogenicity.92, 104 
 
 
 
 
 
 
 
                         Figure 1.14: Chemical structure of parent retinoid with its derivatives. 
R) –CHO      Retinaldhyde 
R) –CHOH   Retinol 
R) –COOH   Retinoic acid 
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From Fig. 1.14, it can be noted that the vitamin-A molecule (retinol) is composed of 
three main building units: the cyclic end group (hydrophobic end); the polyene side-
chain; and the polar end group.105,106 Changing the polar end group from an alcohol to 
an acid gives the active form of vitamin A, retinoic acid or all-trans-retinoic acid 
(ATRA). The polyene linker in naturally occurring retinoids is highly conjugated and it 
is this region that gives the ability to absorb light (at a frequency of 300-400 nm 
depending on the solvent.107 Modification of the structure results in many varieties of 
synthetic retinoid analogues with different biological activity. For example, the active 
form of retinoid is the free carboxylic acid because in several in vitro systems the 
retinoids with a carboxylic acid end group are more active than the corresponding 
analogues with a modified end group such as alcohols, aldehydes, esters and 
amines.108,109 
Even for some derivatives with ethyl ester or etretinate analogues which are inactive, 
could be activated by esterase, which in turn, converted the retinoid into its free acid 
form.110 Also, a drastic improvement in activity was observed in analogues with various 
forms of ring involving either a hydrophobic end group or polyene side-chain, in 
particular, such as indane and tetraline derivatives.111 Recently, a new class of arotinoids 
with substitution of the polyene linker by other stable groups as acetylene showed 
activity of up to 10 times greater than naturally occurring retinoids.112, 113 
 
1.15 Biosynthesis, transport and storage of vitamin A in human body 
The vitamin A that is obtained from the diet is stored in the liver in the form of retinyl 
esters.114 To release this stored form the esters, it is hydrolysed to retinol, which is 
released into the bloodstream for transport round the body bound to plasma retinol-
binding protein. Cells which require retinoic acid take up retinol and convert it to 
retinoic acid through the action of two types of enzymes. The first type of enzyme, the 
retinol dehydrogenases (ROLDH), convert retinol to retinaldehyde which is used in the 
visual cycle, and the second type of enzyme, the retinal dehydrogenases (RALDH), 
convert retinaldehyde to retinoic acid.  
Retinol (ROH) is transported in serum to the target cells as a complex by specific 
retinol-binding proteins CRBPII which protect it from metabolic oxidation into retinoic 
acid and allows it to be reduced into retinol by microsomal retinal (RCHO) 
reductase.115,116  
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Also, CRBP II–retinol complex serves as a substrate for the conversion of retinol into 
R-FA (retinyl esters) by the enzyme lecithin: retinol acyltransferase (LRAT) which is 
incorporated into lipoprotein particles (called chylomicrons in humans)in which it is 
carried to be stored in the main storage organ, the liver.117 A specific circulatory 
transport system for retinol is mediated by serum retinol-binding protein (RBP-4). In 
plasma, holo-RBP circulates as a 1:1 molar complex with transthyretin (TTR) which is 
able to bind retinol from its storage source into target cells.118,119 Numerous target cells 
have a receptor for TTR-RBP to facilitate the uptake of TTR-RBP-retinol and in the 
target cell, retinol undergoes metabolic activation, ultimately supporting the 
biosynthesis to active retinoids, RA and 9-CRA.120,121 Also, esterification proceeds at a 
rate sufficient to store excess retinol as retinyl esters in target cells as a second storage 
source of retinol, while maintaining intracellular non-esterified retinol concentrations 
sufficient to initiate different biological activities and biosynthesis of other hormones122 
(Fig. 1.15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.15: Absorption, transport and activation of naturally occurring retinoids. Carotenoids or other 
retinoids are biochemically converted to retinoic acid (RA), which is essential for modulating a wide 
range of biological processes. first in the intestine, then the liver, and finally in target cells with the 
support of various binding proteins including cellular retinol-binding proteins (CRBPs), retinol-binding 
proteins (RBPs), and cellular retinoic acid binding proteins (CRABPs).123 
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1.16 Cellular metabolism of retinoids 
The oxidative metabolism of retinoids and especially RA by certain enzymes helps to 
maintain tissue retinoid concentrations within appropriate bounds. Recent studies have 
provided new insight into the processes by which RA is catabolized. It is speculated that 
RA might be metabolized with at least three pathways.124 One of these pathways, which 
accounts for nearly two-thirds of RA metabolism, involves the excretion of the retinoid 
with an intact isoprenoid side-chain, which is assumed to include retinoyl-β-glucuronic 
acid. The remaining two pathways apparently involve oxidative loss of the C-14 and C-
15 positions.125,126,127 Recent studies suggested that RA metabolism is catalyzed by an 
enzyme, or enzymes, with properties similar to cytochrome P450–mediated 
monooxgenase systems, however, gene expression and protein analysis showed that the 
predicted cytochrome P450 protein had less than 40% amino acid identity to other 
known cytochrome P450s that binds retinoic acid, and therefore, the gene was classified 
as a member of a new cytochrome P450 gene family, designated CYP26 with P450RAI 
becoming CYP26A1128,129 (Fig. 1.16). 
 
 
 
 
 
 
 
 
Figures 1.16: The major metabolic pathway of vitamin A is through CYP26 enzyme with oxidation at 4- 
position. These oxo- products are easily excreted through glucouridination.124 
 
1.17 Biological function of retinoids 
The retinoids regulate a wide range of biological processes including development, 
differentiation,130 proliferation and apoptosis.131  which is summarized in Fig.1.17. 
Some biological functions of β-carotene include anti-oxidant properties, increasing 
natural killer cell (NK-cell) activity and improving lung function.132  
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Also, retinoic acid shows its activity for inducing differentiation on different types of 
cells, including neural differentiation in the neural plate of developing embryos through 
attenuating fibroblast growth factor (FGF) signaling.133  It has been shown that retinoids are 
able to inhibit mammary carcinogenesis134 in experimental animals and other different types of 
tumours100,135 interfering a variety of biochemical pathways136,137, such as cell proliferation AKT 
pathway 138,139 which is necessary for tumour overgrowth. Also retinoic acid can inhibit the 
tumour growth through activation of RARs especially RAR-β gene and hence, changing their 
behaviour. Another proposed mechanism in neuroblastoma is through to be through the cell-
cycle arrest at G1 which is mediated by increased expression of the p21/WAF1 gene.140  
Moreover, retinoids have other essential in vivo functions in reproduction, 
spermatogenesis through induction of differentiation of type A spematogonia, 
conception through induction of oocyte development and placental formation through 
stimulation of human gonadotropin hormone in trophoblast.141,142 
Vitamin A and its precursor β-carotene also have impact in neurodegenerative diseases 
including Alzheimer’s disease (AD) and Parkinson’s disease (PD). They inhibit the 
formation of amyloid-β (Aβ) fibrils in a dose-dependent manner. Furthermore, they 
destabilize the pre-formation of Aβ fibrils in vitro.143 Oligomerization of Aβ40 and 
Aβ42 can also be prevented by vitamin A and β-carotene. One study showed that 9-
CRA could provide neuroprotection in CNS injury in a transient focal ischemia model 
due to the activation of bone morphogenetic proteins (BMPs).144 Retinoid-dependent 
expression of BMP7 was found to protect neurons against injuries caused or induced by 
neurotoxins, free radicals, and ischemia in vitro and in vivo.145 
Retinoic acid is necessary for renal development and even mild gestational vitamin A 
deficiency can affect nephron endowment. This was first demonstrated by feeding 
pregnant rats a vitamin A-deficient diet that caused reduced vitamin A levels in the fetal 
circulation leading to a significant reduction in nephron number and severe renal defects 
in the newborn rats.146 
Another studies in the mouse showed a requirement for retinoic acid signalling in the 
normal development of the ventral retina and optic nerve through its activities in the 
neural crest cell-derived peri-ocular mesenchyme, dependent on the activities of various 
retinoid receptors RAR-α,-β,-γ and RXR-α,-β,-γ. Retinoic acid-synthesizing enzyme 
(RALDH) and retinoic acid-degrading enzymes (CYP26) also have critical roles in 
embryonic eye development.147 
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        Figure 1.17: Summary of the biological functions of retinoids.83 
 
1.18 Retinoic acid signalling during early embryonic development 
Retinoic acid was known as important molecule for induction of cellular development in 
different species includes human.148 The activity of retinoids starts early at the embryo 
stage and has been shown to include several process; 
 1.18.1 Axis formation 
One of the important pathways that has significant implication on dorso-ventral axis 
formation is Nodal signalling pathway.149 Retinoic acid was shown to interact with this 
pathway through the similar region of RARE in intron 1 and this might suggest the early 
effect of retinoic acid at this stage.150 
Experiments in zebra fish embryos indicate that reduction of retinoic acid by 
ectopic cyp26 decreased the expression of posterior genes meis3.151 This was confirmed 
by knockdown model of of cyp26 which affect on the expression of meis3. On the other 
way, FGF/Wnt signalling was shown to suppress the expression of cyp26, and hence, 
the specification of posterior trunk during the gastrulation.152 This can conclude that both 
retinoic acid and FGF/Wnt signalling have a significant effect on the regulation of the 
antero-posterior axis formation in gastrula embryos.153 
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1.18.2 Neuronal differentiation 
Neuronal differention is the second stage in embryo development and it was shown that 
Neurogenein 2 (Neurog2), the pro-neuronal induction factor has important role in early 
development of the primary sensory neurons. Neurog2 has two RARE sequences in its 
promoter region and hence, this might suggest the biologicl effect of retinoic acid onthe 
level of expression of Neurog2 and its activity and hence, neuronal differentiation.154 
1.18.3 Hindbrain development 
In vertebrate hindbrain, there was shown a correlation between several rhombomeres 
and Hox genes.155 This correlation comes through the link between RARE and the 
promoter region in some of Hox genes which are required for the restricted expression 
in rhombomere.156 This was confirmed by several studies in mouse and fish embryos 
which showed that retinoids could induce ectopic expression of both Hoxa1 and Hoxb1, 
which caused a rhombomere 2 to 4 transformation.157 In addition, another signalling 
pathway of Hnf1b was shown to suppres Hoxb1 expression in rhombomere 5 was also 
regulated by the retinoic acid signalling. These data might suggest that the retinoic acid 
signalling is involved in hindbrain patterning.158 
1.18.4 Development of internal organs 
The retinoic acid signalling also plays essential roles in both endoderm and gastrulation 
development as was observed in several studies in frog, avian, and mice.159 Retinoic 
acid signalling is essential for pancrease development include dorsal and ventral region 
formation.160 Cdx4 and XPDIp were shown to be essential genes under the control of 
retinoic acid signalling for the development of posterior boundary of dorsal pancreatic 
territory and exocrine portion of both dorsal and ventral pancreas respectively.161 The 
formation of cardiac progenitors, the correct modelling of the early heart field and the 
anteroposterior patterning were also under the regulatory effect of retinoic acid.162 
Specific link between retinoic acid inductions of Raldh2 gene can explain the biological 
role of retinoic acid in heart development.163 Moreover, studies in Xenopus and 
zebrafish have demonstrated that ectopic production of retinoic acid increased the size 
of the kidney field, while blocking the pathway inhibited the kidney specification.164 
This is due to both pax8 and lhx1 are both under control of the retinoic acid 
signalling.165 
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Also, in vivo study was done to evaluate the biological activity of new synthetic retinoid 
analogue; EC23 compared to retinoic acid for embryo development. EC23 has very 
similar biological effects to retinoic acid within the appropriate concentration as well as 
the added benefit of being more stable. In addition, when higher doses of EC23 were 
applied, some novel phenotypes were produced compared with ATRA; in particular, a 
novel type of digit duplication was observed (Fig. 1.18).166 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.18: The effect of 0.01mg.ml-1 of EC23 on chick wing development. A) The normal digit 
development, 123 was produced by DMSO and acts as control and B-E) represents the multiplication of 
the wing digits generated by EC23. The whole mount skeletal view is dorsal. The additional digits are 
highlighted by asterisks. 167 
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1.19 Stability of retinoids 
Naturally occurring retinoids, including ATRA, 9-CRA and 13-CRA, can be described 
as chromophores because of the highly conjugated polyene linker region that gives the 
ability to absorb light. This makes these molecules particularly susceptible to photo-
isomerisation and can degrade into a mixture of different retinoic acid isomers and 
decomposition products.105, 106 The resulting concentration of retinoid levels in cells has 
also been shown to decrease markedly over time in culture and this could be a 
consequence of both their degradation and metabolism.135 Moreover, ATRA is 
temperature sensitive and is known to oxidize readily. A paper warning cell biologists 
of this issue of stability has been published relating to using retinoic acids as inducers of 
cell differentiation and that the isomers of ATRA differentially affect the ability of 
mammalian stem cells to differentiate along alternative lineages and stated that extreme 
care should be taken to protect retinoic acid from isomerisation in such experiments.106 
To reduce such variability in differentiation response and improve reproducibility, it is 
essential that whatever compound is used to induce cell differentiation to be sure it is in 
the same form and concentration every time is used.  
Currently, this cannot be guaranteed when using reagents such as ATRA and its 
stereoisomers, all of which are light and heat sensitive and are prone to undergo 
isomerisation under sample preparation, under storage of stock solution and in culture 
conditions. It is because the different isomers have diverse effects on cells that some 
attempts have been made to control ATRA’s sensitivity and tendency to isomerise. For 
example, a number of additives preventing cis-trans interconversion or oxidation of 
retinoic acids have been evaluated, including bovine serum albumin (BSA), fibrogen, 
lysozyme, phosphatidylcholine N-ethylmaleimide and vitamin C.130 However, the 
addition of such molecules to cell culture media is often not possible and such additives 
may affect cell behaviour in their own way, and none of these additives can completely 
prevent isomerisation. The use of BSA, for example, would not be possible also in 
serum free culture media. 
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1.20 Cellular differentiation 
Cell differentiation is an important biological phenomenon that is involved in numerous 
physiological and pathological significant processes occurs during multiple stages of 
development.168 Once cell differentiate, phenotypic characters change dramatically in 
response to signalling molecules to generate a new genotypic characters characterized 
by specific combination of genes that are turned on or off (expressed or repressed) once 
cells become specialized. Retinoid derivatives are one of the most potent agents known 
for induction of cellular differentiation as they exert highly di-versified effects on cells 
irreversibly at nano-molar concentration. This effect is thought to be mediated through 
two classes of nuclear receptors; the retinoic acid receptors (RARs) and the retinoid X 
receptors (RXRs).22 These ligand-regularly nuclear receptor complexes modulate 
expression of their target genes by binding to cis-regulatory DNA sequences to initiate 
the cellular differentiation process. RXRs can act as transcriptional co-regulator with its 
cognate RARs, or other receptors as thyroid hormone receptors to form heterodimers 
complexes.169 ATRA, as well as its natural isomer 9-CRA, are widely used to direct the 
in vitro differentiation of many cell lines including stem cells.170 
 
Cellular differentiation by the vitamin A derivative ATRA has been studied with 
different undifferentiated cell lines including pluripotent embryonic carcinoma (EC) 171 
and embryonic stem (ES)172 cells in vitro. Both cellular systems are suitable for the 
study of differentiation of other cell types, because they recapitulate the early stages of 
mouse embryogenesis. In vivo, ATRA was identified as a signalling molecule 
influencing gene expression in a complex manner via a family of RA receptors.173 Thus, 
In vitro cellular differentiation offers several advantages over comparable approaches in 
the whole embryo for many reasons. First, the generation of mature lineages from ES 
cells in culture provides access to populations of early precursors that are difficult, if not 
impossible, to access in vivo.174 Second, the developmental potential of ES cells 
carrying targeted mutations of genes essential for embryonic development can be 
determined in culture. Analyses of these mutations in vivo are often complicated by 
early death of the embryo in uterus.175 So here, it is susceptible to in vitro differentiation 
studies to demonstrate the diverse activity of ATRA on various cell lines and possible 
mechanisms for the induction of neuronal differentiation. 
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1.21 In vitro neuronal differentiation 
1.21.1 Stem cells modulation 
1.21.1.1 Human embryonic stem cells (ES) 
In vitro differentiation of embryonic stem cells (ES) has attracted wide interest as an 
experimental system to investigate cell development/differentiation.176 In addition, the 
isolation of human ES cells177  has raised the possibility that differentiation may provide 
a novel source of cells for tissue replacement or repair.178 Therapeutic use of ES cells 
will require robust and reliable methods for producing specific neural cell types. Early 
work on ES celldifferentiation found that aggregation of cells into embryoid bodies, 
combined with exposure to RA, enhanced the efficiency of ES cells conversion to a 
neural phenotype.179,180,181 Although ES cells can differentiate spontaneously or with 
serum free differentiation (SFD) media, into many other cell lineages, however, cells 
with a brief exposure to RA were able to differentiate, lose stem cell identity, adopt a 
neural fate, and acquire mature axonal/dendritic polarity more rapidly than cells induced 
with SFD medium alone.182 
There are many advantages to using ATRA in ES cells for neuronal differentiation such 
as the conversion of neural progenitor cells to postmitotic neurons which undergo their 
final mitosis at an earlier time point than cells induced spontaneously or with SFD 
medium alone.183 Also ATRA directly induces genes associated with neuronal 
maturation at early stages so that young neurons are able to initiate formation and 
outgrowth of neurites that ultimately become axons and dendrites in structure.184 
Many gene level changes occur upon neuronal differentiation of ESs with retinoids, 
including an increase in the expression of tumour suppressor gene p53,185,186 cyclin-
dependent kinase inhibitor(p21)187 and CKI genes,188 that is the likely cause of cell 
cycle arrest which stops proliferation at the expense of differentiation.189 In addition, 
many other genes which are implicated directly in the process of neuronal 
differentiation are over expressed such as SoxII,190 Pax6,191 Nestin,192 neurofilament 
L,193 (GAD67, GAD65)
194 and MashI.195 On the other hand, ATRA reduces gene 
expression of Nanog,196 one of the genes required for the maintenance of pluripotency 
and suppression of cyclin genes to control the progression of cells through the cell cycle.  
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1.21.1.2 Haematopoietic stem cells (HSCs) 
Although ATRA signaling is known to accelerate the differentiation of generated 
hematopoietic progenitors to more mature blood cells, its role in hematopoiesis and 
HSC biology in particular, is still unclear. Based on its ability to differentiate both 
normal197 and malignant198 promyelocytes, studies using murine or human umbilical 
cord blood HSCs show apparent contradictory roles for ATRA signaling.199 Murine 
models have shown that HSC expansion can be achieved either by activation of the 
ATRA pathway200 or its inhibition via retroviral-mediated expression of dominant 
negative RARα.201 This difference in such activity may be explained due to ATRA’s 
pleiotropic effects on different hematopoietic progenitors and RAR subtypes, since 
RAR signaling is down-regulated in CD34+CD38− cells compared with the more 
differentiated CD34+CD38+ cells.202 Also, it is hypothesized that CYP26-mediated 
lowering of retinoid levels might also be an important physiologic mechanism for 
determining HSC fate. Thus, blood development depends on an ATRA concentration 
since at low level with activity of CYP26 enzymes will lead to cellular development 
while at higher concentration this differentiation will be abolished.203 
 
1.21.1.3 Mesenchymal Stem Cells (MSCs)  
Mesenchymal stem cells (MSCs) are pluripotent adult stem cells that can be induced to 
differentiate into various mesenchymal lineages, including osteocytes,205 chondrocytes 
204 and adipocytes.205 Because of their ability to trans-differentiate across embryonic 
boundaries into neuronal cells, MSCs are considered good potential candidates for 
treating neurodegenerative disorders and nerve injury diseases.206 It was found that RA 
pre-treatment could improve neuronal differentiation efficiency of MSCs and promote 
neuronal differentiation and survival of MSCs after transplantation into an animal 
model of hypoxic-ischemic brain damage.207 This could indicate that MSCs became 
“sensitized cells”, that are sensitive to neuronal induction microenvironments following 
pre-induction by RA to display a distinct neuronal shape, express neuronal markers and 
acquire neuron-like functional characteristics. RA pre-induction of MSCs was closely 
related to the activation of RAR-β signalling because of it is a neural specific receptor, 
highly expressed in neural tissues to regulate the physiological functions of nervous 
system and nerve regeneration.206 
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1.21.1.4 Induced pluripotent stem cells (iPSCs) 
Human induced pluripotent stem cells (hiPSCs) are considered to be suitable tools to 
study basic molecular and cellular mechanisms of neurodevelopment. The directed 
differentiation of hiPSCs via the generation of a self-renewable neuronal precursor cell 
line allows the standardization of defined differentiation protocols. It was found that 
ATRA treatment of hiPSCs leads to higher yields of neurons vs. glia cells and longer 
axons than unconditioned controls, glutamatergic activation and depolarization.208,209,210 
However, there are diversity in protocols and methods used for the induction of 
neuronal differentiation using RA from hiPSCs which depends on applied 
concentrations, starting time point of application and the duration of treatment during 
neuronal differentiation. However, without doubt, retinoic acid treatment at the early 
stages of neurolation phase in hiPSCswill increase the yield of neuronal phenotypes, but 
does not have impact on the functionality of the terminally differentiated neuronal 
cells.211 Many methods have been used to confirm cellular and functional aspects of 
generated cells such as quantification of neurite length, soma size, synaptic connectivity, 
cell-type specification and neuronal excitability.212, 213, 214 Also, cell differentiation of 
hiPSCs into neurons is pre-programmed and co-ordinated by down-regulation of 
pluripotent genes and concomitant up-regulation of neurons-specific lineage genes such 
as Nanog and Oct4 are down-regulated before Pax6 becomes over-expressed.215, 216 
 
1.21.2 Cancerous cells neuronal modulation 
1.21.2.1 Embryonal carcinoma stem Cells (EC) 
Embryonal carcinoma (EC) cells are the stem cells of teratocarcinoma. They are deriven 
from the inner cell mass of blastocyst of human or mice embryos.217 There are many 
advantages in using these cells in vitro as they are adaptive to any condition changes, 
proliferating faster and becoming easier to maintain with time in culture. Furthermore, 
these adaptive cells can be inoculated into a SCID (severe combined immunodeficient) 
mouse, teratocarcinoma to obtain histologically recognizable stem cells with similar 
properties to the starting ES cells.217 There are many examples of EC stem cells such as 
F9 teratocarcinoma,218 P19 embryonal carcinoma219 and NTERA-2.cl.D1.220  
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Many of these EC cell lines have some practical difficulties for their routine use 
especially when it is necessary to expand cultures and produce larger amounts of cell 
material. Furthermore, it is well known that suboptimal culture conditions can lead to 
spontaneous differentiation of human ES cells, introducing contaminating cell types.221 
The independently derived TERA-2.cl.SP12 teratoma cells222 can provide a robust and 
simple culture systems to study certain aspects of cellular differentiation in a pertinent 
to human embryogenesis. It is also a good model used for the study and biological 
evaluation of the potency of synthetic derivatives of retinoic acid.223,224 RA was found to 
induce ectoderm differentiation and the formation of neuronal cell types.225 Also, this 
has helped to understand the cellular and molecular mechanisms that control the growth 
and differentiation of neural tissues. The mechanisms by which RA induces 
differentiation suggest binding to nuclear receptors, especially RAR-β226 mediated by a 
cytoplasmic receptor proteins as CRABPI and CRABPII.227 Moreover, many genes 
were reported to be over-expressed at early stages of differentiation, driven by RA 
under serum-free conditions like neural (Mash-1)228 and neuroectodermal (Pax-6),229 
endodermal (GATA-4, alpha-fetoprotein).230 
1.21.2.1 Neuroblastoma (NB) 
Neuroblastoma originates from precursor neuroblasts of the sympathetic nervous system. 
Unlike most other cancer types, neuroblastoma is characterized by a unique capacity for 
spontaneous complete regression, at least partly through neuronal differentiation, in a 
proportion of patients, and is therefore, regarded as a cancer due to cell differentiation 
blocking.231,232 The differentiated neuroblastoma cells show an increased expression of 
noradrenalin, adrenaline and neuron-specific enolase (NSE), differentiation markers 
which are employed for the diagnosis of neuroblastoma in patients.233 Using 
differentiation therapy shows minimal side-effects on normal cells, because normal non-
malignant cells are already differentiated. Many types of neuroblastoma are identified 
and they are classified basically according to cellular phenotypic characteristics into 
three types; sympathoadrenal neuroblasts (N), non-neuronal precursor cells (S) and third 
type (I) type. N-type is characterized as grow poorly attached aggregates of small, 
rounded cells with short neuritic processes, immature nerve cells and usually reliable for 
retinoic acid differentiation effect. Non-neuronal precursor cells (S) are flattened 
multipotent precursors to Schwann cells, melanocytes and glial cells and form the non-
neuronal lineage of the neural crest.  
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I-type cells are intermediate with respect to N- and S-type cells in terms of morphology 
and biochemical markers represent either a stem cell or an intermediate stage in the 
trans-differentiation between N- and S-type cells.234 SHSY5Y cell is the most popular 
cell line used for retinoic acid differentiation and can act as a good model for evaluation 
and understand the mechanism of cellular differentiation in neuroblastoma cell 
lines.235,236 ATRA was shown to induce concentration dependent morphologic 
differentiation and growth inhibition even despite removal of ATRA from media.237 The 
effects of retinoids in neuroblastoma cell lines are mediated by two classes of non-
steroid nuclear hormone receptors, the retinoic acid and the retinoic X receptors and 
mainly RAR-β.238,239 Retinoic acid induces SHSY5Y cellular differentiation through 
many possible mechanisms, including induction of RAR-β and CRABP-II genes 
expression for cellular differentiation and cellular metabolism control respectively.240 
The activity of RAR-β receptor is not a single activity but it was found that it works as 
heterodimer complex with RXR-α to induce cellular differentiation.238,241  
Furthermore, ATRA stimulates nerve growth factor (NGF)-dependent survival in 
sympathetic neurones which responsible for neurites outgrowth after prolonged 
retinoids treatment.237 Also, it induces the expression of TrkB, the receptor for the 
neurotrophins BDNF, NT-3 and NT-4/5 which are responsible for mature and functional 
neurons.242 On the other hand, ATRA is able to inhibit the cellular growth of 
neuroblastoma and SHSY5Y, specifically through induction of apoptosis pathway.138,243 
Moreover, the cell cycle blockage occur in G1/S phase through high protein levels of 
cyclin-dependent kinase inhibitors, p21 and p27Kip which inhibit cell proliferation after 
RA treatment.244 
1.21.2.3 PC12 cell line 
Pheochromocytoma of rat adrenal medulla-derived cell lines can be induced to express a 
sympathetic neuroblast-like phenotype by nerve growth factor treatment.245 A single 
exposure to RA was sufficient to cause neurite formation and inhibit cell division for a 
period of greater than 3 weeks, suggesting that ATRA may cause a long-term, stable 
change in the state of these cells.246 In contrast to the differentiating effects of nerve 
growth factor, retinoic acid treatment has a negligible effect on cellular morphology, 
however it enhanced the survival of PC12 cells following oxidative injury generated by 
H2O2 treatment in a manner that is qualitatively similar to that observed after nerve 
growth factor treatment.247 
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1.22 Cancerous cells non-neuronal modulation 
1.22.1 Acute promyelocytic leukaemia (APL) 
Acute promyelocytic leukaemia was first defined by a specific morphological feature 
and by a bleeding diathesis. Two features specifically define the disease: the 
morphology of the malignant cells; and the pathology of coagulation (coagulopathy).248 
Retinoids are able to induce terminal differentiation of leukemic cell lines, such as 
HL60 and U937 with high remission percentage.249 However, some limitations were 
observed with retinoids upon treatment of APL, which includes secondary resistance 
occurring in all patients treated with ATRA after a short time and relapsing within 6 
months.250 Also, lower plasma concentrations were initially noted at the time of relapse 
in patients with APL causing a shift in the ATRA dose-response curve in vitro because 
of up regulation in the expression of CRABP in relapsed patients.251 In addition there 
had been reported several adverse effects after clinical application of RA.252 Many 
approaches now try to solve these problems by either combining ATRA with other 
intensive chemotherapies253 to decrease resistance, or by using other RA isomers such 
as 9-CRA which is more potent than ATRA at lower doses to minimize adverse 
effects.254 
 
1.23 Neuronal cell markers 
Neurons are the basic signalling components of the nervous system. Consequently, a 
fundamental part of any attempt to understand how neurons work as a network enquires 
the investigation of functionally distinct cell types. For this point, immunohistochemical 
markers have emerged as one of the most valuable tools available to neuroscientists for 
studying cells expressing a neuronal phenotype, and moreover, collect information 
regarding their morphological characteristics and expression of specific proteins. In this 
section, some examples of neuro markers are explained that have some impact on the 
characterization and functionality of mature differentiated neurons. 
1.23.1 Neuron specific enolase (NSE) 
NSE is a glycolytic isoenzyme which is located in central and peripheral neurons, and 
neuroendocrine cells. There is also another enolase isoenzyme, non-neuronal enolase 
(NNE) found in glial cells. During the development of nervous system, NNE is 
dominant at the first stages of developing brain and later NSE is ascendant.255  
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ATRA is able to induce over-expression of mRNA for the gamma isoform of the 
neuronal glycolytic enzyme enolase in mouse neuroblastoma cells, in addition to 
extension of long neurites.256 Even pre-induction of SHSY5Y with ATRA improved 
neuronal differentiation of rat MSCs for a short time (24 hours) which was sufficient to 
induce high levels of NSE supporting that ATRA pre-induction promotes maturation 
and function of derived neurons at early stages.257 Sequential treatment of SH-SY5Y 
cells with retinoic acid and brain-derived neurotrophic factor was also very useful and 
sufficiently potent to give rise to fully differentiated, neurotrophic factor-dependent, 
human neuron-like cells with high level of NSE.258 NSE is also a very useful marker for 
the diagnosis of damaged neurons since the amount of chloride ion entering such 
damaged neurons is reduced affecting the activation and stability of NSE, and 
consequently there damaged cells will not need more for such NSE with reduced 
depolarization.255 
1.23.2 Neuronal nuclei (NeuN) 
It is a neuronal specific nuclear protein which is detected in most neuronal cell types 
throughout the central and peripheral nervous systems of adult mice. The appearance of 
the NeuN corresponds temporally to the withdrawal of neuronal cells from the cell cycle 
and/or with initiation of terminal differentiation.259 It is usually found complexed with 
Fox-3; a protein involved in the regulation of mRNA splicing and is expressed 
exclusively by neurons suggesting that NeuN plays a role in regulating neural cell 
differentiation and nervous system development.260 This marker secretion is 
characteristic for late stage maturation of neurons in the nervous system which can be 
related to the establishment of electrical polarity of the neural membrane, the onset of 
biosynthesis and release of neurotransmitter substances, and the establishment of 
synaptic circuitry.261 There is no specific correlation between the secretion of NeuN and 
ATRA activity on cells, except that ATRA can induce the release of arachidonic acid 
and its metabolites during differentiation and apoptosis in LAN-1 cells. Arachidonic 
acid is mainly released by the action of phospholipase A2 (PLA2) and phospholipase C 
(PLC)/diacylglycerol lipase pathways which are based mainly through nuclear 
stimulation signal. So it is suggested that retinoic acid-induced stimulation of 
phospholipase A2 activity is a retinoic acid receptor-mediated process that correlated 
with other nuclear stimulation includes NeuN.262 
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1.23.3 Microtubule associated protein-2 (MAP-2) 
This protein is related to a group of microtubule associated proteins and it is mainly 
found in the dendrites of neurons as it stabilizes microtubules in the dendrites of 
postmitotic neurons.263 It is also found in primary melanoma and could disrupt the 
dynamic instability of microtubules, inhibit cell division and prevent or delay tumour 
progression.264 ATRA induces cellular differentiation of P19 cells with higher level of 
MAP-2 due to several possible mechanism include the high level of acetylated P53 
which activate the promotor region of MAP-2, 265 synergistic activity of CRABP-
II/RAR266 and high level of SOX6 gene expression through Wnt-1 pathway of cell 
differentiation. 267 
 
1.23.4 β-Tubulin III (TUJ-1) 
Tubulins are a major building block of the microtubules, which are structural 
components of the cytoskeleton, attributed with roles in cell structure maintenance, 
mitosis, meiosis and intracellular transport among others. It is thought to be involved 
specifically during differentiation of neuronal cell types. 268 TuJ1 is found in the cell 
bodies, dendrites, axons and axonal terminations of immature neurons. One of the 
significant advantages associated with the use of immunohistochemical detection of 
TuJ1 is the degree to which it reveals the fine details of axons and terminations, and 
how it can be co-expressed with other early neuromarkers such as nestin for the 
indication of cellular differentiation. 269 It is also found that β-tubulin isotypes play a 
role in cell proliferation during neuronal differentiation.  
Cell viability in differentiated cells was examined after knocking down a specific β-
isotype before and after ATRA treatment of neuroblastoma cells, and it was found that 
undifferentiated cells, knocking down any single isotype, had no effect on viability. In 
differentiated cells, in contrast, the viability of cells in which βI was knocked down 
decreased by 53% compared to the control cells, which were transfected with negative 
control siRNA, while silencing βII or βIII had no effect on viability as shown by trypan 
blue assay. 270 Also, in P19 embryonal carcinoma cell lines after ATRA differentiation, 
TUJ-1 was increased in mRNA in the mitotic spindle of neuroblasts indicating early 
cellular differentiation. 271 
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1.23.5 Neurogenic differentiation 1 (NeuroD-1) 
The ability to generate new neurons provides the brain with an important level of 
plasticity for maintaining cellular homeostasis and potentially underlies a response to 
injury. However, cell-intrinsic transcription factors are also required to generate and 
promote the survival of newborn neurons that have not been yet fully elucidated. 272 So, 
NeuroD1 is one of the neuro markers predominantly expressed in the nervous system 
late in development, and is therefore, more likely to be involved in terminal 
differentiation, neuronal maturation and survival. 273 Various cell lines express NeuroD 
while being differentiated into neurons. For example, expression of NeuroD is observed 
during the differentiation of P19 teratocarcinoma cells, F11 human neuroblastoma cells, 
and HC2S3 immortalized neuronal progenitor cells and in murine cerebral cortical 
neurons. 272 In the case of the human neuroblastoma cell lines, the neurotrophin receptor 
TrkB (cognate receptor for BDNF neurotrophin) and the cyclin dependent kinase 
inhibitor p21 (Cip1) are concomitantly expressed. These two genes contain E-box 
elements within their promoters and can be activated by NeuroD and E47 in the absence 
of retinoic acid treatment. 274 In Cushing's disease, ATRA was found to be an effective 
treatment for regulation of ACTH secretion as RA, or synthetic retinoid AM-80, were 
able to activate RAR-α which consequently increases the expression of NeuroD1 and 
Tpit binding elements which activate the proopiomelanocortin (Pomc) gene expression 
to control secretion of ACTH secretion. 275 
1.23.6 Nestin  
Nestin is an intermediate filament protein that is known as a neural stem/progenitor cell 
marker. It is expressed in undifferentiated CNS cells during development, but also in 
normal adult CNS and in CNS tumour cells, however it is expressed in neural 
stem/progenitor cells and was downregulated upon differentiation. 276  Nestin also has an 
important function for proper survival and self-renewal of multipotent neural stem cells 
(NSCs) uncoupled with any of cytoskeleton neuromarkers. 277 Also, because nestin has a 
role in cell signalling, organogenesis and cell metabolism, it was found that it is a strong 
prognostic marker for glioma malignancy as it has been detected in primary CNS 
tumours but not in carcinoma metastases. 278 Studies showed that mouse ES cells can be 
differentiated into neural cells with low concentrations of ATRA within 2 days of 
differentiation with enhanced expression of nestin indicating early cellular 
differentiation. 279 
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Interestingly, in some cases such as neuroblastoma, combined therapy of ATRA and a 
proteasome inhibitor was effective at inducing cellular differentiation and inhibiting cell 
growth. However, after 5 days of recovery, both chemicals were withdrawn and the 
expression of stem cell markers such as Nestin, Sox2, and Oct4 were reduced, 
indicating a relapse and resistance occur which means early indication of stopping 
cellular differentiation.280 
 
1.23.7   Retinoic acid receptor–β (RAR-β) 
The retinoic acid receptor beta (RAR-beta) gene is a member of the family of retinoic 
acid/thyroid hormone receptor genes, encoding retinoic acid-inducible transcription 
factors. 281 It was shown that RA is a morphogen that has a development effect on many 
mammalian organs including CNS, limbs, craniofacial and the central axial skeleton. At 
early stages in the formation of an organ, the expression patterns were different in the 
epithelium, the adjacent mesenchyme and in mesenchyme more distant from the 
epithelium, suggesting a role for ATRA and RARs in epithelial-mesenchymal tissue 
interactions. RAR-β plays a role in mediating retinoid effects on the differentiated stage 
of these epithelia.  
CRBP expression domains showed a high degree of overlap with RAR-β and RAR-γ, 
and mutual exclusivity with CRABP expression domains where it can help with RAR-β 
to store and release retinol where high levels of ATRA are required for specific 
morphogenetic processes. 282 ATRA induces both a greater number of neurites as well 
as increased neurite length, as well as being capable of dictating their direction of 
growth and because ATRA is acting on the transcription level, it is observed that RAR-
β2 plays a crucial role in ATRA signal transduction, cellular differentiation and neurite 
outgrowth rather than a RAR-α or a RAR-γ specifically. 283 This was also confirmed by 
studying NGF, NT-3 and BDNF dependent neurons, isolated from recently developed 
embryo and by addition of RA to each of the neuronal classes only the NGF and NT-3 
dependent neurons responded by extending neurites due to the presence of RAR-β2 
which consequently was found over-expressed. 284 
RAR-β can work sequentially with other RAR types as RAR-α for the induction of 
cellular differentiation of adult forebrain neural progenitor cells. This was shown to 
occur through stimulation of fibroblast growth factor (FGF) and Sonic hedgehog (Shh) 
signalling pathways to promote neurogenesis in the SVZ region of the brain. 285  
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Also the order and timing of expression of these retinoic acid receptors was found to be 
essential during the neuronal cell differentiation from NPCs as astrocytes and 
oligodendrocytes are predominantly formed in the presence of activated RAR-α, 
whereas motoneurons are formed when RAR-β is activated. Two transcription factors 
involved in neuronal fate especially islet-1 and islet-2, which are members of the LIM 
homeodomain family. 286 Activated RAR-β up-regulates islet-1 expression, whereas 
activation of RAR-α can either act in combination with RAR-β signalling to maintain 
islet-1 expression or induce islet-2 expression in the absence of activated RAR-β. RAR-
γ cannot directly regulate islet-1/2 but can down-regulate RAR-β expression, which 
results in loss of islet-1 expression. 287 
The RAR-β2 isoform also has been associated with the tumour-suppressive effects of 
the retinoids due to use of the RAR-β gene promoter P2 which contains a strong RAR 
element, suggesting that RAR-β expression is up-regulated by retinoic acid and places 
RAR-β2 as a potential target gene underlying the growth-suppressive effects of retinoic 
acid.23, 288, 289 Furthermore, the loss of the RAR-β2 expression was reported during the 
early phases of cancer development including breast and lung tumors. 290 In contrast, the 
expression of RAR-α and RAR-γ as well as RXR-α are mostly unaltered in malignant 
tissues. This was confirmed by using ATRA or RAR-α/-β selective agonists with taxol 
to dramatically lower the effective dose of taxol needed to induce cytotoxicity of a wide 
range of tumour cell lines.291 
 
1.24 Raman spectroscopy analysis 
The ability to analyze single cells for their biochemical composition in terms of small 
molecule content, their proteomic and genomic content, or possibly even their 
epigenome has become increasingly more important as we continue to improve our 
understanding of cellular biology. Furthermore, most diseases initially start at the level 
of single cells (the initial cell that stopped responding to apoptosis signals, the initial 
point of a bacterial or viral infection). 292 Electron microscopy has a similarly wide 
range of analytical capabilities and achieves even higher spatial resolution, but a lack of 
a similarly wide range of contrast agents and typical sample preparation steps have 
limited it to providing snapshots of cells, rather than supporting extended live-cell 
imaging. 293 Secondary ion-mass spectrometry, another analytical imaging technique, 
destroys cells during the imaging process. 294  
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Raman micro spectroscopy is based on the dispersion and detection of photons that are 
in elastic scattering by molecular vibrations. When a monochromatic laser is used to 
probe a sample, most of the interacting photons undergo elastic scattering, while just a 
small fraction of photons scatters in elastically off molecular bonds and thereby 
exchanges energy with the vibrational energy levels of the molecules in the sample. 295 
 
1.24.1 Recent development in instrumentation for single cell Raman spectroscopy 
Sir Raman observed the first spectra of light that was scattered by molecular bonds by 
focusing sunlight into a sample by using a telescope with an 18 cm–diameter large lens. 
296 For filters, he used colored glasses. Even though in further experiments he began 
using mercury vapor lamps and more compact spectrometers to observe the inelastic 
light-scattering properties of gases and liquids. The performance of these components 
has changed remarkably. A lot of development in lasers, high-quality optical filters, and 
modern charge-coupled device (CCD) cameras and similar detectors had been occurred. 
Raman spectra can now be acquired directly from almost any biological sample, with 
little difficulty. 297, 298 To acquire Raman spectra of biological samples, there are some 
key requirements that have to be satisfied. Auto fluorescence from the sample and the 
sample substrate has to be minimized or creative ways for isolating the different signals 
have to be developed, and sample damage has to be avoided. The majority of Raman 
microspectroscopy systems are designed in a confocal-like optical arrangement, which 
helps acquire Raman spectra from very small volumes, on the order of 1 femtoliter (fL), 
and allows us to reject signals that are not generated in the very focus of the laser beam. 
Many biological applications of this technique are now implemented in vitro for the 
non-invasive characterization of specific metabolic states of eukaryotic cells, the 
identification and characterization of stem cells, and the rapid identification of bacterial 
cells. 299,300 
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1.25 Conclusion 
This review has shown three dimensional levels for the activity of retinoids toward their 
cognate target; retinoic acid receptors. The molecular level showed the crystallographic 
structure of these receptors, their ligand binding region, sequence alignment between 
the different RAR residues inside the binding sites responsible for their differential 
selectivity. The retinoid-receptor binding interaction level showed the overall dynamic 
rearrangement of this complex to mediate the biological activity of retinoids. Also, the 
impact of chemical structure modification in retinoids was studied and how this had 
effect on the difference in binding affinities to RAR and RXRs. The cellular and 
biological level also has shown the wide varieties and essential roles of retinoids as 
small molecules for the induction of cellular differentiation, highlighting the basic role 
of retinoids and their physiological roles in in vivo system. Natural retinoids have also 
some limitations for use in vitro, and this is why synthetic retinoids approaches become 
an essential step for the enhancement of stability and biological potency. Some 
members of these synthetic retinoids, in addition to the parent ATRA, have been shown 
to have potential therapeutic applications such as chemotherapy and chemo-preventive 
for cases as APL and neuroblastoma. Understanding the differences in biological 
activity between these molecules based on understanding the level of molecular 
interactions is essential for the future design and synthesis of further analogues of high 
potency and selective activity which can be used for clinical treatments. 
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1.26 Project aims 
 
This work aims to combine theoretical and practical tools in order to understand the 
relative differences between the new synthetic retinoid derivatives. In particular, this 
help in the design of new synthetic analogues with higher stability and potency. The 
compounds presented in this thesis are new synthetic derivatives with known higher 
laboratory stability to overcome the highlighted problems mentioned previously with 
ATRA and its isomers. 
 
The first part of this research will focus on the investigation of the molecular binding 
interactions of these compounds and their relative binding affinities to RARs using the 
combined molecular docking and receptor binding assay studies. All software will be 
updated and under the license of Chemistry Department, Durham University. 
Optimization of procedure will depend on ATRA and other characterized synthetic 
retinoid derivatives. 
 
The second part will evaluate the biological potency of these compounds in both 
prolonged time of exposure using TERA-2.cl.SP12 stem cells and short time of 
exposure using neuroblastoma cells. The compounds will be evaluated for their ability 
to induce cellular differentiation using many different biological assays. The major aim 
is to find a correlation between the investigated molecular binding interactions and the 
actual biological response. 
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Materials and methods 
2.1 Molecular modelling study of small synthetic retinoids into ligand 
binding domain of retinoic acid receptors (RARs) 
 
2.1.1 General procedures 
In this study, a combination between Spartan10 (Wavefunction Inc., Irvine, CA)301 and 
GOLDsuite 5.3302 modeling programs was carried out for preparation of files and 
docking processes. Also, visualization of the docked complexes and images captions 
were processed through the UCSF Chimera program.303  
 
2.1.2 Choosing PDB files from database 
All PDB files used for crystal structures of different RAR types were obtained from 
RCSB protein data bank website. PDB files for RAR subtypes were 3KMR for RAR-α, 
1XAP for RAR-β and 2LBD for RAR-γ. The selection of these files was based on 
specific parameters, suchas the quality of the atomic model obtained from the 
crystallographic data (R-Value and free R-value) and the diffraction pattern to show the 
fine details of the crystal (resolution value). 
 
2.1.3 Protein Sequence alignment 
Expasy SIB Bioinformatics Resource Portal and UniportKBwebsites were used for 
protein sequence alignments between the different isomers of RARs (-α, -β and –γ) to 
check for areas of similarities and differences inside the ligand binding domains, and 
also to find any deletion or insertion in PDB files used. The sequence alignment was 
expressed as percentage of the homology, sites of homology and classification of 
different amino acid types inside each sequence.  
 
2.1.4 Preparation of. Mol2 files 
Spartan10 was used to draw the 3D-structures of these synthetic retinoids compounds 
based on understanding their chemical structures provided and crystal structures 
available for some of them. 
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Computational calculation was the second step to provide a gateway for prediction of 
the different conformational states and identification of the lowest energy conformation. 
Semi-empirical molecular orbital model methods were 2-3 times faster for equilibrium 
and transition-state geometry calculations than quantum chemical methods, and hence, 
it was employed in conjunction with the Monte Carlo methods for calculation. The 
different conformational states based on calculation in vacuum using the AM1 method 
applied to systems with 100-200 atoms. The lowest energy conformation structure was 
saved as Mol2 files for further docking processes and it was checked that all bond types 
were correct and no bonds were missed. 
 
2.1.5 Setting up the protein files 
3.1.5.1 Protein hydrogen atoms, ionization states and tautomeric states 
All hydrogen atoms were added and geometric positions of residue were automatically 
optimized by the GOLD suite program. This step was useful since it allowed the GOLD 
suite program to control the protonation and tautomeric state of Asp, Glu and His 
residues during docking process. 
 
2.1.5.2 Handling water 
All water molecules were removed, including those inside the ligand binding domain, 
since by inspection, it was found that they were generally not linear/or >120° and > 2 
Å.304 
2.1.5.3 Flexible Side Chains 
The flexibility of the protein side-chain in RARs files was not explicitly controlled as 
this could give false positive results and increase the search space that must be explored, 
however, the GOLD program can allow torsional rotation of one or more residues 
around one or more of its acyclic bonds. 
2.1.6 Setting up the ligand files 
2.1.6.1 Essential steps in setting up a ligand 
The correct entry of all bond types was ensured and that no dummy atoms were present 
although this did not affect the docking prediction process.  
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The starting geometry of the ligand should be reasonably low in energy, since GOLD 
will not alter bond lengths or angles, or rotate rigid bonds such as amide linkages, 
double bonds and certain other iterations, such as trigonal nitrogen. 
 
2.1.6.2 Ligand hydrogen atoms, ionization states and tautomeric States 
The Spartan 10 program adds hydrogen atoms in the right positions to ligand structures, 
hence, GOLD deduces hydrogen-bonding abilities and ionization states of carboxylic 
and amide groups from the presence or absence of hydrogen atoms during the docking 
process. Although it is important to note that the negative charge on the carboxylic acid 
terminal group was considered during calculation to be de-localized rather than 
protonated as this is more realistic with respect to physiological environments. 
 
2.1.6.3 Ligand geometry, conformation and stereochemistry 
The ligand conformation was varied by GOLD during the docking process so that the 
starting conformation therefore did not matter. However, it was essential to start with 
the minimum energy conformation. 
 
2.1.6.4 Ligand flexibility 
Allowing ligand bond flexibility was similar to the naturally occurring systems in nature 
either by flipping ring corners, amide bonds, planar bonds, pyramidal nitrogen and 
protonated carboxylic acid. 
 
2.1.7 Setting and releasing constraints 
Specific bond constrains were not added or specified between ligand and RAR protein 
residues to allow free binding interactions for the accurate determination of different 
binding possibilities. 
 
2.1.8 Choice of geometric algorithm 
GOLD offers a lot of different algorithms: GoldScore, ChemScore, ASP, protease 
inhibitors, etc. Chemkinase was chosen as the genetic algorithm function to allow 
details detection of Population Size, Selection Pressure, Number of Operations, Number 
of Islands, Niche Size and van der Waals and Hydrogen Bonding Annealing Parameters. 
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2.1.9 Sumaary for the steps used for ligand, protein and docking preparations: 
 For the retinoid structuretion preparation: 
1- Retinoic acid and the synthetic analogues were drawn using ChemDraw and 
transformed into 3D-structures using Spartan 10 software. 
2- Semi-empirical molecular orbital modelling using geometric distribution was applied 
to calculate potential energies, molecular structures, geometry optimizations, atom 
co-ordinates, bond length and bond angles.  
3- AM1 method of calculation was used in vaccum for 100 cycles and all structures 
were calculated with neutral charge. The lowest energy conformations for each 
structure were saved as a Mol2 file for further examination in GOLD suite software 
to avoid any un-defined atoms in the structure.  
4- The calculated lowest energy conformations were compared to the X-ray crystal 
structures to find out that the starting point of ligand docking to receptors. 
 For the protein structure preparation: 
1- All Pdb files were checked for resolution, R- and free R- values to ensure that they 
are within the standard values. 
2- All water molecules were removed, including those inside the ligand binding domain. 
3- All hydrogen atoms were added and geometric positions of residue were 
automatically optimized by the GOLD suite program. 
4- The binding site sizes of different RARs were identified based on the structure 
already present ligands inside the receptor within range of 15 Å. 
 For the docking of both ligand and protein files using GOLD suite software: 
1-  Chemplp was chosen as the fitness scoring function and Chemkinase as the genetic 
algorithm function to allow detailed detection of hydrogen bonding, torsion angles, 
van der Waals forces and any short contacts. 
2- The detection of the centre for the ligand binding pocket was based on the 
previousely identified docked retinoid structure in the choosen Pdb files. 
3- Early termination was not allowed so that the program could find all available 
solutions within 10,000 population sizes. A Cluster size of 2 was also specified to 
increase the gap between different diverse solutions but within the acceptable range 
of 2.0 Å. 
4- Each retinoid- RAR docked complex was export as Pdb file and explored using 
Chimera software. 
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2.2 Receptor binding assay of small synthetic retinoids molecules to 
their retinoic acid receptors (RARs) 
 
2.2.1 General procedure 
All reactions were performed under air, in a dark room to avoid degradation of retinoic 
acid. RAR kits were stored under the conditions stated by the manufacturer. 
 
2.2.2 LanthaScreen™ TR-FRET retinoic acid receptor coactivator assay 
All reagents were purchased from Life Technologies®and used without further 
purification. Dry DMSO was purchased from Sigma Aldrich as molecular biology grade 
with purity ≥99.9%. 
 
2.2.3 Analytical techniques 
The TR-FRET analyses were performed on a PHERAstar FS Microplate Reader using a 
dedicated UV-laser for TR-FRET measurements, validated in March 2012. The assays 
were performed in black, 384-well assay plates, low-volume and round-bottom (non-
binding surface) assay plates from Thermo Scientific's Nunc ® range. 
 
2.2.3.1 Principle of FRET and TR-FRET assay 
The principle of the TRFRET assay is based on using suitable pairs of fluorophores 
which are brought within close proximity of oneanother. Excitation of the first 
fluorophore (the donor) can result in energy transfer to the second fluorophore (the 
acceptor).  
This energy transfer is detected by an increase in the fluorescence emission of the 
acceptor and a decrease in the fluorescence emission of the donor. The TR-FRET assay 
uses a long-lifetime lanthanide chelate as the donor species. Lanthanide chelates are 
unique in that their excited-state lifetime (the average time that the molecule spends in 
the excited state after accepting a photon) can be of the order of a millisecond or longer. 
TR-FRET assays are performed by measuring FRET after a suitable delay, typically 50 
to 100 microseconds after excitation by a flash lamp excitation source in a microtiter 
plate reader.  
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This delay not only overcomes interference from background fluorescence or light 
scatter, but also avoids interference from direct excitation due to the non-instantaneous 
nature of the flash lamp excitation source.The lanthanide used here in these TR-FRET 
assays for HTS is terbium and the common fluorophore is fluorescein as the acceptor. 
(Fig.2.1). 
 
 
 
 
 
 
 
 
 
Figure 2.1: Principle of the nuclear receptor (NR) agonist dependent co-activator peptide recruitment 
assay. The purified ligand binding domain of RAR is tagged with GST which is attached with terbium 
anti-GST antibody and upon binding with retinoid ligand, induction of conformational change occurs in 
the ligand binding pocket. This allows the second consequent event to occure, where the tagged co 
activator with fluorescen attaches the ligand bind domain surface. The close proximity between 
fluorescen and terbium allows the excitation-emission signal to propagate and hence, can be measured as 
indication for binding interaction of retinoids with RAR LBD. The figure adopted from the kit manual at 
Invitrogen website. 
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2.2.4 Kits components: According to (Table 2.1) 
 
Table 2.1: Kit component for the three RARs-types (-α,-β and-γ). 
Component Composition Amount Storage 
temperature 
*Fluorescein 
coactivator305 
100 µM in 10 mM Na2CO3, pH 
11.0  
Sequence: 
LPYEGSLLLKLLRAPVEEV 
 
100 µl 
 
–20°C 
 
**RAR LBD, GST 
RAR ligand-binding domain in a 
buffer (pH 8.0) containing protein 
stabilizing reagents and glycerol. 
See Certificate of Analysis for the 
recommended molar concentration 
for this kit. 
 
75 pmol 
 
-80°C 
 
LanthaScreen™ Tb 
anti-GST antibody 
Terbium labeled anti-GST antibody 
in HEPES buffered saline (137 
mMNaCl, 2.7 mMKCl, 10 mM 
HEPES pH 7.5). See Certificate of 
Analysis for lot specific 
concentration 
 
25 µg 
 
–20°C 
***TR-FRET Co-
regulator Buffer 
Proprietary buffer (pH 7.5) 
including  
20% glycerol 
 
25 ml 
 
4°C 
DTT, 1 M In water 1 ml –20°C or –
80°C 
 
* Fluorescein-D22 (RAR-α), Fluorescein-SRC2-2 (RAR-β), Fluorescein-PGC1a (RAR-γ). 
** RAR LBD (-α,-β and-γ). 
*** Buffer D (RAR-α), Buffer E (RAR-β), Buffer C (RAR-γ). 
 
 
General settings: 
 
 
 
 
 
 
2.2.5 Testing up the instrument (Kit validation) 
2.2.5.1 Setting up the instrument 
Instructions were available from (www.invitrogen.com/insrumentsetup) to obtain the 
specific set-up guide for the instrument. The settings are shown here, were optimized 
specifically for LanthaScreen® TR-FRET assays. 
 
Excitation 340 nm filter (30 nm bandwidth) 
Emission 520 nm filter (25 nm bandwidth) 
Emission 490 or 495 nm filter (10 nm bandwidth) 
Delay time 100 µS 
Integration time 200 µS 
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2.2.5.2 Preparation of the Acceptor (LanthaScreen® fluorescein substrate or 
peptide) 
1- Preparation of 30 μM acceptor stock solutions: 
Fluorescein substrate/ 
peptide 
Stock 
concentration 
Dilution to prepare a 30 μM 
solution 
Fluorescein-poly GT 30 μM No dilution needed 
Fluorescein-poly GAT 30 μM No dilution needed 
Fluorescein peptides 
for kinases 
Various  Add 6μL of 1mg/mL peptide stock 
to 94μL of TR-FRET dilution 
buffer.(1mg/mL with a MW 
=2KDa= 500μM 
Fluorescein Co-
regulator peptides for 
NRs 
100 μM Add 30μL of 100 μM peptide stock 
to 70μL of TR-FRET Co-regulator 
buffer. Do not add DTT 
 
2- Preparation of 120 μL of each 2X acceptor concentration from the 30 μM stock 
96- well plate  A1 B1 C1 D1 E1 
2X acceptor 
concentration 
10,000 
nM 
5,000 
nM 
2,500 
nM 
1,250 
nM 
400 nM 
Final 1X acceptor 
concentration 
5,000 nM 2,500 
nM 
1,250 
nM 
625 nM 200 nM 
Volume TR-FRET 
dilution buffer or 
NR Co-regulator 
buffer 
80 μL 100 μL 110 μL 115 μL 117.5 μL 
Volume 30 μM 
acceptor (prepared 
above) 
40 μL 20 μL 10 μL 5 μL 2.5 μL 
 
 
2.2.5.3 Preparation of the donor (Tb-chelates labelled antibody) 
A 2X stock solution of Tb-chelates at 125 nM was prepared that resulted in a final assay 
concentration of 62.5 nM. This method relied on the concentration of Tb-chelates, NOT 
on the concentration of antibody. 
Example calculation:  for preparation of 1,000 µL of Tb-chelate:    
Tb-antibody = 0.5 mg/mL (3.3 µM) with a chelate: antibody ratio of 11   
Chelate:  stock = 3.3 µM x 11 = 36.3 µM = 36,300 nM.          1X = 62.5 nM; 2X = 125 
nM 
Hence, 3.4 μL of 36,300 nM of stock solution was added to 996.6 μL of TR-FRET 
dilution buffer or NR co-regulator buffer. 
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2.2.5.4 Addition of the reagents to the 384-well plate and read 
For the donor, 10 µL of 2X Tb-chelates was transferred to rows A through J and 
columns 1 through 5 of the 384-well assay plate. Since only a single concentration was 
required this solution was transferred with a multichannel pipette from a basin to all 50 
wells. 
For the acceptor, 10 µL of the indicated concentration of 2X acceptor was transferred to 
the rows A-J of the corresponding column of the 384-well. Then the specified 
wavelengths were recorded. The raw data was plotted (ratios vs. acceptor concentration 
nM) and normalized data (normalized ratio vs. acceptor concentration nM) and finally 
calculation of the "assay window" in terms of Z'-factor.306 
 
2.2.6 Agonist assay (for RAR-α,-β and-γ) 
3.2.6.1 Preparation of complete TR-FRET co-regulator buffer and agonist controls 
Note:  The RAR-LBD was thawed prior to use and all other components were 
equilibrated to room temperature. 
1. A complete TR-FRET co-regulator buffer was prepared by adding 1 M DTT to TR-
FRET co-regulator buffer for a final concentration of 5 mM DTT. This was prepared 
fresh daily as required. 
Note:  complete TR-FRET co-regulator buffer was kept at room temperature for the 
preparation of all reagents except for 4X RAR -LBD, which was prepared with cold 
buffer.  
An appropriate volume of buffer was reserved on ice for preparation of 4X RAR alpha-
LBD (see step 8 for concentrations and example volumes needed). 
2. For the “no agonist” controls, DMSO was added to Complete TR-FRET Co-regulator 
Buffer for a final concentration of 2% DMSO. 10 μl of this solution was added to row 
C, columns 1–24 of a 384-well assay plate  
For example: Add 10 µl of DMSO to 490 µl of Complete TR-FRET Co-regulator 
Buffer D. 
3. Preparation of control agonist solution (all-trans retinoic acid is recommended) was 
done at 100X of the final desired maximum starting concentration-using DMSO.  
For example: If the final desired maximum starting concentration of agonist is 1 µM, so 
a solution of 100 µM agonist was prepared in DMSO. 
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4. For the “maximum agonist” controls, 100 X agonist solution from step 3 was diluted 
to 2X using Complete TR-FRET Co-regulator Buffer. 10 μl of this solution was added 
to row D, columns 1–24 in the 384-well assay plate. 
For example: 10 µl of 100X agonist solution was added to 490 µl of Complete TR-
FRET Co-regulator Buffer. 
 
2.2.6.2 Preparation of 2X agonist dilution series 
Note: Although steps 5 and 6 below required more pipetting than other methods of 
preparing a serial dilution of agonist, it has been found that this approach provided a 
robust method for preparation of the dilution series without problems due to agonist 
solubility. 
5. Preparation of 12-point 100X dilution series of agonist in a 96-well plate was done by 
serially diluting the 100X agonist solution from step 3 three-fold using DMSO.  
For example: 20 µl of DMSO was added to wells A2–A12 in a 96-well polypropylene 
plate. To well A1, 30 µl of the 100X agonist solution prepared in step 3 was added.  
Three-fold serial dilution was performed by transferring 10 µl of the 100X agonist 
solution from well A1 to the 20 µl of DMSO in well A2, mixed by pipetting up and 
down and repeated for wells A2–A12. 
6. Each 100X agonist serial dilution from step 5 was diluted to 2X using Complete TR-
FRET Co-regulator Buffer.   
For example: 5 µl of each of the 100X agonist serial dilutions from row A of the 96-
well plate (wells A1–A12) was transferred to row B (wells B1–B12).  
245 µl of Complete TR-FRET Co-regulator Buffer D was added to each well in row B 
of the 96-well plate and mixed by pipetting up and down. 
7. 10 µl of each of the 2X agonist serial dilutions was transferred to duplicate columns 
of rows A and B of a 384-well assay plate. 
For example: columns 1 and 2 of rows A and B of the 384-well assay plate received 10-
µl aliquots from well B1 of the 96-well assay plate, wells A and B in columns 3 and 4 
of the 384-well assay plate received 10-µl aliquots from well B2 of the 96-well assay 
plate, and so on. 
 
 
 
Chapter II 
57 
 
 
2.2.6.3 Preparation of 4X RAR –LBD (differ from-α,-β,-γ) 
8. 4X RAR-LBD was prepared using cold Complete TR-FRET co-regulator buffer in 
step 1. The recommended molar concentration of RAR for the kit was listed on the 
Certificate of Analysis (Table 2.2).  
 
Table 2.2: Molar concentration for the three RARs-types (-α,-β and-γ). 
RAR 
type 
Stock 
solution 
Recommended 
final solution 
Preparation procedure 
RAR-α 7900nM 3.5nM 4X concentration=14nM 
Dilution factor 1RARα: 564.3 buffer 
RAR-β 6100nM 2.5nM 4X concentration=10nM 
Dilution factor 1RARβ: 610 buffer 
RAR-γ 5430nM 3nM 4X concentration=12nM 
Dilution factor 1RARγ: 452.5 buffer 
 
Note: RAR-LBD stock or dilutions was not vortexed. It was mixed by pipetting or 
gentle inversion. This solution was kept on ice until needed for use in the assay.   
9. 5 μl of 4X RAR -LBD was added to rows A–D, columns 1–24 of the 384-well assay 
plate. 
 
2.2.6.4 Preparation of 4X specific Fluorescein type / 4X Tb anti-GST Antibody 
(differ from α, β, γ) 
10. Solution containing 200 nM specific fluorescein type (4X) and 20 nM Tb anti-GST 
antibody (4X) was prepared using Complete TR-FRET Co-regulator Buffer at room 
temperature. This stock concentration of fluorescein differs according to RAR types in 
(Table 2.3). 
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Table 2.3: stock concentration of fluorescein for the three RARs-types (-α,-β and-γ). 
Fluorescein type Stock 
solution 
Recommended 
final solution 
Preparation procedure 
Fluorescein-D22 
(RAR-α) 
100 µM 50nM 4X concentration=200nM 
Dilution factor 1D22: 500 
buffer 
Fluorescein-SRC2-2 
(RAR-β) 
100 µM 0.125 µM 4X concentration=0.5 µM 
Dilution factor 1SRC2-2: 
200 buffer 
Fluorescein-PGC1a 
(RAR-γ) 
100 µM 0.25 µM 4X concentration=1µM 
Dilution factor 1PGC1a: 
100 buffer 
 
Also the concentration of Tb anti-GST antibody is indicated on both the vial label and 
the Certificate of Analysis of RAR types kits (1 mg/ml = ~6.7 µM antibody).  
For example in RAR-α: Add 4 µl of 100 µM fluorescein-D22 and 6 µl of 6.7 µM Tb 
anti-GST antibody to 1990 µl of Complete TR-FRET Coregulator Buffer D.  
11. Add 5 μl of 4X peptide/4X antibody solution to rows A–D, columns 1–24 of the 
384-well assay plate. 
 
2.2.6.5 Plate incubation and reading 
12. Gently mix the 384-well plate on a plate shaker and incubate at room temperature 
protected from light. The plate may be sealed with a cover to minimize evaporation.   
13. Read the plate after 4-6 hours at wavelengths of 520 nm and 495 nm, using the 
instrument settings.  
 
2.2.7.6 Agonist assay—data analysis 
The TR-FRET ratio was calculated by dividing the emission signal at 520 nm by the 
emission signal at 495 nm. Then, a binding curve was generated by plotting the 
emission ratio vs. the log [ligand]. The data was expressed as a ratio of signal at 520 nm 
and 490 nmfitted to a three-parameter ligand-binding sigmoid equation shown below 
using Sigmaplot (version 12.5, Systat Software Inc., San Jose CA) and normalized to 
the lower asymptote of each binding curve. The symmetrical sigmoidcurves produced 
were varied in the location of the mid-point (EC50) and upper asymptote. 
f = min + (max-min)/(1+10^(logEC50-x)) 
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2.3 Biochemical model of the TR-FRET binding assay 
The readout of the LanthaScreen TR-FRET binding assay was based on the signal 
generated from the interaction between a terbium-labelled anti-glutathione-S-transferase 
(GST) antibody and a fluorescein-labelled coactivator peptide terbium-labelled anti-
GST bind the LBD fusion protein, thus the output of the assay relied on two binding 
interactions: ligand with LBD and ligand-bound LBD with the co-activator peptide. As 
both interactions were affected by the fit of ligand to the binding pocket of the LBD, 
biochemical pathway simulator COPASI307  was used to build a simple model of how 
the FRET signal output in the assay varied according to differential changes in the 
kinetics of the two binding interactions. Reactions were modelled deterministically 
using mass-action kinetics described by ordinary differential equations (ODE) within 
COPASI. 
The species in the model: 
Ligand  (L),  Receptor  (R),  Ligand-Receptor complex  (LR), Co-activator (Co.A) and 
Ligand-Receptor Co-activator complex (LRCo.A). 
The model is based on two reversible reactions 
 
 
* Where k1, k2 and k3, k4 are the rate constants controlling the rate of LR and LR.CO.A complex 
formation, respectively. 
Thus: 
k1 [L] [R] = k2 [LR] 
And k1/k2  = [L] [R]/[LR] 
Similarly k3 [LR] [CO.A] = k4 [LRCO.A] 
And therefore k3/k4 (Kd) = [LR] [CO.A]/[LRCO.A] …………….….…………….. (2)308 
All species concentrations were expressed as µmol. L-1 and changed during the 
simulation by dynamic evaluation of ODEs 
Starting concentrations;  
L= 10 µmol. L-1  to 0.03 nmol. L-1, R= 0.0035 µmol. L-1 (defined by the TR-FRET 
assay formulation), CO.A = 30 µmol. L-1 (defined by the TR-FRET assay formulation), 
LR = 0 µmol. L-1 and LRCo.A = 0 µmol. L-1.Steady states for LRCo.A were derived 
from the range of ligand starting concentrations (10 µmol. L-1  to 0.03 nmol. L-1) using 
the Steady State and Parameter Scan functions within COPASI. 
*k2 * k4 
 
             L+R      LR              LR+CO.A   LRCO.A …………………. (1) 
*k1 *k3 
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2.4 Biological characterization of small synthetic retinoids molecules 
 
2.4.1 General procedure 
All laboratory research work was done under safe laboratory practice guidelines to 
minimize any chemical and biological hazardous. Handling and dosing of synthetic 
retinoids especially retinoic acid occurred using latex double gloves and only under 
reduced light to prevent isomerization and degradation. 
 
2.4.2 Retinoid stock solutions 
All retinoid compounds were prepared using tissue culture grade DMSO solvent 
(Sigma) as 1 ml of 10 mM stock solutions of soluble compounds. Small aliquots of ~ 
300 µL in each tube were stored either at -80 ˚C for long time storage or at -20 ˚C for 
short time storage and thoroughly defrosted in a water bath set at 37 °C prior to use. 
Overview of different synthetic retinoids used in this study in addition to the molecular 
modeling is mentioned in the list of retinoid chemical structures. 
 
2.4.3 Cell cultures 
2.4.3.1 TERA2.cl.SP12 EC stem cells 
Human pluripotent TERA2.cl.SP12 embryonic carcinoma stem cells were cultured as 
2D in T25 (BD falcon) flasks using the standard protcol.309,221 The components of 
growing matrix media wereDulbecco’s modified Eagle’s medium (DMEM, high 
glucose, Lonza BE12 614F) supplemented with 10 % fetal calf serum (Sigma 10270), 
2mM L-glutamine (Lonza BE17 605F) and 100 active units of Penicillin and 
Streptomycin (Lonza DE17 602F). Cells were incubated at 37 °C in a 5 % CO2 
humidified atmosphere. Media was kept in water bath at 37 °C before use for feeding 
cells every day till after 3-4 days the cells will reach 95% confluence and must be 
passage during acid washed sterile glass beads (Fisher Scientific G/0300/50) in 3ml 
fresh warm media and split 1:3 into T75 flasks for further incubation and proliferation. 
Cell Passage numbers from 20 to 36 were used as these passages were readily available 
in the laboratory at the time of carrying out this research using this cell type and all the 
passages showed the same characteristic embryonic carcinoma stem cell morphology. 
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2.4.3.2 SHSY5Y neuroblastoma cells 
SHSY5Y cells were cultured according to standard procedure,310 in brief the 
components of matrix media are Dulbecco's modification of Eagle's medium F12-Ham 
containing 2mM L-glutamine, supplemented with 10% fetal bovine serum (FBS) and 
were grown at 37 °C with 5% CO2 in air. For cell suspensions, cell flasks were treated 
with 3ml sterile PBS and incubate flasks at cell incubator at 37 °C for 3-5 minutes for 
cell detachment. Centrifugation of the cell suspensions were done at 1000 rpm for 3 
minutes, PBS was removed , re-suspended in fresh media and split into 1:3 into T75 
flasks (Sigma) and incubated for further cell proliferation. Cell passage numbers from 
20 to 30 were used experimentally without difference in reproducible data. 
 
2.4.3.3 Storage of cells 
Once cell growth reached 95% confluence, passaging of cells was carried out using 
either acid washed glass beads for TERA-2.cl.SP12 or sterile PBS solution for SHSY5Y 
to get single cell suspension solution in 15 ml falcon tubes.  
Centrifugation was done at 1000 rpm for 3 min at 4 ˚C and any media was carefully 
aspirated leaving cell pellets in the bottom of the tube. The cell pellets were re-
suspended in freezing solution (FBS supplemented with 10% DMSO) with good 
dispersion very well. Frozen solution contains 1ml of each cells were transferred into 
cryovials and slowly frozen at – 80 ˚C for one day using Dr.freeze (filled with 95% 
isopropanol) and then transferred to permanent storage at -150 ˚C. 
 
2.4.4 Preparation of control cells for mono-layer 2D cell cultures 
Control cells represent those were treated with DMSO organic solvent at concentration 
not more than 0.1%. The dilution factor used for DMSO all over the experiments was 
similar to that used for dilution of retinoid solutions. After 95% confluency of cells, 
either TERA-2.cl.SP12 or SHSY5Y cells were seeded with the recommended starting 
concentration of cells for another 24 hours in new T25 flask under the same incubation 
conditions. The next day, cells were treated with 0.1% DMSO and kept for the time 
required for each individual experiment with changing the media with fresh DMSO 
when necessarily. 
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2.4.4 Induction of differentiation protocol for mono-layer 2D cell cultures using 
different retinoids compounds  
2.4.4.1 For TERA-2.cl.SP12 stem cell line 
At 95% confluence, cells in T75 flasks, single cell suspension were obtained as 
mentioned previously and counted using haemocytometer using trypan blue dye and 
specific number of cells (as well be mentioned for each experiment) was seeded in 
warm media 37 °C into either T25 flask (for flow cytometry and gene expression 
experiments) or 6-well Nunc ®plates (for Immunecytochemistry, cytotoxicity and 
florescent imaging experiments) and incubated at 37 °C in a 5% CO2 humidified 
atmosphere for 12-24 hours before cellular induction of differentiation. Cell 
flasks/plates were observed next day for attachment with the same morphology of EC 
stem cell without any spontaneous differentiation. Dilution of 10 mM of each synthetic 
retinoids solutions were done inside the tissue culture hood to 10 µM working solution 
using pre-wormed tissue culture media. The old media were aspirated and fresh 
retinoids media were added to each flask/well with incubation in standard condition 
mentioned before and changing media every 3-4 days for 7, 14 and 21 days according to 
each experiment requirement. Each experiment was done in triplicate for three 
independent experiments.  
 
2.4.4.1 For SHSY5Y cell line 
Single cell suspensions were obtained by previously mentioned techniques and single 
cells were counted by haemocytometer using trypan blue dye and specific number of 
cells (as well be mentioned for each experiment) was seeded in warm media 37 °C into 
either T25 flask (for gene expression and Raman analysis experiments) or 6-well Nunc 
®plates (for cytotoxicity experiment) and incubated at 37 °C in a 5% CO2 humidified 
atmosphere for 12-24 hours before cellular induction of differentiation. Cell 
flasks/plates were observed next day for attachment with the same morphology of 
polygon shape of N-type SHSY5Y neuroblastoma cells. Dilution of 10 mM of each 
synthetic retinoid solutions were done inside the tissue culture hood to different working 
concentration solutions using pre-wormed tissue culture media. The old media were 
aspirated and fresh retinoids media were added to each flask/well with incubation in 
standard condition mentioned before and changing media every 3-4 days for the definite 
time scale of each experiment. 
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2.4.5 Flow cytometry analysis of TERA-2.cl.SP12 stem cell line 
Cell surface antigens expression specific for TERA2.cl.SP12 stem cells and their 
retinoids induced differentiation derivatives were analysed by extracellular flow 
cytometry. Primary monoclonal antibodies specific to the antigens associated with 
pluripotent stem cells globoseries glycolipid (SSEA-3, University of Iowa Hybridoma 
Bank), keratan sulfate-related (TRA-1-60, Abcam) and neural cell marker (A2B5, R&D 
Systems)were used to investigate the differentiation status of EC cells and their 
derivatives grown in media enriched with test retinoids. A suspension of 0.25 x 106 live 
cells was used as a starting population in each T25 flask for induction of cellular 
differentiation and after 7 days for retinoid treatment or 0.1% DMSO control cells, 
single EC cell suspensions were obtained and centrifuged at 1000 rpm and re-suspend in 
wash buffer (0.1% BSA in PBS) and added to a 96-well plate at concentration of 0.2 x 
106 cells with round bottom as a suspension for incubation with primary antibodies 
according to (Table 3.4). This was followed by several washes with wash buffer and 
then incubation with FITC-conjugated secondary antibody IgM (Sigma, 1:128). 
Labelled cells were analysed in a Guave EasyCyte Plus System (Millipore) flow 
cytometer. Thresholds determining the numbers of positively expressing cells were set 
against the negative control antibody P3X (generous gift from Prof. P. Andrews, 
University of Sheffield). Guava Express Pro and WinMDI flow cytometry software 
were used for data acquisition and analysis respectively. 
 
Table 3.4: Primary antibodies and its corresponding working dilutions for extracellular flow cytometry analysis 
Primary monoclonal antibody Dilution 
SSEA-3 1:10 
TRA-1-60 1:50 
A2B5 1:40 
 
2.4.6 Genes expression analysis of both TERA-2.cl.SP12 stem cell and SHSY5Y 
neuroblastoma cell lines 
Real time PCR was carried out on both cell lines lysates immediately after treatment 
with 0.25% trypsin–EDTA. For TERA-2.cl.SP12, cells were seeded at a density of 
1x106 cells per 25 cm2 flask (BD falcon) 12-24 hours before treatment with different 
retinoids solutions at concentration of 10 µM for 3, 5 and 7 days. Control cells had the 
same treatment condition with 0.1% DMSO. 
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For SHSY5Y, cells were seeded at a density of 1 x 106 cells per 25 cm2 flask (Sigma) 
12-24 hours before treatment with different retinoids solutions or DMSO as control cells 
at different concentrations (1, 0.1, 0.01 and 0.001 µM) and at different time scales 2-12 
hours. Commercial RNA extraction kits (Qiagen) and reverse transcription (Applied 
Biosystems) kits were purchased and procedures used according to manufacturer 
instructions.Purity of RNA samples were determined using nanodrop absorbance at 230, 
260 and 280 nm. 260/280 and 260/230 ratios were measured and should be 1.8-2.2 and 
any samples higher or lower than this were removed and repeated.  
 
RNA integrity was also checked using formaldehyde denaturated agarose gel. This was 
followed by reverse transcription to obtain cDNA. Also, real time PCR was performed 
using the TaqMan® Universal PCR master Mix (Life technologies) and TaqMan® gene 
expression system (Applied Biosystems) based on probe sets to the specific genes to be 
analysed. PAX-6, NeuroD1 were used for TERA-2.cl.SP12 cell genes analysis.RAR-β, 
CYP26-A1, RAR-α and RAR-γ were used for SHSY5Y cell genes analysis. GADPH 
and ACTB were used as internal reference genes for TERA-2.cl.SP12 and SHSY5Y, 
respectively. Data were normalized against both the internal reference genes and control 
cells based on 2–ΔΔCt method and equation as follow; 
Ct GOI s - Ct norm s = ΔCt sample 
 Ct GOI c - Ct norm c = ΔCt calibrator 
ΔCt sample - ΔCt calibrator = ΔΔCt 
Fold difference = 2-ΔΔCt 
Where; CtGOI s (Ct value of unknown sample of gene of interst), Ctnorm s (Ct value of 
internal normalizing gene) and CtGOI c (Ct value of control sample of gene of interst). 
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2.4.7 Immunocytochemistry analysis of TERA-2.cl.SP12 stem cells 
TERA-2.cl.SP12 cells grown on poly-D-lysine (25µg/ml) coated cover slips 22 x 22 
mm, high precision (170 ± 5μm) in 6-well plates for 12-24 hour at 5000 cells per well 
12-24 hours before treatment with either 0.1% DMSO as positive control or 10µM of 
different retinoids solution for 7, 14 and 21 dayswith changing media ever 3-4 days. The 
cells then were fixed in 4% para-formaldehyde (PFA) in PBS for 30 min at room 
temperature and rinsed with PBS. One set of experiment used for extracellular marker 
A2B5 (R&D systems diluted 1: 100) staining and the other set used for intracellular 
staining as the cell membranes were permeabilised by treatment with 1% Triton- X-100 
(Sigma) in PBS for 10 min at room temperature. Nonspecific labelling was blocked by 
incubation on a bench-top shaker (Fischer Scientific) for 1 h at room temperature with a 
solution of 1% goat serum (Sigma) containing 0.2% Tween-20 (Sigma) in PBS. Primary 
antibodies were diluted in blocking solution and incubated with cells for 1 h at room 
temperature according to (Table 2.5). After washing three times for 15 min with PBS, 
cells were incubated for 1 hour in the dark with secondary antibody according to (Table 
2.6). Hoechst 33342 nuclear staining dye (Molecular Probes, 1:1000) was used in 
blocking solution after secondary antibody staining step for nucleus staining.Stained 
coverslips were inverted and mounted on microscope slides in Vectashield Mounting 
Medium (Vector Laboratories) and the coverslips sealed using nail varnish. Stained 
cover-slips were examined using a fluorescence confocal microscope (Leica SP5CLSM 
FLIM FCCS).  
 
Table 2.5: Primary antibodies and its corresponding working dilutions, sources for immunocytochemistry 
staining. 
Primary monoclonal antibody Dilution Source 
β-III tubulin antibody (TUJ-1) 1:200 Affymetrix eBioscience 
Cytokeratin-8 (CK-8) 1:500 Affymetrix eBioscience 
 
 
Table 2.6: Secondary antibodies and its corresponding working dilutions, sources for 
immunocytochemistry staining. 
Secondary monoclonal antibody Dilution Source 
Anti-mouseFITC-conjugated secondary antibody 
IgM for A2B5 
1:128 Sigma 
Anti-mouse Alexafluor®488 IgG for TUJ-1 and 
CK-8 (green florescence) 
1:600 Invitrogen 
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2.4.7.1 Leica SP5 confocal laser scanning microscope 
All experiments were done on poly-D-lysine (25 µg/ml) coated cover slips 22 x 22 mm, 
high precision (170 ± 5 μm) in 6-well plates for specific time and concentration scale 
(as mentioned for each experiment). After the experiments finished, cells were then 
fixed in 4% para-formaldehyde (PFA) in PBS for 30 min at room temperature and 
rinsed with PBS. Coverslips were inverted and mounted on microscope slides in 
Vectashield Mounting Medium (Vector Laboratories) and the coverslips sealed using 
nail varnish. Stained cover-slips were examined using oil-immersion fluorescence 
confocal microscope (LeicaSP5CLSM FLIM FCCS). 
The following specifications were set up during the acquisition of images; 
Laser excitation wavelength: 50 mW - Diode laser (405nm), 50 mW - Argon laser (488 
nm and 458, 477, 514 nm), 10 mW - Helium Neon laser (633 nm). 
Laser power: 60% on all experiments. 
Acquisition mode: xyz (for images acquisition) 
Filters: fully adjustable, 3 sequential (400-450 nm), (450-600 nm) and (600-775 nm). 
Lens used: 63X HCX PL APO Oil immersion UV. 
Image resolution: laser speed rate 100 HZ and resolution of 1024x1024 
Pinhole size:  200 µm, 1 Airy unit, bidirectional laser beam 
Zoom 1.5, line average 5 and Accuracy 1. 
 
2.4. 8 Raman spectroscopy analysis of SHSY5Y cells 
2.4.8.1 Experimental set-up for Raman spectroscopy analysis of SHSY5Y cells 
SHSY5Y cells were seeded at density of 2 x 106 cells per 25 cm2 flask (Sigma) and 
incubated at standard conditions for 12-24 hrs before treatment with different synthetic 
retinoids at concentration of 10 µM for 3 days as one shot treatment without changing 
media. Then cells were de-attached from the reservoir flask using pre-warmed PBS 
solution, centrifuged at low speed and fixed using 4% para-formaldehyde. Instrumental 
set-up, validation, analysis and recording data were done by Graeme Clemens at 
Chemistry Department, University of Central Lancashire.  
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2.4.8.2 Samples preparation (cytospinning onto 1 mm CaF2 plates)  
100 Microliters of fixed SHSY5Y treated or control cellssolutions were dispensed into 
individual labelled cytospinning cuvettes. The loaded cuvettes were spun at 950 rpm for 
five minutes firing a number of SHSY5Y onto the CaF2 substrate window. The micro-
slides were left to dry overnight, dipped carefully into double distilled water to remove 
any residual salt and left to air dry. 
 
2.4.9 X-gal assay  
Sil-15 cells were plated in a 0.1% gelatin-coated 96-well plate and grown to about 85-
90% confluence in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% 
fetal calf serum (Invitrogen/Gibco) and 0.8mg/ml G418 sulfate (Sigma) for 
selection.Serial dilutions of ATRA, EC23 and EC19 were prepared from the stock 
solutions. Standard curve of RA was included in the experiment as positive control. All 
retinoid dilutions were added to the seeded Sil-15 cells in the 96-well plate and then the 
plate was wrapped with aluminum foil and incubated overnight in a humid atmosphere 
containing 5% CO2 at 37°C. All the concentrations for ATRA and the two synthetic 
retinoids were tested in triplicates. The next day, Sil-15 cells were washed twice with 
1X PBS, fixed with 100 µl per well of 1%glutaraldehyde fixation solution for 15 
minutes, washed again two times with 1X PBS and finally β-galactosidase activity was 
visualized by adding 100 µl of a freshly prepared X-Gal developing solution (5-bromo-
4-chloro-3-indolyl-β-d-galactopyranoside)to each well. The plate was incubated 
overnight at 37°C in 5% CO2. The plate was read on an Emax microplate reader at 650 
nm.  
 
2.4. 10 Neurite outgrowth assay of SHSY5Y cells  
13 Mm diameter cover slips (Agar Scientific) were acid treated in a mixture of 70% 
nitric acid (VWR) and 37 % hydrochloric acid (VWR) in a 2:1 ratio for two hours. The 
cover slips were then washed extensively with distilled water until the pH of the water 
reached levels of 5.5-6. Until needed, the cover slips were stored in a jar containing 70% 
ethanol. The cover slips were sterilized by putting them on a 70% ethanol soaked tissue 
paper under the cell culture hood for 5 minutes. Then, the cover slips were placed in 
12well plates. After that they were coated by adding 1 ml of poly-L-lysine solution 
above each cover slip in the well.  
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The final concentration of poly-L-lysine solution used for coating was 0.002% and the 
incubation time was 2 hours at 37 °C. Two washes with sterile 1X PBS followed and 
afterwards the cover slips were air dried in the cell culture hood. SH-SY5Y cells were 
first grown in T-25 culture flask in Dulbecco’s modified Eagle’s medium (DMEM) 
containing 10% fetal calf serum. Then, the cells were removed from the flask by the 
standard PBS protocol and were plated at an approximate density of 10000 cells per 
well in 12-well plates containing acid treated/Poly-L-Lysine coated cover slips. The 
plates were maintained at 37°C in a humid atmosphere containing 5% CO2 for 24 hours. 
The next day, two dilutions (0.1 and 10 µM) of EC23 and EC19 were prepared from the 
given stock solutions in DMEM medium. DMSO containing DMEM medium was used 
as a control. The dilutions were added above the seeded SH-SY5Y cells in the 12-well 
plates and then the plates were wrapped with aluminium foil and incubated for 5 days in 
a humid atmosphere containing 5% CO2 at 37°C. All the concentrations for the two 
chemicals and the controls were tested in triplicates.  
 
SH-SY5Y cells grown on cover slips were washed two times in 1X PBS before fixing 
them in 4% para-formaldehyde for 20 minutes at room temperature, and then they were 
washed again two times with 1X PBS. The plates were stored at 4 °C in 1X PBS until 
use. Prior to immunocytochemical staining, the cells on cover slips were washed three 
times in 1X PBS before blocking them in 10% donkey serum, 0.1% triton X-100 in PBS 
for 1 hour at room temperature. The cells were then labelled by incubating them 
overnight at 4°C with β-III tubulin primary antibody (1:1000; Sigma) diluted in the 
blocking buffer. Next day, the cells were washed three times with PBS containing 0.1% 
triton X-100 before incubating them with anti-mouse monoclonal secondary antibody 
(1:300 in PBS with 0.1% triton X-100; Jackson Immunoresearch) for 2 hours at room 
temperature. Finally after 3 washes in PBS containing 0.1% triton X-100 and a final 
wash in 1X PBS, the cover slips to which the cells were attached were mounted on 
slides in mounting medium (1 mg/ml bisbenzimide (Pierce) in 1:1 glycerol (Sigma): 4% 
PFA and 2.5% 1, 4-Diazabicyclo [2.2.2] octane solution – DABCO (Sigma) and sealed 
with nail polish.  
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For each neurite outgrowth experiment, 3 cover slips (in 3 wells) were used. 10 different 
randomly selected images were taken for each cover slip and the numbers of neurites 
were counted and traced them in each of the 10 images. After that, the average neurite 
length for each picture was calculated by dividing the total neurite length by the total 
number of neurites in that picture. This is ended up with 10 values for the average 
neurite length for each cover slip; the average of the 10 values was taken to get one 
value for the average neurite length in each cover slip. By the end of experiment, 3 
values of average neurite length; one value per each cover slip of the three. 
The tracing was done using a semi-automatic NeuronJ plugin in ImageJ software (Fig. 
3.2). The mouse anti β-III tubulin secondary antibody was used for fluorescent labelling 
of neurites. After taking the images using the microscope, each image was converted 
into an 8-bit image then the image was subsequently optimised using brightness and 
contrast tool in GIMP (GNU Image Manipulation Program). After that, individual traces 
were drawn for each visible clearly identifiable neurites in the image using the tracing 
tool in NeuronJ plugin in ImageJ software. The length was measured by pixels and then 
it was transformed from pixel value into the corresponding length in µm depending on 
the magnification used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Measuring of total neurite length using NeuronJ. (A) The original picture; (B) The picture 
was converted into an 8-bit image; (C) The brightness and contrast of the 8-bit image was changed for 
easily and accurate identification of neuritis and (D) Traces were individually drawn above the neurites 
and then were quantified using ImageJ software. 
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Investigation of the molecular interactions between novel 
synthetic retinoids and the ligand-binding domains of retinoic 
acid receptors 
3.1 Introduction 
Retinoids interact with their cognate protein receptors (RARs) through consequence of 
different intermolecular interactions. These interactions include specific interactions 
binding in the LBD site as well as dynamic conformational changes outside the binding 
pocket. The complexity of interactions between these proteins and target retinoids is 
determined by the considerable selectivity between retinoid ligand, the RAR binding 
site and the structural rearrangements that occur upon binding to form a minimal energy 
active complex structure that initiates signal transduction.A goal of many biophysical 
studies in the retinoid area is to determine the molecular forces that control biological 
interactions and to use this information to rationally design synthetic retinoids with 
higher binding affinities to RARs, which are then able to induce signal transduction 
successfully. Computational structure prediction of ligand-protein complexes using 
docking methods such as DOCK, FLEXx and GOLD311,312,313 is useful to understand the 
molecular interaction of retinoids in the binding pocket of RARs. 
 
In this chapter, the procedure for in silico molecular modelling of different synthetic 
retinoid molecules introduced into ligand binding domains of different types of RARs. 
This modelling is then compared to experimental estimates of binding affinities using 
receptor binding assays. This is a useful starting step for further investigations of the 
binding interactions of other synthetic retinoids with either selective interaction to one 
type of RAR or with broad binding interactions to all of them. By the end of this chapter, 
it is expected to be able to predict the characteristic features of binding affinities of 
these molecules based on their differences in binding interaction poses within the 
protein binding pockets of the RARs. A combination of different computational and 
docking software was used for optimization of both retinoids and proteins and for 
visualizing the complexes of docked structures. Also, bimolecular simulation software 
was used to correlate how the values of EC50 have impact on the binding affinities of the 
retinoids to the RARs. 
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3.2 Study of retinoic acid receptor (RAR) structure and sequence 
alignment. 
Retinoic acid receptors mainly consist of three main regions; DNA binding domain 
(DBD), hinge region and ligand binding domain (LBD). The LBD consists of 220 
amino acid residues and it is the essential part for retinoid binding interaction with its 
RARs to initiate the active conformational change in the proteins. Sequence alignment 
was the first step done to check the similarity and differences between LBDs in 
comparison with other regions of RARs. Protein sequences and sequence alignment was 
retrieved using UniportKB as a common alignment resource and the results are shown 
in (Fig. 3.1 and Fig. 3.2) .The first analysis of different amino acid sequences in LBDs 
and DBDs of RAR-α, -β and -γ receptors showed that major variations in amino acid 
sequences were found in the LBDs with 83% similarity compared to the most robust 
and conserved region in DBD of 94%, the residues responsible for these differences in 
LBD of each type of receptors are shown by blue arrows.  
 
 
 
 
Figure 3.1: Sequence alignment in LBDs of RAR-α,-β and –γ. The green arrows represent the difference 
in amino acid sequences between different RARs. The similarity between LBD of RARs was shown to be 
83%. 
 
 
 
 
Query sequences 
 
Identity 83.182% 
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Figure 3.2: Sequence alignment in DBDs of RAR-α,-β and –γ. The blue arrows represent the difference 
in amino acid sequence between DNA binding domains of RAR. The similarity was greater than 90%. 
 
PDB files necessary for molecular docking were retrieved from RCSB protein data bank 
website as shown (Table 3.1). The selection of these PDB files was based on the quality 
of the atomic model obtained from crystallographic data (R-Value and free R-value) and 
the diffraction pattern to show the fine detail of the crystal (resolution value). 
 
 
Table 3.1: PDB file used for molecular docking of RARs retrieved from protein data bank showing the 
essential crystallographic parameters. 
PDB files R-Value Free R-value Resolution 
1DKF 0.197 0.237 1.8 
1XAP 0.213 0.253 2.10 
2LBD 0.210 0.313 2.06 
 
 
It is necessary to understand the topographic structure of the ligand binding domains of 
these receptors, Fig. 3.3 which shows how ATRA is buried in the hydrophobic pocket 
of RAR-γ formed by residues located in H1, H3, H5 helixes, β-turn and H11-H12 loops. 
Also, some hydrogen bonding and van der Waals contacts stabilize the bound ATRA 
molecule inside the pocket. 
 
 
 
Query sequences 
 
 
 
 
 
 
 
 
Identity 93.939% 
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Figure 3.3: The crystal structure of RAR–γ bound to all-trans-retinoic acid. PDB accession code 2LBD. 
The ligand is ATRA bounded in the ligand binding pocket between H1, H3, H5, H7 and H12.52 
 
3.3 Preparation of retinoid 3D molecules as .mol2 files 
Preparation of mol2 files of the retinoid starting molecules was carried out using 
Spartan10 computational software. Molecules were prepared using the Spartan drawing 
facility which creates 3D structures. Semi-empirical calculations in vacuum were used 
to calculate the energy of each possible conformation, from which the lowest energy 
conformer was created. Table 3.2 and Table 3.3 show the calculated energies of the 
lowest energy conformers with other subsequent higher energy conformers. It was 
obvious that there were differences between lowest, 2nd lowest and highest energy 
conformers for the naturally occurring molecules of ATRA, ATRA methyl ester and 9-
CRA because of the presence of conjugated double bonds which might have effect on 
the different possible energy conformations.  
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For ATRA, the methyl groups on the cyclohenyl ring consistently produced low energy 
conformations in which the conjugated polyene twists out of plane with the 6-membered 
ring. In addition, the lowest energy conformation adopts one s-cis sigma-bond rotation 
in the middle of the polyene, again seemingly relieving strain due to the presence of one 
of the methyl group substituents. A completely s-trans-conformation for ATRA was 
also found as the fourth lowest energy conformation at 288 kJ mol-1, which was within 
around 3 kJmol-1 of the lowest energy conformation. In fact, all these low energy 
conformation for ATRA all showed an out of plane twisting of the polyene from the 
plane of the cyclohexene ring and especially the endo-cyclic alkene. Otherwise, the 
conformations only differ in terms of which sigma bonds show s-cis conformations, and 
hence, all are selectable as possible structures that could bind to the receptor sites since 
all such conformations would exist at almost the same concentrations in solution at 
room temperature (Table 3.2). 
 
For 9-CRA, the lowest energy conformation showed somewhat similar trends to that of 
ATRA, with the polyene section twisting out of plane from the cyclohenyl ring due to 
steric repulsion for the 6-ring methyl groups, and similar s-cis sigma bond rotation 
effects were also present. However, in the case of 9-CRA, two conformations were 
within 1 kJmol-1 of each other, with the next lowest energy conformation being around 
18 kJmol-1 higher in energy, hence, it seems that 9-CRA exhibits lower conformation 
flexibility with only two major conformations being those that the receptors could select 
from in solution at room temperature(Table 3.2). Other synthetic retinoid analogues, this 
energy difference between different conformers was minimal, less than 1 kJ/mol, in 
many cases because of decreasing the degree of flexibility and rotation around bonds 
with using aromatic or hetero cyclic ring systems(Table 3.3). 
 
3.3.1 Validation of calculated retinoid structures 
Validation of lowest energy conformers in comparison to X-ray crystal structures is an 
essential step to be sure the starting point of docked retinoid molecules are 
similar.Calculated structures of EC19 and EC23 were initially superimposed onto the 
experimental crystal structures known for these two molecules (CCDC Ref code; 
688680 KOHHIZ for EC23 and 688681 KOHHOF for EC19)314 to validate the correct 
starting point for docking.  
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The calculated 3D structures and crystal structures had higher agreement in term of 
R.M.S.D, to conclude that these conformations as the most likely lowest energy (Fig. 
3.4). 
 
Table 3.2: Different conformers of ATRA and 9-CRA with calculated energy using Spartan 10 
ATRA Conformation Energy 
(kJmol-1) 
(conformer-1) 
lowest energy 
 
 
 
 
 
291.57 
(conformer-2)  
 
 
 
 
 
290.58 
(conformer-3) 
 
 
 
 
 
289.67 
(conformer-4) 
 
 
 
 
 
288.38 
(conformer-5) 
highest energy 
 
 
 
 
 
276.91 
9-CRA Conformation 
 
Energy 
(kJmol-1) 
(conformer-1) 
lowest energy 
 
 
 
 
 
288.85 
(conformer-2)  
 
 
 
 
 
288.05 
(conformer-3) 
highest energy 
 
 
 
 
 
 
270.54 
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3.4 GOLD 5.2 suite program validation 
The next step was to validate GOLD 5.2 program by extracting the docked retinoid 
structure from all three PDB files and re-dock them and superimpose both the original 
and docked structure and calculate R.M.S.D. All geometric functions were tried until 
ChemKinase was found as the best one to give minimal R.M.S.D.                                                                                                     
less than 1.5 Å. All hydrogen atoms were added to amino acid residues in RARs protein 
files and all H2O molecules were removed from the binding pockets.  
Also, there were no specific constrain through protein or ligand to allow the software to 
find all the available results. The pharmacophore binding size was detected based on the 
docked retinoids in the various PDB files within a range of 15 Å. Chemplp was chosen 
as the default fitness scoring function to allow detection of hydrogen binding, torsion 
angles, van der Waals force and any short contacts. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Calculated EC19 and EC23 Structure overlay with X-ray crystal structures; a) structure 
overlays for EC19 with R.M.S.D = 0.38 Å; and b) Structure overlays for EC23 with R.M.S.D. = 0.25 Å. 
All least squares superposition was calculated with Olex2.315 
 
3.5 De-localization of carboxylate ion 
It is important to note that the negative charge on the carboxylate terminal group was 
considered during calculation to be de-localized rather than protonated, as this is more 
realistic with respect to the physiological environment. Docking with the H-atom and a 
neutral carboxylate group led to unfavourable binding modes (Fig. 3.5). 
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Table 3.3: Lowest energy conformers of retinoids and other conformational energies.  
Retinoid Lowest energy conformation 
(KJ/mol) 
2nd lowest energy 
confirmation 
(KJ/mol) 
Highest energy 
confirmation 
(KJ/mol) 
ATRA- 
methyl ester 
 
 
 
 
 
-262.74 
 
 
-261.32 
 
 
-247.07 
TTNBP 
 
 
 
 
 
 
 
-272.34 
 
 
-272.32 
 
 
-272.21 
TTNN 
 
 
 
 
 
 
 
-229.94 
 
 
-229.90 
 
 
-229.87 
AM580 
 
 
 
 
 
 
 
-431.20 
 
 
-430.83 
 
 
-418.53 
CD437 
 
 
 
 
 
 
-410.25 
 
 
-410.24 
 
 
-397.25 
EC19 
 
 
 
 
 
 
 
-95.54 
 
 
-95.22 
 
EC23 
 
 
 
 
 
 
 
 
-96.00 
 
 
-95.99 
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EC19- methyl 
ester 
 
 
 
 
 
 
 
-40.37 
  
EC23- methyl 
ester 
 
 
 
 
 
 
 
-39.77 
  
GZ18 
 
 
 
 
 
 
-504.96 
 
 
-504.87 
 
 
-492.90 
GZ22 
 
 
 
 
 
 
-18.55 
 
 
-18.44 
 
 
-17.98 
GZ23 
 
 
 
 
 
 
 
-149.34 
 
 
-194.12 
 
 
-148.49 
GZ24 
 
 
 
 
 
 
 
-22.14 
 
 
-21.93 
 
GZ25 
 
 
 
 
 
 
 
 
-152.96 
 
 
-152.77 
 
 
-152.48 
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Figure 3.5: Least-squares superposition of the docked structures of EC23 in the ligand-binding pocket of 
RAR-α in the protonated form (red) and negatively delocalized charge (blue). The negatively charged 
carboxylate group of the retinoid might induce dynamic changes of some residues inside the binding 
pocket to produce, for example, a closer orientation of Ser287 and fewer steric clashes between the 
phenyl groups of EC23 and Phe221. UCSF CHIMERA316 was used to produce this figure. 
 
 
3.6 Molecular binding interactions of naturally occurring retinoid 
(ATRA) into RARs receptors 
Validated procedures from the GOLD program were used for molecular docking of 
ATRA into three target RARs (-α, -β and –γ) for further comparison with other 
synthetic retinoids. Closer inspection of the highest binding score for the docked 
complexes of ATRA with different RAR-types revealed that the carboxylate ion plays a 
key role in interacting with some conserved residues in the RARs binding pocket. One 
carboxylate oxygen of ATRA formed a salt bridge with the protonated Arg residue in 
the LBD. In addition, the other oxygen of the carboxylate ion of ATRA formed 
hydrogen bonds with the hydrogen atoms of the hydroxyl group of Ser. Table 3.4 
summarizes these binding interactions of ATRA with different residues in the RAR 
LBDs with measured distances in Å, which were in the expected range for salt bridges 
and hydrogen bonding.317  
 
 
Phe221 
Ser287 Arg276 
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The results from the docked RAR-γ-ATRA complex structure parallels that of the 
known co-crystallized crystal structures deposited in the Protein Data Bank.88 
Furthermore, the binding mode appeared to be stabilized by hydrophobic interactions 
between the tri-methyl-cyclohexene moiety of ATRA with Leu270 (4.0 Å) and Val395 
(3.5 Å) for RAR-α, Ile263 For RAR-β and Ala397, Leu416, Phe230, Ala234 for RAR-γ 
(Fig.3.6). In addition, it is noteworthy that there may be additional subtle effects 
operating particularly in relation to the shape, i.e. conformation, of these types of small 
molecules. In particular, comparing RAR-α and -β with RAR-γ. This can be seen by 
comparing Fig.3.6a and Fig. 3.6b, by examining the bound conformations of ATRA in 
the LBDs of each protein. The crystallography reports did not show the actual bound 
conformation of ATRA in the RAR protein binding sites. From these results, we 
tentatively propose that RAR-α and -β prefer to recognize a similar ATRA 
conformation, whereas RAR-γ prefers to recognize a more extended nearly all s-trans-
conformation which might be a receptor selective interaction, specific to the 
conformation of ATRA. 
 
Table 3.4: Molecular hydrophilic binding interactions and distances observed from molecular docking of 
ATRA and 9-CRA on different RAR LBDs 
 
3.6.1 Calculation of EC50 for ATRA with RARs receptors 
The readout of the LanthaScreen TR-FRET binding assay was based on a Forster 
resonance energy transfer (FRET) signal generated from the interaction between a 
terbium-labeled anti-glutathione-S-transferase (GST) antibody fused with GST tagged 
RAR ligand- binding domain. The interaction between the LBD and the fluorescein-
labeled coactivator peptide was driven by the binding of ligand to the LBD, and 
detected by the FRET signal from the terbium/fluorescein interaction when the terbium-
labeled anti-GST binds the LBD fusion protein.  
 
Retinoid 
analogue 
Molecular binding interaction (Å) 
RAR-α RAR-β RAR-γ 
Arg276 Ser287 Arg269 Ser280 Arg278 Ser289 
ATRA 2.9 2.8 2.9 2.6 3 2.8 
9-CRA 3.7 2.6 3.8 2.5 3.7 2.7 
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The output of the assay thus relied on two binding interactions: ligand with LBD and 
ligand-bound LBD with the coactivator peptide. As both the two consequent 
interactions are affected by the fit of retinoid ligand to the binding pocket of the RAR 
LBD, it was useful to calculate the sum of all these binding interactions as a total 
binding affinity (EC50). All results were calculated compared to the blank DMSO 
solvent and graphs presented using Sigmaplot statistical software.  
 
The results of the binding assays are summarized in Table 3.5 and Fig. 3.7, showing the 
measured EC50 for ATRA in the TR-FRET receptor binding assay for the different 
RARs. ATRA had similar binding affinities to all RAR-types, with slightly higher 
binding affinity to RAR-γ, which might be explained by the selective binding of the 
extended nearly all s-trans-conformation. 
 
3.6.2 9-CRA molecular binding interaction versus ATRA 
9-CRA was the second naturally occurring retinoid discovered and the predominant 
alternative isomer of ATRA with one cis-double bond that affects the molecule’s length, 
although it has the same number of carbon atoms as ATRA, but is more bent in the 
ligand binding pocket. The EC50 of 9-CRA in all RAR types are slightly higher 
compared to ATRA which indicates that the binding affinity of 9-CRA is lower than 
ATRA (Table 3.4 and Fig.3.8). Also, molecular docking showed similar consistent 
effects for 9-CRA on all RARs LBDs, with one oxygen of the carboxylate group 
forming a hydrogen bond with the Ser residue in each RAR LBDs, because it is unable 
to hit the Arg to achieve an interaction to form salt bridge that would be stronger than 
the Ser hydrogen bond in all RARs binding pockets. This suggests that one cis-double 
bond effectively shortens the molecule and the carboxylate cannot quite reach the Arg 
residue which consequently affects the binding affinity and interaction of 9-CRA 
compared to ATRA. In addition, inside the ligand binding pocket of RAR-α and RAR-β, 
ATRA exists with in a single s-cis conformation which is ideal for best fit interactions with Arg 
and Ser residues compared to s-trans form of 9-CRA. While, in the ligand binding pocket of 
RAR-γ, ATRA and 9-CRA both exist in a mostly s-trans form with much better interactions for 
ATRA (Fig.3.9).  
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Figure 3.6: ATRA binding mode of interaction onto its cognate RARreceptors; a) ATRA bound to RAR-
α showed hydrogen bond with Ser287 and salt bridge with Arg276; and b) ATRA bound to RAR-γ 
showed hydrogen bond with Ser289 and salt bridge with Arg278. 
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Figure 3.7: Sigmoid representation for the receptor binding assay for ATRA on all RAR-types for 
calculation of binding affinity (EC50) which represented mid-point on graphs to produce 50% of FRET 
signal. Calculation was done using Sigmaplot statistical software and data normalized to lower asymptote 
values. 
Table 3.5: Comparison between EC50 of ATRA for different RARs  
 
 
 
 
  
                                     *(EC50± % S.E.M) 
 
 
 
 
 
 
 
 
 
 
Figure 3.8: Sigmoid representation for the receptor binding assay of ATRA and 9-CRA on RAR-γ 
showed EC50 of ATRAwas 14.7 nM and 36.7 nM for 9-CRA which indicated ATRA binding affinity was 
approximately double that of 9-CRA. 
Retinoid 
analogue 
*EC50 (nM) 
RAR-α RAR-β RAR-γ 
ATRA 16 ± 1% 17.6 ± 3.1% 14.7 ± 2.2% 
9-CRA 28.8 ± 0.7% 27 ± 0.7% 36.7 ± 1% 
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Figure 3.9: ATRA and 9-CRA binding mode and interactions into its cognate receptor RARs; a) RAR-α; 
b) RAR-β; and c) RAR-γ. ATRA bound through hydrogen bonds with Ser and salt bridge with Arg 
residues while 9-CRA bound only through hydrogen bond with Ser and away from Arg (~ 4.5 Å ) to form 
salt bridge. Note the difference between s-cis form of ATRA in RAR-α and - β and s-trans form of ATRA 
in RAR-γ. ATRA is yellow and 9-CRA is magenta color.   
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3.6.3 Carboxylic acid terminal active group versus ester group 
Methyl retinoate was another naturally occurring retinoid form which was thought to be 
a storage form of ATRA during the metabolism of retinoic acid. It was interesting to 
compare the free carboxylic acid form of retinoic acid to the methyl ester form of 
ATRA and find out if this has an impact upon the binding interaction poses in the LBD 
of the RARs. Molecular modelling of methyl retinoate had an overall lower fitness score 
compared to ATRA. The reason for this is suggested to be the presence of extra methyl 
group of the ester, which could direct the oxygen of carboxylate away from the binding 
pocket of all the RARs, so that there is no salt bridge formed with Arg residue, and 
hence, weaker binding than that of ATRA. This can be revealed from the distance 
between the oxygen of ATRA and Arg was on average of 2.8-3.0 Å while that of 
oxygen and Arg in methyl retinoate was 3.3 Å, and hence, there was a drop in the 
strength of binding interaction inside the binding pocket (Fig.3.10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: ATRA and methyl retinoate binding mode of interactions onto its cognate receptor RAR-γ, 
ATRA bound to RAR-γ through salt bridge with Arg278 with distance 3.0 Å while methyl retinoate was 
not able to bind to Arg278. ATRA is blue and methyl retinoate is gold color. 
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3.7 Molecular binding interaction of synthetic retinoids 
There are some synthetic molecules in the literature have similar retinoids structures 
with replacement of conjugated double bonds system by more stable derivatives which 
have proposed biological activity as retinoids and more stability. This study compared 
the molecular binding affinities of these molecules to ATRA and highlighted the 
differences in molecular binding interactions between all of them. 
 
3.7.1 Pan-RARs synthetic retinoids agonists (TTNBP and TTNN) 
Chemically, the parent retinoid structure is defined as a di-terpenoid derived from a 
monocyclic compound with five carbon-carbon double bonds and a functional group at 
the terminus of a cyclic portion. However, this definition does not account for some new 
synthetic derivatives which are tri-cyclic or tetra-cyclic retinoidal benzoic acid 
derivatives (arotinoid acids) as TTNBP and TTNN. Such new synthetic derivatives can 
be modified in future to yield almost an unlimited number of retinoids with different 
potency compared to monocyclic parent retinoids. 
 
Receptor binding assays studies showed that TTNBP has the lowest EC50 of all different 
RARs compared to ATRA and TTNN; 3-fold lower on RAR-α, 7-fold lower on RAR-β 
and 100-fold lower on RAR-γ compared to ATRA which indicated it had broad, higher 
binding affinities to all types of RARs. This receptor binding data matched with Table 
1.3 in introduction chapter, since both ATRA and TTNBP are able to bind all RARs 
however, they have relatively higher binding affinity to RAR-γ. It might be suggested 
that the hydrophobic naphthalene side chain of TTNBP will favour the van der waals 
contacts in the more hydrophobic pocket of RAR-γ especially with Met residues in H11 
and H12. TTNN was ranked with a lower binding affinity than TTNBP and ATRA on 
both RAR-α and RAR-γ, while it also had a higher binding affinity to RAR-β (2-fold 
higher than ATRA), this suggests its potential selectivity for RAR-β over other types 
(Table 3.6 and Fig.3.11).  
Molecular docking of these arotinoids to the LBD of the RARs explained this higher 
binding affinity of TTNBP, since this molecule fitted in the binding pockets of RARs 
with the formation of two strong hydrogen bonds with the Ser residue (2.5, 2.2 Å for 
RAR-α), (2.02, 2.22 Å for RAR-β) and (2.5, 2.016 Å for RAR-γ).  
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Also, it was able to form one strong salt bridge with the Arg residue in the pocket (2.5 Å 
for RAR-α), (2.16 Å for RAR-β) and (3 Å for RAR-γ). TTNN had a higher fitness score 
than ATRA on molecular docking of RAR-β and also a lower EC50, and the reason for 
this may be the stronger two hydrogen bonds formed with Ser280 (2.02, 2.218 Å) 
compared to ATRA, however, for RAR-α and RAR-γ the binding interactions were 
similar to ATRA and TTNBP, but more much reduced binding affinity than ATRA 
(Fig.3.12). 
 
Table 3.6: Comparison between EC50 of ATRA, synthetic retinoids TTNBP and TTNN on different 
RARs  
 
 
 
 
 
 
 
                                 *(EC50± % S.E.M ) 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11: Sigmoid representation for the receptor binding assay of synthetic retinoids TTNBP and 
TTNN compared to natural retinoid ATRA on RARs; a) RAR-α ; b) RAR-β; and c) RAR-γ. 
Retinoid 
analogue 
*EC50 (nM) 
RAR-α RAR-β RAR-γ 
ATRA 16 ± 1% 17.6 ± 3.1% 14.7 ± 2.2% 
TTNBP 5.7 ± 3.3% 2.7 ± 13.7 1.2 ± 0.5% 
TTNN 20 ± 0.7% 8.2 ± 2% 70 ± 0.2% 
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a) 
b) 
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Figure 3.12: TTNBP and TTNN binding mode of interactions in its cognate RARreceptors; a) RAR-α; b) 
RAR-β; and c) RAR-γ. TTNBP and TTNN bind with the same mode of binding interaction to Ser and 
Arg residues with coincidental overlay in the binding pocket of RAR-α, -β and some twisting compared 
to TTNBP in RAR-γ binding pocket.  TTNN is blue and TTNBP is in gold color.   
 
3.7.2 Selective synthetic retinoids agonists (AM-580 and CD437) 
Synthetic retinoids targeting all retinoic acid receptors have been developed for a 
variety of therapeutic applications; however, their success has been limited in part due 
to lack of selectivity. This is why some new RAR agonists has been developed that can 
distinguish between different RARs-types and in some cases, between different 
isoforms. The selectivity for each retinoic receptor is based on the nature of the 
pharmacophore region (hydrophilic or hydrophobic) and the presence of one or more 
sets of targeted amino acid residues that can bind selectively to specific groups in 
retinoid molecules. Two examples of synthetic retinoids with potential RAR-selectivity 
are represented in this chapter.   
 
 
 
c) 
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3.7.2.1 Am580 as RAR-α selective agonist 
Interestingly, the measured EC50 for AM-580 on RAR-α was 3.8 nM, compared to 16 
nM for ATRA (5-fold lower than that of ATRA) which indicated that AM-580 has a 
higher binding affinity, 5-times more than ATRA (Fig. 3.13a). The molecular 
observation of the LBD of RAR-α revealed that several amino acids from α-helices H1, 
H3, H5, H11 and H12 were directed as contact residues between the receptor and ligand. 
Two positions were important and could be responsible for anchoring retinoids with 
hydrophilic groups such as Ser287 and Ser232. These two amino acids therefore, were 
elements for examining RAR-α selective candidate. Molecular docking of AM-580 into 
the RAR-α LBD could probably help to understand the difference in binding affinity to 
ATRA since hydrogen bonding would not be permitted between the hydroxyl of ser232 
and the hydrophobic linker of ATRA, while it can form such hydrogen bond with the 
amide linker in Am580. As a consequence, AM-580 might adapt a well fitted 
conformation in the RAR-α binding pocket to form three strong hydrogen bonds with 
Ser287 (2.06, 2.4 and 2.2 Å)  and one strong salt bridge with Arg276 (2.0 Å) compared 
to one hydrogen bond and one salt bridge for ATRA (Fig.3.14).  
 
 
 
 
 
 
 
 
Figure 3.13: Sigmoid representation for the receptor binding assay of synthetic RAR-selective retinoids; 
a) EC50 of AM-580 was 3.8nM compared to 16nM for ATRA showed higher binding affinity of AM-580 
to RAR-α; and b) EC50 of CD437 compared to ATRA showed comparable to slightly lower binding 
affinity of CD437 to RAR-γ. 
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Figure 3.14: Am580 and ATRA binding mode of interactions onto its cognate receptor RAR-α showed 
additional hydrogen bonding of AM-580 to Ser232 which favours the higher binding selectivity and 
fitting of AM-580 into the LBD pocket. 
 
3.7.2.3 CD437 as RAR-γ selective agonist 
On the same concept of the presence of conserved residues in the LBD of RARs which 
play key roles in retinoid selectivity, it was found that Met272 was a key amino acid 
residue that adopts different conformations in the LBD for RAR-γ selectivity. Met272 
locates above the ligand binding site and arranges itself for best hydrogen bonding 
between its sulphur atom and the ligand. This might add extra hydrogen bond for the 
ligand in LBD consequently results in higher binding affinity and a stronger interaction. 
Also, Lys236 was one of the backup residues in the LBD which thought to be essential 
either to overcome the drop in binding interaction with Ser or Arg residues or to act as 
one of the selective residues in the RAR-γ pocket.   
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CD437 was one of the admantyl bulky group retinoid derivatives that had measured 
EC50 of 25 nM, compared to 14 nM of ATRA (Fig.3.13b). The molecular docking 
revealed that the phenyl group side-chain of CD437 could form hydrophobic contacts 
with Met272, which consequently added to the overall interaction with CD437 in the 
LBD of RAR-γ. The admentayl side chain can also form hydrophobic contact with the 
surrounded Met residues in H11 and H12 which might be added to the overall 
interaction. In addition, CD437 also formed three hydrogen bonds; two of them with 
Ser289 (2.4, 2.5 Å) and one with Lys236 (2.1 Å), one salt bridge with Arg278 (2.5 Å) 
and this is why it was proposed that CD437 had some selective binding affinity to RAR-
γ (Fig.3.15).   
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15: CD437 binding mode of interactions into its cognate receptor RAR-γ showed additional 
hydrophobic contacts between of Met272 with phenyl group and Met406, Met387 with admantyl group of 
CD437 which favoured the higher binding selectivity and fitting into the LBD pocket. 
 
3.8 Molecular docking study of new synthetic retinoid analogues 
The activity of natural retinoids, ATRA and 9-CRA has limited in vitro application 
because of photo induced isomerization and radical oxidation which consequently 
affects their stability and biological activity. The Whiting group has designed new 
synthetic chemical retinoid analogues that possess similar or higher activity than natural 
retinoids.  
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In this part of the chapter, we study different types of these new synthetic retinoids to 
understand what factors affect retinoid binding to RARs, especially as a function of the 
chemical structure of the small molecule ligand. To address this, receptor-binding 
assays are required to test predictions from structural modelling studies and explain how 
structural differences relate to the thermodynamics of the different ligand binding 
events. 
 
3.8.1 EC19 and EC23 arotinoids 
Two derivatives which are 4-(5,5,8,8-tetramethyl-5,6,7,8 tetrahydronaphthalen-2-
ylethynyl)benzoic acid (EC23) and 3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-
2-ylethynyl)benzoic acid (EC19). In these compounds, the tetra-methylcyclo-hexanyl 
ring and conjugated tetraene are replaced by robust structural units; two aromatic rings 
(di-phenyl acetylene) and this why they called arotinoids. Another a key chemical 
difference between these derivatives in the position of the carboxylic group from meta- 
(EC19) and para-substitution (EC23) which will be studied in details. 
The results of the TR-FRET receptor binding assays are shown in Fig. 3.16, with the 
measured EC50 values for each ligand with the different RAR types summarised in 
(table 3.7).The midpoints of the fitted curves represented the binding affinities, 
expressed as EC50, and the level of the upper asymptote was a measure of the affinity of 
co-activator for the ligand-bound LBD. For RAR-α, EC23 had the highest binding 
affinity (EC50 3.7 nM) compared to other ligands while EC19 had the lowest (EC50 194 
nM), with intermediate values for the RA isomers. Upper asymptotes were highest for 
ATRA and EC23 compared to EC19. For RAR-β, there was a narrower range of ligand 
binding affinities, with EC23 having the greatest affinity (EC50 3.1 nM), (Table 3.7). In 
contrast to RAR-α, the upper asymptotes suggested that co-activator recruitment was 
best for ATRA but relatively inefficient for EC23. Thus, EC19 had a relatively high 
affinity for the RAR-β LBD and ligand binding also facilitates co-activator recruitment. 
For RAR-γ, ATRA and EC23 had similar high binding affinities (EC50 14.7 nM and 
16.7 nM, respectively) with EC19 the lowest (EC50 96.4 nM). Conversely, 9-CRA had 
the highest asymptote suggesting greater efficiency of co-activator recruitment 
compared to the other ligands, with EC19 being the least effective. 
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Table 3.7: Comparison between EC50 of ATRA, synthetic retinoids EC19 and EC23 on different RARs  
 
 
 
 
 
                                   *(EC50± % S.E.M) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16: Sigmoid representation for the receptor binding assay of synthetic retinoids EC19 and EC23 
compared to natural retinoid ATRA on RARs; a) RAR-α ; b) RAR-β; and c) RAR-γ. 
 
 
Comparisons of EC23 and EC19 docked into the different RAR sub-types with the 
standard binding interactions for ATRA, showed some differences in behavior, 
particularly with respect to the orientation of the active carboxylate group. The para-
substitution of the carboxylate ion facilitated a good fit of EC23 to the binding pocket in 
all RARs by forming a strong salt bridge with the conserved residue Arg and two 
hydrogen bonds with the conserved Ser residue.  
 
 
Retinoid 
analogue 
*EC50 (nM) 
RAR-α RAR-β RAR-γ 
ATRA 16 ± 1% 17.6 ± 2.1% 14.7 ± 2.2% 
EC19 194 ± 0.2% 12.1 ± 7% 96.4 ± 0.6% 
EC23 3.7 ± 4.6% 3.1 ± 6% 16.7 ± 2% 
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In contrast, the meta-substitution of the carboxylate ion of EC19 altered the geometry of 
the molecule such that the carboxylate oxygensare too far away to form a salt bridge or 
hydrogen bond in the binding pocket of the RAR-α and RAR-γ (Table 3.8, Fig.3.17 and 
Fig. 3.19). For RAR-β, EC19 was anchored into the pocket by forming a salt bridge 
with Arg and a hydrogen bond with Ser, thus might give enhanced binding interactions 
compared to the binding interactions of EC19 with RAR-α and –γ (Fig. 3.16). The 
reason for such enhancement in binding interaction of EC19 to RAR-β was suggested to 
be due to topography and size of the LBD was different and has an extra-groove (space) 
compared to either RAR-α or RAR-γ; this may accommodate ligands with bulky 
substituents or geometries unfavourable for binding to RAR-α or RAR-γ, given 
sufficient anchorage by interaction with Arg and/or Ser at the other end of the pocket 
(Fig.3.20). The molecular modelling also suggested that the meta-position of the 
carboxylate group of EC19 caused change in orientation of the tetra-methyl-tetra-
hydronaphthalene moiety which consequently formed short contacts and clashes with 
some residues in ligand binding pocket, such as Ile270 and Val309 in RAR-α and 
Ala397, Leu416, Phe230, Ala234, Met415, Phe288 and Ser289 in RAR-γ which affect 
the active conformation of H12, and thereby, the recruitment of co-activators and 
initiation of the transcription process. The differences in binding between EC19 and 
EC23 clearly concluded that the para-substitution of the carboxylic acid in EC23, i.e. a 
linear structure and ATRA-like in shape, which might create a more favourable binding 
interaction inside LBDs. 
 
Table 3.8: Molecular hydrophilic binding interactions and distances in observed from molecular docking 
of ATRA, EC19 and EC23 on different RAR LBDs 
 
 
 
 
 
Retinoid 
analogue 
Molecular binding interaction (Å) 
RAR-α RAR-β RAR-γ 
Arg276 Ser287 Arg269 Ser280 Arg278 Ser289 
ATRA 
2.99 2.8 2.9 2.6 3 2.8 
EC19 2.4 3.7 2.1 2.5 3.7 2.1, 2.6 
EC23 2.2 2.7, 2.2 2.5 2.4, 2.6 2.6 2.6, 2.7 
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Figure 3.17: EC19 and EC23 binding mode showing interaction into its cognate receptor RAR-α; a) 
EC19 lost its hydrogen bond interaction with Ser287 due to twisting away from binding pocket; and b) 
EC23 bound to Ser287 with two strong hydrogen bonds due to best fit in LBD of RAR-α. EC19 is grey 
and EC23 is the brown gold colour. 
 
 
 
 
 
 
 
 
Figure 3.18: EC19 and EC23 binding mode showing interactions onto its cognate receptor RAR-β; a) 
EC19 bound both hydrogen bond with Ser280 and salt bridge with Arg269; and b) EC23 formed both salt 
bridge with Arg269 and additional hydrogen bond with Ser280 and this can account for higher binding 
affinity of EC23 than EC19 in LBD of RAR-β. EC19 is grey and EC23 is the brown gold colour. 
 
 
 
 
 
Figure 3.19: EC19 and EC23 binding mode showing interactions onto its cognate receptor RAR-γ; a) 
EC19 lost its salt bridge interaction with Arg278 due to twisting away from binding pocket; and b) EC23 
formed this salt bridge with Arg278 due to best fit in LBD of RAR-γ. EC19 is grey and EC23 is the 
brown gold colour. 
 
 
Chapter III 
97 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.20: Structure overlay between binding pockets of the docked structure for EC19 in RAR-β and 
ATRA in RAR-γ showed the extra groove (blue arrows) in the RAR-β binding pocket (green color) that 
might accommodate the bulky components of EC19, compared to the RAR-γ binding pocket (red color) 
that lacks this groove. EC19 experiences greater steric hindrance with surrounding residues than in RAR-
β binding pocket. EC19 is green and ATRA is red. Pymol was used to produce this figure. 
 
3.8.1.1 Methyl ester of EC19 and EC23 
Methyl ester derivatives of EC19 and EC23 were synthesized by the Whiting group to 
investigate if the ester form can enhance the activity of either EC19 or EC23 and the 
measured EC50s for methyl esters of EC19 and EC23 showed that was no increase in 
binding affinity of EC19 methyl ester to any of RARs, except slightly to RAR-α, but 
still the binding affinity was lower than ATRA and EC23. However, methyl ester 
derivative of EC23 caused massive drop in binding affinity to all RARs compared to 
ATRA and EC23 with acid form. This matches previous observations of the binding 
affinity of methyl ester of ATRA (methyl retinoate) (Table 4.9) which was similarly 
reduced.  
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Molecular docking of methyl esters of EC19 and EC23 caused a drop in the binding 
interactions with the Ser and Arg conserved residues in the LBD of all RARs and only a 
small improvement in binding affinity of EC19 methyl ester was observed due to two 
hydrogen bond with Ser287. Also, EC23 methyl ester caused additional short contact 
clashes with the adjacent Arg278 and this also caused a drop in binding interactions 
(Fig.3.21). 
 
Table 3.9: Comparison between EC50 of ATRA, synthetic retinoids EC19 and EC23 and its methyl ester 
derivatives on different RARs 
 
 
 
 
 
 
 
                             *(EC50± % S.E.M) 
 
 
 
3.8.2 Thiazole derivatives (GZ-derivatives) 
This was the second class of synthetic retinoids which have the conjugated tetraene 
replaced with a thiazole ring. The incorporation of thiazole group has the effect of 
creating a bend in the structure which might affect the structure activity of the resulting 
retinoid derivatives. In addition, these thiazole derivatives have different molecular 
lengths and are shorter, longer or similar to that of ATRA depending on other motifs in 
the molecule which is second criterion affecting the retinoid binding activity. And again, 
esters of these derivatives were also studied for these retinoid thiazole derivatives. 
Receptor binding assay studies showed that EC50 for all of the GZ-derivatives were 
higher than for ATRA, except for GZ25, on all its RAR-types, and GZ23 on RAR-β. 
This means that only GZ25 has similar to higher binding affinity to all the RARs 
compared to ATRA. Also, GZ23 has a higher binding affinity to RAR-β, similar to 
ATRA compared to the lower binding affinity to RAR-α and RAR-γ (Fig.3.22 and 
Table 3.10).  
 
 
Retinoid analogue EC50 (nM) 
RAR-α RAR-β RAR-γ 
ATRA 16 ± 1% 17.6 ± 2.1% 14.7 ± 2.2% 
EC19 194 ± 0.2% 12.1 ± 7% 96.4 ± 0.6% 
EC23 3.7 ± 4.6% 3.1 ± 6% 16.7 ± 2% 
EC19-methyl ester 49 ± 0.8% 30 ± 0.5% 97.7 ± 0.3% 
EC23-methyl ester 20.4 ± 0.6% 14.1 ± 1.2% 847.2 ± 0.39% 
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Figure 3.21: Binding mode interactions of methyl ester of EC19 and EC23 into its cognate RARreceptors; 
a) EC19 and EC19 methyl ester binding interaction showed different behaviour of interaction with methyl 
ester oriented away from both Arg276 and Ser287 in LBD of RAR-α; and b) EC23 and EC23 methyl 
ester with potential short contact clashes between methyl ester and Arg278 in LBD of RAR-γ. 
EC19/EC23 is blue and EC19/EC23 methyl ester is the gold colour. 
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Interestingly, to understand these differences in binding affinity, molecular lengths have 
been measured from the carbon atom of carboxylate /ester group to the carbon atom of 
the cyclohexyl side-chain by UCSF Chimera wizard, and summarized in (Table 3.10). It 
was suggested that some molecules were shorter than ATRA, as GZ18 and GZ24, while 
some were longer than ATRA as GZ22 and GZ23, and only GZ25 was similar in length 
to ATRA. GZ25 seemed, therefore, to be the optimal length to hit the LBD of all the 
RARs, as most of these derivatives formed salt bridges and hydrogen bonds with the Ser 
and Arg residues (Table 3.11).However, the hydrophobic pockets must also be filled 
with the optimum side-chain to form sufficient contact surface with residues of H11-
H12 (AF-2) to keep it in the active conformation, thereby enabling the recruitment of 
co-activators and the initiation of the transcription process. Examples of the important 
residues of AF-2 that play important roles in recruitment of the co-activators are; (Arg 
294, Ile270, Leu398, Met406, Val395 and TRP225 for RAR-α); (Ile266, Leu262 and 
Met406 for RAR-β); and (Met272, Ile275, Leu271 and Leu400 for RAR-γ). Fig.3.22a 
and Fig. 3.22b show the differences between the GZs derivatives in forming 
hydrophobic interactions with these residues based on ligands with shorter chains (as 
with GZ18) failed to create sufficient contact surfaces with the AF-2 residues, while 
increasing the number of carbons in the alkyl chain (as with GZ23) might cause steric 
clashes which consequently orient H12 helix in a position not active for co-activator 
recruitment. In addition, GZ analogues were shown to have a considerable lower EC50 
(higher binding affinity) to RAR-α and –β compared to RAR-γ. This might be explained 
by the additional hydrogen bond formed between the nitrogen atom of thiazole and 
hydrogen atom of Ser232 (in RAR-α) and the extra groove in RAR-β that might 
accommodate the relatively bulky analogues of GZ derivatives. 
Table 3.10: Comparison between EC50and molecule lengthof ATRA, synthetic thiazole retinoids 
derivatives on different RARs 
     *(EC50± % S.E.M) 
Retinoid 
analogue 
Molecule length 
(Å) 
*EC50 (nM) 
RAR-α RAR-β RAR-γ 
ATRA 13.11 16 ± 1% 17.6 ± 2.1% 14.7 ± 2.2% 
GZ18 12.20 98.94 ± 0.2% 56 ± 1.3% 141.2 ± 0.38% 
GZ22 13.93 82 ± 0.32% 136.3 ± 0.1% 38.3 ± 1% 
GZ23 15.19 89 ± 0.44% 12.1 ± 0.83% 847.22 ± 0.47% 
GZ24 11.52 77.5 ± 0.18% 77.8 ± 0.8% 109.2 ± 0.46% 
GZ25 13.31 8.2 ± 2% 11.0 ± 1% 15 ± 1% 
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Figure 3.22: Sigmoid representation for the receptor binding assay of GZs synthetic thiazole retinoids; 
GZ18, GZ22, GZ23, GZ24 and GZ25 on RARs; a) RAR-α; b) RAR-β; and c) RAR-γ. 
 
 
Table 3.11: Molecular hydrophilic binding interactions observed from molecular docking of GZ 
derivatives on different RARs 
 
 
 
 
 
 
 
 
 
 
Retinoid 
analogue 
Molecular binding interaction (Å) 
RAR-α RAR-β RAR-γ 
Arg276 Ser287 Ser232 Arg269 Ser280 Arg278 Ser289 Lys236 
GZ18 2.3 2.5,2.5 2.5 2.5 2.0 1.8 2.1,2.2 2.3 
GZ22 2.3 2.1,2.2 2.5 X X X X X 
GZ23 2.1 2.4,2.6 2.5 2.4 2.5,2.5 X 2.4 2.4 
GZ24 2.5 2.4,2.7 2.4 2.5 2.4,2.5 2.8 2.1,2.2 2.5 
GZ25 2.4 2.4,2.8 2.6 2.2 2.4,2.5 2.4 2.4,2.4 2.5 
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Figure 3.22: Binding mode of interactions of GZ derivatives its cognate receptor RARs; a) GZ18 binds to 
LBD of RAR-α fails to fill in the hydrophobic cavity and form contacts withAF-2 residues Ile270, 
Arg294 and Leu398; b) GZ23 bind to LBD of RAR-γ forming short contact clashes with  AF-2 residues 
Leu271, Leu400 and Leu275. Both GZ18/GZ23 ligands are the gold colour. 
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Figure 3.23: Binding mode of interactions of GZ25 derivatives its cognate receptor RARs; a) GZ25 binds 
to LBD of RAR-α with best fit and fill in the hydrophobic cavity and formed contacts with AF-2 residues 
Ile270, Arg294 and Leu398 and hydrogen bond with Ser232 similar to Am580; b) GZ25 bind to LBD of 
RAR-β with best fit with AF-2 residues. GZ25 is the gold colour. 
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In contrast, GZ25 was suggested to be the best fitting molecule, similar to ATRA in its 
binding interactions to LBD of all RARs, and with enhanced binding affinity to RAR-α. 
This was revealed from the modelling due to the formation of an extra hydrogen bond 
with the Ser232 conserved residue which was discussed before as one of the residues 
responsible for selectivity of Am580 to RAR-α. Also, the length of GZ25 was suitable 
for fitting into the hydrophobic space of the LBD of all the RARs and form contacts 
with all AF-2 residues to induce co-activator recruitment (Fig.3.23). The only exception 
to this was GZ23 which showed enhanced binding affinity to RAR-β, similar to ATRA, 
and although it had an ester group replacing the carboxylate acid form and bulk side-
chain, but it might fit the LBD of RAR-β and formed the required hydrogen bonds and 
salt bridge with Ser280 and Arg269. Thed suggest reason for this is the extra groove 
found in the LBD of RAR-β, which might accommodate the bent structure of GZ23 and 
the extra bulk side-chain (Fig.3.24). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.24: GZ23 binding into the LBD of RAR-β showed the extra groove pocket might accommodate 
the bent structure of GZ23 and the extra bulk of the side-chain. GZ23 is yellow colour. 
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3.9 COPASI biochemical simulation model 
The readout of the Lanthascreen TR-FRET binding assay was based on FRET signal 
generated from the interaction between a terbium-labelled anti-glutathione-S-transferase 
(GST) antibody and a fluorescein-labelled co-activator peptide. The RAR ligand-
binding domain (LBD) is a GST fusion protein and interaction between the LBD and 
the fluorescein-labelled co-activator peptide was driven by the binding of ligand to the 
LBD, and detected by the FRET signal from the terbium/fluorescein interaction when 
the terbium-labelled anti-GST binds the LBD fusion protein. The output of the assay 
thus relied on two binding interactions: ligand with LBD, and ligand-bound LBD with 
the co-activator peptide.  
 
Both interactions may be affected by the fit of the ligand to the binding pocket of the 
LBD. COPASI9 was used as a biochemical pathway simulator to help in building a 
simple model of how the FRET signal output in the assay would vary according to 
differential changes in the kinetics of the two binding interactions. Reactions were 
modelled deterministically using mass-action kinetics described by ordinary differential 
equations (ODE) within COPASI. The component of the model and chart for 
construction of the model is shown in (Fig.3.25). 
 
This model helped us to assess the effect of different rate constants and varying ligand 
concentrations on the formation of the final ternary complex that was the read-out from 
the LanthaScreen TR-FRET assay. The two coupled equilibria given in equation1 were 
controlled by four rate constants, k1-k4. The concentration of the starting species are 
ligand= 10 µmol. L-1 to 0.03 nmol. L-1, RAR= 0.0035 µmol. L-1 (defined by the TR-
FRET assay formulation), co activator = 30 µmol. L-1 (defined by the TR-FRET assay 
formulation). The Rate constants from analogous ligand-nuclear receptor systems318,319 
were used as the starting point for calculating the EC50 (half maximal effective 
concentration) for ATRA. These rate constants (k1=0.6 µmol. L
-1, k2=0.1 min
-1, 
k3=0.014 µmol. L
-1 and k4=0.2 min
-1) were then altered individually, or together, to 
model different possible scenarios. The simulation results show that the k1/k2 ratio 
reflected the affinity of the ligands for LBD, which directly affects EC50 values, while 
alteration in k3/k4 ratio reflected the affinity of co-activator for the ligand-LBD complex 
(LR), which changes both the EC50 and upper asymptote. 
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* Where k1, k2 and k3, k4 are the rate constants controlling the rate of LR and LR.CO.A complex 
formation, respectively. 
 
 
 
 
 
 
 
Figure 4.25: Representation of the biochemical COPASI model of the different components of reaction, 
binding constants and the direction of reaction. 
 
To understand the way by which receptor binding assay data was interpreted, three 
different retinoids were compared to ATRA,by changing either ligand receptor binding 
constants or ligand receptor co-activator complex binding constants or changing both 
(Fig.3.26). Three main conclusions would be made from these examples; 1) Changing 
ligand receptor affinity alone shifts the EC50 but not upper asymptote; 2) changing 
ligand receptor co-activator affinity alone changed the upper asymptote AND EC50; and 
3) changing both in the same direction gave a bigger effect on the EC50, but not on the 
upper asymptote. Even if the retinoid compounds had EC50s lower than ATRA, but had 
lower k3/k4 ratios, then meant the retinoid compound failed to induce co-activator 
recruitment and this had been observed in Fig. 3.27. 
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Figure 3.26: Biochemical simulation analysis of TR-FRET assay using COPASI software assumed 3 different retinoid 
compounds to show the effect of changes in k1/k2 and k3/k4 values on EC50 compared to ATRA withk1/k2=6, k3/k4= 
0.07). (a) High ligand-receptor binding affinity and high induction of co-activator binding (k1/k2 = 10, 20, 30 and 
k3/k4 = 0.1, 0.2, 0.3) leads to low EC50 values in the range of 9-27 nM for the virtual compounds C1, C2, C3 which 
are hypothetical ATRA analogues with increasing k1/k2 and k3/k4 values. Increasing both ratios leads to decreased 
EC50 values and increasing upper asymptotes (b) Lower ligand-receptor binding affinity and co-activation binding 
(k1/k2 = 4, 2, 1 and k3/k4 = 0.05, 0.025, 0.0125) leads to higher EC50 values in the range of 102-729 nM for the virtual 
compounds C1, C2, C3 which are hypothetical ATRA analogues with lower k1/k2 and k3/k4 values. Decreasing both 
ratios leads to increased EC50 values and decreased upper asymptotes (c) No change in ligand-receptor binding 
affinity and lower co-activation binding (k1/k2 = 6 and k3/k4 = 0.05, 0.025, 0.0125) leads to higher EC50 values in the 
range of 102-729 nM for the virtual compounds C1, C2, C3 which are hypothetical ATRA analogues with lower k3/k4 
values. Decreasing k3/k4 ratio leads to increased EC50 values and decreased upper asymptotes (d) Lower ligand-
receptor binding affinity and no change in co-activation binding (k1/k2 = 4, 2, 1 and k3/k4 = 0.07) leads to higher EC50 
values in the range of 82.6-324 nM for the virtual compounds C1, C2, C3 which are hypothetical ATRA analogues 
with lower k1/k2 values. Decreasing k1/k2 ratio leads to increased EC50 values only. Graphs were produced by 
Sigmaplot based on steady state calculated by COPASI and using the 3-parameter sigmoid curve f = min + (max-
min)/(1+10^(logEC50-x)) to fit the output. 
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Figure 3.27: Summary of biochemical simulations for the TR-FRET assay using COPASI assuming 7 
different retinoid compounds to show the relationships between ligand-receptor-co-activator affinity, 
EC50 and upper asymptote. All these compounds had lower EC50 compared to ATRA (red line) with 
different scenarios, green line (both k1/k2 and k3/k4 are higher than ATRA), blue line (similar k1/k2 and 
higher k3/k4 than ATRA), pink line (higher k1/k2 and similar k3/k4 to ATRA), black dashed lines (higher 
k1/k2 and lower k3/k4 than ATRA). Graphs were produced by Sigmaplot based on steady state calculated 
by COPASI and using the 3-parameter sigmoid curve f = min + (max-min)/(1+10^(logEC50-x)) to fit the 
output. 
3.9.1 Application of COPASI bio-simulation model on the TR-FRET assay data 
COPASI is bio-simulation software that uses mathematical equations to simulate 
different biochemical reactions. It was important to understand, not only the difference 
between different retinoids in the measured EC50, but also the ability of formation of 
ligand-receptor complex which was able to induce co-activator recruitment based on 
different binding constants k1, k2, k3 and k4. Fig. 3.14 shows the sigmoid FRET signal 
of EC19 and EC23 compared to ATRA and it was shown that EC19 came in higher 
EC50 than EC23 and ATRA on RAR-α and RAR-γ. This was accompanied with a 
corresponding low upper asymptote as well which might suggest that EC19 had both 
lower k1/k2 ratio (lower binding affinity to RAR-α and –γ) and also hada lower k3/k4 
ratio (not able to induce co-activator recruitment). In contrast, its behaviour on RAR-β 
was different as it had a relatively lower EC50 with also, a lower asymptote which can 
be explained by its binding to the LBD of RAR-β. However, it might not induce co-
activator recruitment in a similar way as EC23. In another example, such as the  GZ 
derivatives in Fig. 3.19, GZ25 showed a lower EC50 on all the RARs compared to the 
other GZ derivatives, suggesting it had the higher binding affinity to the pocket, 
however, the upper asymptote was the highest on RAR-γ but not on RAR-α and RAR-γ.  
From these two examples, it can be concluded that the first part of the COPASI 
assumption about ligand-receptor binding affinity is based on k1/k2 ratio which perfectly 
matches the actual behaviour of measured EC50. 
Chapter III 
109 
 
 
The second part which is related to co-activator recruitment based on the k3/k4 ratio was 
not matched completely with the bio-simulation software observation as it might need 
further validation by addition of other factors contribute to the dynamic transactivity of 
RAR binding pocket. 
3.10 Conclusion 
In silico molecular modelling based on accurate docking algorithms by GOLD software 
was used to help in explaining possible binding interactions of both natural and novel 
synthetic retinoids. The binding modes of interactions were correlated with the retinoid 
binding affinities measured as EC50s by a sensitive TF-FRT assay. This could be useful 
for suggesting and finding reasons of the differences in the biological activity of these 
retinoids. In this study, some synthetic retinoids were shown to have a broad range of 
binding to all RARs such as TTNBP and TTNN. Some were suggested to be selectively 
bound to one specific type of receptor, such as Am580 for RAR-α and CD437 for RAR-
γ. Also, it was noticed that it might be tentatively proposed that RAR-α and -β prefer to 
recognise a similar ATRA conformation, whereas RAR-γ prefers to recognise a more 
extended, nearly all s-trans conformation. Understanding such factors is likely to be an 
important matter and one in which much further work is required in order to fully 
understand molecular interactions of these retinoids. For some synthetic derivatives as 
EC19 and EC23, changing the orientation of carboxylic group from the para-position of 
EC23 to the meta-position as in EC19 massively decreased the binding affinities, due to 
enforced changes in the orientation of this molecule within the LBD of the different 
RARs relative to ATRA and EC23.  
In other derivatives, such as the GZ derivatives, the length of the molecule and ester 
form had a great impact on binding interactions and binding affinities, such as the short 
molecule, GZ18 did not show a proper binding to the active Ser and Arg residues in 
binding pocket of the RARs. Longer molecules, such as GZ22, had little impact on co-
activator recruitment which might be due to the steric clashes with AF-2, while GZ25 
was the optimum molecular length and similar to ATRA. The use of calculated 
chemical structures, receptor binding assays and molecular docking tools was suggested 
to be useful in order to probe, and hence, understand, the biological activity of certain 
synthetic retinoids. The ultimate goal is designing more specific synthetic retinoic acid 
derivatives, as well better understanding the downstream effects. 
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Characterization of biological potency of synthetic retinoids 
for induction of neuronal cell differentiation 
4.1 Introduction 
4.1.1 Retinoids for cellular differentiation 
The induction of differentiation of a wide variety of human cell lines is now playing an 
important role in the biomedical research field, offering alternative ways of treatment of 
chronic diseases such as Alzheimer’s.320,321 It also provides an in vitro model to study 
the process of neuronal differentiation of many specific neuron-inducing agents, such as 
naturally occurring ATRA. ATRA is a developmentally regulated morphogen that has 
diverse roles in both in vivo and in vitro systems includes controlling the generation of 
primary neurons in Xenopus,322 development of the hindbrain,323 motor neuron 
specification324 and limbbud formation in chick embryo.325 Also, ATRA plays a crucial 
role for the in vitro differentiation of stem cells326 into a range of various cell types such 
as neurons,327 insulin-producing cells,328 osteoblast329 cells and epithelialcells.173 This is 
not the only role of retinoids, but they also have a practical application in the cancer 
field, and there have been great advances in this area such as in promylocytic anemia 
and neuroblastoma. Many studies have shown that retinoids can suppress the process of 
carcinogenesis in vivo and these results are now the basis of current attempts to use 
retinoids for cancer prevention in humans.330,331 
The mechanism by which retinoids exert their pleiotropic effects involves a complex 
signalling pathway because of presence of other main cognate receptors that are 
responsible for the activation of the transcriptional process. These receptors are called 
retinoic acid receptors, including the RARs and RXRs,332 and these act as RXR/RAR 
heterodimers333 to the polymorphic acting response elements of RA target genes.334 
These receptors can also initiate a cross-interaction with the other cell surface 
signaling335,336 pathways or co-activator/co-repressors337 to generate additional levels of 
complexity for the combinatorial pleiotropic effects. The goal of this chapter is to study 
the biological activity of new synthetic retinoid analogues and evaluate their effects in 
both stem cells and one cancer cell line. This can be useful to understand the difference 
between these compounds based on the previous information of modelling and binding 
assay studies in chapter 3.  
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4.1.1.1  TERA-2.cl.SP12 teratocarcinoma stem cells 
Embryonal carcinoma (EC) is stem cells from germ tumours origin and is considered 
the malignant counterparts of embryonic stem (ES) cells. EC cells are a useful model to 
investigate the molecular mechanisms that control differentiation, especially TERA-
2.cl.SP12 cell type for neural development which behave in a manner similar to human 
embryogenesis.338  TERA-2.cl.SP12 was choosen as a model for cellular differentiation  
as it’s robust model and very sensitive for differentiation by retinoids. ATRA is the 
active retinoid molecule that has been found to induce neuronal differentiation of these 
cells depend on the concentration of retinoic acid used and the time of exposure.339 It 
was found that in an average of 7 days, TERA-2 cells tend to differentiate into 
aggregates termed neuro spheres which contain neuro progenitor cells. After 14 - 21 
days of growth in suspension, neuro spheres are readily dissociated to release neural 
cells for growth as adherent monolayers on poly-D-lysine coated surface.340 
 
During the induction of differentiation, TERA-2-derived cells rapidly lose their EC stem 
cell phenotype and acquire different growth characteristics and morphologies. This 
includes, loss of their expression of cell-surface antigens specific for pluripotent human 
stem cells (e.g. SSEA3, SSEA4 and TRA-1-60) and simultaneously acquiring a variety 
of other antigens that commonly appear on the surface of TERA-2 differentiated cells 
such as A2B5.335 Notably, the expression of some intracellular markers such as nestin, 
NeuroD1 and Pax6 are markedly up-regulated after TERA-2-derived cells lose their 
pluripotency upon cellular differentiation.340 
 
4.1.1.2 Neuroblastoma (SHSY5Y) 
SH-SY5Y cells contain many characteristics of dopaminergic neurons and have, 
therefore, been used extensively to study neuron-like behavior in response to 
neurotoxins in the context of Parkinson disease.340 These cells can respond well to 
retinoic acid exposure and differentiate into neuron-like structures, and hence, lose their 
carcinogenic characteristics.341 This was interestingly seen through the resistance of un-
differentiated cells by retinoic acid to oxidative stress-inducing compounds such as 6-
hydroxydopamine, whereas neuronal cells are generally thought to be more 
susceptible.232 
 
Chapter IV 
 
112 
 
 
During in vivo neuro-differentiation of SHSY5Y, various proteins change in their 
expression levels as a consequence of cellular specialization. Tyrosine hydroxylase (TH) 
as an example, TH catalyzes the rate-limiting step in the synthesis of dopamine and 
other catecholamines, namely the conversion of tyrosine to dihydroxy phenylalanine. 
This makes TH one of the markers of choice for dopaminergic neuron's screening.342 
Also, Synaptophysin, which is an integral membrane glycoprotein, is a marker for 
synaptic vesicles that store and release classical neurotransmitters. Thus, its presence 
indicates secretory activity typical for neurons and neuroendocrine cells.343 As a 
consequence for over-expression of TH and dopamine; this will stimulate the expression 
of Dopamine transporter (DAT) as a sodium-dependent dopamine reuptake carrier 
expressed only in dopaminergic neurons at early stage of SHSY5Y differentiation.342 In 
addition, microtubule-associated protein 2 (MAP-2) is an abundant neuronal 
cytoskeletal phosphoprotein that binds to tubulin and stabilizes microtubules, essential 
for the development and maintenance of neuronal morphology, cytoskeleton dynamics 
and organelle trafficking.344 Once the neuronal cells become mature and have 
dopamenrgic activity (secretion and uptake of dopamine), this needs MAP-2 as 
constructive protein to build and stabilize the neuron structure. All these previously 
mentioned markers are harmony working protein markers that are responsible for 
functional characterization of differentiated neuroblastoma cells. The next question will 
be, whether undifferentiated SHSY5Y cells are suitable for studying the early stage 
effects of natural and synthetic retinoids to be able to use for treatment of 
neuroblastoma and other neurodegenerative diseases.  
In this chapter, a comparison was considered between the long-term effects on TERA-
2.cl.SP12 and the early stage differentiation of SHSY5Y. This work was to assist with 
screening the biological effects of a large number of new synthetic retinoids that have 
been prepared in the search for more efficient compounds than ATRA. This screening 
was based mainly on any obvious morphology changes in both cell lines, quantitative 
changes in gene expression level that can be correlated to the differentiation products, 
and hence, the nature and maturity of resulting cell types. Terminally differentiated, 
functional neurons are a potentially valuable resource for screening other new synthetic 
retinoids, testing their toxicity and to use these cells as a potential source of 
transplantable material to correct neurodegenerative diseases.  
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4.2 Flow cytometry analysis of cell surface markers in TERA-2.cl.SP12 
stem cell 
The primary characteristic feature of TERA-2.cl.SP12 cells is their ability to maintain 
pluripotent behaviour of stem cells for unlimited cell passages. Several markers are 
characteristic for human pluripotent stem cells and these proved to be useful tools to 
monitor their undifferentiated phenotype. In our study, we showed that the expression of 
a set of important cell surface pluripotent markers such as SSEA-3 and TERA-1-60 are 
useful for monitoring of cell pluripotency during retinoid exposure. In addition, the 
neural differentiation cell marker A2B5 was an early marker that can track the stage at 
which differentiation occurs. The level of expression of these markers depends on the 
exposure time and the concentration used of these retinoid compounds.  
Flow cytometry analysis of these markers was the tool of choice for the quantitative 
assessment for the biological potency of these retinoid analogues. The control un-treated 
cultures, or those treated with DMSO solvent, showed high levels of SSEA-3 and TRA-
1-60 (60-70% of cells expressed these markers), which might suggest that the cells 
retained their un-differentiated state. The 2D plots in fig. 4.6 show thresholds 
determining the numbers of positively expressing cells were set against the negative 
control P3X antibody. Control cells treated with DMSO were gated in the lower right-
hand side of the quadrant plot. This indicated that cells expressed high level of SSEA-3 
and the same pattern was seen with the TRA-1-60 marker. In contrast, less than 20% of 
control cells expressed A2B5 and so, cells were gated in the lower left-hand side of 2D 
plot and histogram of A2B5 (Fig. 4.6). Cultures treated with 10 µM of ATRA or EC23, 
EC19 or their methyl esters for 7 days showed a significant reduction in expression of 
these pluripotent markers especially with ATRA and EC23 as SSEA-3 (less than 20%) 
and TRA-1-60 (less than 50%), (Fig. 4.7a and Fig.4.7b). This was revealed in fig. 4.6 as 
few gated cells expressed SSEA-3 or TRA-1-60 is in the lower right-hand side of the 
2D plot. 
A2B5 is another cell surface marker over-expressed as a consequence of cellular 
differentiation. The cultures treated with ATRA or EC23 showed the highest expression 
levels of A2B5 and so, gated cells were shown to be in the right-hand side of the 2D 
plot and histogram. This might suggest that cells exposed to ATRA and EC23 were 
induced to differentiate in away similar to neuronal fate (Fig. 4.7). 
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 EC19 treated cultures showed lower expression levels of both SSEA-3 but not TRA-1-
60 however; the expression level of A2B5 was remained not over-expressed. This might 
suggest there was specific way of cellular changes upon treatment with EC19 but the 
effect is different than ATRA or EC23. Only the methyl ester of EC23 was able to show 
higher biological potency similar to EC23 (Fig. 4.7). 
 
For the second class of thiazole synthetic retinoids, GZ25 was the only one that 
displayed a profile similar to ATRA. SSEA-3 and TRA-1-60 levels were down-
regulated to less than 10 % and 20 % respectively compared to control cultures. 
Additionally, the A2B5 level was up-regulated more than 80% compared to 60% for 
ATRA. This might be releated to the molecule’s length of GZ25 is close to ATRA as 
discussed before in chapter 3. The other GZ derivatives, such as GZ18, GZ22 and GZ23 
showed reduction in the level of SSEA-3 expression. This might be explained ad 
aconsequence of the cellular loss for its pluripotent character compared to control 
cultures but there was not higher increase in A2B5 as with ATRA or GZ25 cultures. 
Additionally, the ethyl ester analogues of GZ24 did not show any significant 
improvement of the biological activity than their parent acid form (Fig. 4.8). 
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Figure 4.6: Flow cytometry analysis of TERA-2.cl.SP12 cells treated with 10µM ATRA, EC19 and EC23 
after 7days, A) 2D plots and histogram representation of gated cells expressing SSEA-3 and A2B5 after 
treatment with retinoids. Graphs were analysed and drawn using WinMDI2.9. Results are presented as 
n=3. 
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Figure 4.7: Flow cytometry analysis of stem cell surface markers a) SSEA-3; b) TRA-1-60; and c) early 
stage neuronal marker A2B5. Control TERA-2.cl.SP12 cultures represent cells treated with 1% DMSO. 
TERA-2.cl.SP12 cultures were treated with 10 µM of different synthetic retinoids and analysis was done 
7 days after exposure. All retinoids showed significant reduction in level of SSEA-3 and TRA-1-60 which 
might suggest cellular change. However, the level of A2B5 as neuronal marker compared to control was 
markedly increased with ATRA, EC23 and EC23 methyl ester. Results are presented as ± SEM, n = 3 and 
un-paired t-test followed by F-test analysis (test of varience) was used for analysis at (p < 0.05) in 
comparison to control cells treated with 0.1% DMSO. 
 
Retinoid 
compound 
Probability P value Significant? 
ATRA P < 0.05 0.0021 Yes ** 
EC19 P < 0.05 0.0002 Yes*** 
EC23 P < 0.05 < 0.0001 Yes **** 
EC19 M P < 0.05 0.0001 Yes *** 
EC23 M P < 0.05 < 0.0001 Yes **** 
Retinoid 
compound 
Probability P value Significant? 
ATRA P < 0.05 < 0.0001 Yes **** 
EC19 P < 0.05 0.0708 NS 
EC23 P < 0.05 < 0.0001 Yes **** 
EC19 M P < 0.05 0.0048 Yes ** 
EC23 M P < 0.05 0.0033 Yes ** 
Retinoid 
compound 
Probability P value Significant? 
ATRA P < 0.05 < 0.0001 Yes **** 
EC19 P < 0.05 0.0243 Yes * 
EC23 P < 0.05 < 0.0001 Yes **** 
EC19 M P < 0.05 0.0020 Yes ** 
EC23 M P < 0.05 < 0.0001 Yes **** 
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Figure 4.8: Flow cytometry analysis of stem cell surface markers a) SSEA-3; b) TRA-1-60; and c) early 
stage neuronal marker A2B5. Control TERA-2.cl.SP12 cultures represent cells treated with 1% DMSO. 
Other cultures were treated with 10 µM of different thiazole synthetic retinoids and analysis was done 7 
days after exposure. All retinoids showed significant reduction in level of SSEA-3 and TRA-1-60 which 
might suggest cellular change. However, the level of A2B5 as neuronal marker compared to control was 
markedly increased with ATRA, GZ25 and GZ23. Results are presented as ± SEM, n = 3 and un-paired t-
test followed by F-test analysis (test of varience) was used for analysis at (p < 0.05) in comparison to 
control cells treated with 0.1% DMSO. 
 
Retinoid 
compound 
Probability P value Significant? 
ATRA P < 0.05 0.0021 Yes ** 
GZ18 P < 0.05 0.0026 Yes** 
GZ22 P < 0.05 0.0015 Yes ** 
GZ23 P < 0.05 < 0.0001 Yes **** 
GZ24 P < 0.05 0.0550 NS 
GZ25 P < 0.05 < 0.0001 Yes **** 
Retinoid 
compound 
Probability P value Significant? 
ATRA P < 0.05 < 0.0001 Yes **** 
GZ18 P < 0.05 0.0088 Yes** 
GZ22 P < 0.05 0.2750 NS 
GZ23 P < 0.05 0.0016 Yes ** 
GZ24 P < 0.05 0.3726 NS 
GZ25 P < 0.05 < 0.0001 Yes **** 
Retinoid 
compound 
Probability P value Significant? 
ATRA P < 0.05 < 0.0001 Yes **** 
GZ18 P < 0.05 0.0237 Yes * 
GZ22 P < 0.05 0.0069 Yes ** 
GZ23 P < 0.05 0.0008 Yes *** 
GZ24 P < 0.05 0.0170 Yes * 
GZ25 P < 0.05 < 0.0001 Yes **** 
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4.3 Immunocytochemistry analysis of TERA-2.cl.SP12    
Immunocytochemistry is an important tool for visualization of some specific neuronal 
proteins as an indication for the induction of cellular differentiation. There are many 
extra- and intra-cellular proteins that are secreted upon induction of differentiation in 
TERA-2.cl.SP12 with specific markers for early stages; A2B5 and TUJ-1. It is 
convenient to compare the changes in the level of expression of these proteins with the 
time of exposure to retinoids. This helps in the evaluation for the potency of these 
molecules and to observe the stage at which differentiation occurs. On the other hand, it 
is also useful to investigate the non-neuronal cell types such as epithelial cell which is 
usually associated with differentiation of weaker acting retinoids. CK-8 is one of these 
markers, which is known for its specific secretion with many types of epithelial cell345 
and hence, it can be used for evaluation of retinoids’ activity. Primary antibodies for 
TUJ-1 and CK-8 were used in this study after treatment of cells with 10 µM of different 
synthetic retinoids for 7, 14 and 21 days.  
In Fig. 4.9, the control DMSO cultures showed low levels of expression for both 
neuronal markers A2B5 and TUJ-1 and epithelial marker CK-8, which might suggest 
that the cells were in un-differentiated pluripotent state. It was also noted that the low 
level of TUJ-1 in the control cells mainly coincided in the cytoplasm. Upon exposure of 
cells to ATRA and EC23 for 7 days, the levels of A2B5 (around the cell surface) and 
TUJ-1 (in the cytoplasm) were increased as an early stage of neuronal differentiation 
with the minimum level of CK-8. After 14 and 21 days, the level of TUJ-1 expression 
continued to increase with obvious formation of more mature, differentiated neuronal 
cells. TUJ-1 was localized in both cytoplasm and diffused also into the peripherals of 
neurons. Moreover, it was found that levels of CK-8 with ATRA, and EC23 treated 
cultures was kept low, such as most of the cells differentiated into the neuronal cell 
types. In contrast, EC19 did not show any increase in either the level of A2B5 or TUJ-1 
after 7 days, with a minimum level of TUJ-1 positive cells even after 21 days as a late 
stage of exposure. However, CK-8 level increased in EC19 treated cultures after three 
weeks, as an indication of the epithelial fate of this cellular differentiation (Fig. 4.9).   
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Additionally, the biological potency of the thiazole retinoid derivatives was investigated 
and GZ25 was the only synthetic analogue that showed similar behaviour as ATRA and 
EC23. Higher levels of A2B5 and TUJ-1 were observed with GZ25 treated cultures 
(stained both extracellular and intracellular content) after 7 days with formation of 
neuron aggregates expressing TUJ-1 in peripherals (Fig. 4.10). GZ18 and GZ22 
expressed minimum level of TUJ-1 up to 21 days. This might suggest the lower potency 
of these analogues compared to GZ25 to induce neuronal differentiation (fig 4.10). The 
CK-8 level was also kept low with GZ25 treated cultures even after 21 days while, 
GZ18 and GZ222 showed an increase in number of positive stained cells for CK-8 after 
14 days and enhanced after 21 days (Fig. 4.11). This can reveal that GZ25 was potent 
enough to induce most of TERA-2.cl.SP12 cells into mature neurons in a way similar to 
ATRA and EC23 while GZ18 and GZ22 are intermediate compounds that induce a 
mixture of different cell types, of much lower number of neurons and higher number of 
epithelial cells. In conclusion, this accurate cell marker counting helped in evaluating 
the biological potency of these synthetic retinoids, compared to the levels of secretion of 
A2B5 and TUJ-1, which was also useful to differentiate the behaviour between retinoids 
as ATRA, EC23 and GZ25 from the other EC19, GZ18, GZ22, GZ23 and GZ24. 
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Figure 4.9: Expression of neuronal (A2B5 and TUJ-1) and epithelial (CK-8) proteins in TERA-2.cl.SP12 
treated with 10 µM of ATRA and synthetic analogues; EC19 and EC23 for 7, 14 and 21 days. Cells were 
fixed by 4% PFA and permeabilised using 1% Triton-X-100, stained with primary antibodies for A2B5, 
TUJ-1 and CK-8 followed by green fluorescent IgM secondary antibody (for A2B5) and IgG 
Alexafluor488 (for TUJ-1 and CK-8). High levels of A2B5 and TUJ-1 were observed only with culture 
treated with ATRA and EC23 with the minimum level of CK-8 expression. EC19 showed high level of 
CK-8 expression after 21 days as a result of epithelial cell differentiation with the low level of TUJ-1. 
Control cells treated with DMSO did not show any expression of either marker. Scale bar; 25 µm.   
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Figure 4.10: TERA-2.cl.Sp12 cells treated with 10 µM of thiazole synthetic analogues for 7, 14 and 21 
days. GZ25 showed high levels of A2B5 and TUJ-1 within time of exposure and formation of neurons 
rosette like structure stained with TUJ-1. GZ18 and GZ22 showed high level of TUJ-1 only after 21 days 
as indication of late stage biological potency. Control cells treated with DMSO did not show any 
expression of either marker. Scale bar; 25 µm.   
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Figure 4.11: TERA-2.cl.Sp12 cells treated with 10 µM of thiazole synthetic analogues for 7, 14 and 21 
days. GZ25 did not show any increase in level of CK-8 similar to control culture treated with DMSO 
solvent. While, GZ18 and GZ22 showed high levels of CK-8 after 14 days and increased after 21 days as 
a fate of epithelial cell differentiation. Scale bar; 25 µm.   
 
4.4 Induction of cellular differentiation - gene expression analysis 
The gene expression levels in TERA-2.cl.SP12 cells and SHSY5Y after retinoid 
treatment were analyzed using real time PCR. This can help in elucidating the biological 
activity and potency of ATRA and other new synthetic retinoids for induction of 
differentiation of both stem cells and cancer cells. During in vivo neuro-differentiation 
using retinoic acid, various genes and proteins change in their expression as a 
consequence of cellular specialization, In SH-SY-SY neuroblastoma cells, the 
expression of RAR-β is rapidly induced in response to ATRA. RAR-β gene has been 
relatively well characterized,346 and its induction may be important for the retinoic acid-
mediated expression of other “late” genes so that, it may be a valuable marker for 
evaluating the action of different synthetic retinoic acid derivatives.  
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Besides RAR-β gene investigation, this study investigated the expression of CYP26A1 
since it is the major enzyme responsible for the metabolic breakdown of ATRA and 
might be some other retinoids. CYP26 is a type of cytochrome P450 group of RA-
metabolizing enzymes (producing inactive hydroxylated products; 4-hydroxy-RA and 4-
oxo-RA) that may explain specific cellular effects on stability of retinoids. Hence, the 
induction of cellular differentiation for some synthetic retinoids, the SHSY5Y 
neuroblastoma cell line was studied in parallel to the cellular metabolism. This can test 
the reliability of this model of SHSY5Y for evaluation of the biological potency of any 
other synthetic retinoid analogues. To address this question, a comparison was done to 
test the biological activity of EC19, EC23 and methyl esters analogues as synthetic 
retinoids in TERA-2.cl.SP12 stem cells using different neuronal markers in 
undifferentiated and differentiated SHSY5Y neuroblastoma cells. This helped in further 
investigation of the biological potency of other synthetic analogues, such as GZ 
derivatives, for late and early stages of induction of cellular differentiation. 
 
Fig. 4.12 shows the difference in gene expression level of NeuroD1 (Fig. 4.12a) after 
TERA-2.cl.SP12 cells treated with 10 µM of different retinoids for 3, 5 and 7 days. 
NeuroD1 was up-regulated 5 days after treatment not with ATRA but with EC23, 
methyl esters of EC19, EC23 and increased significantly, after 7 days. EC19 treated 
cultures showed increase in level of NeuroD1 after 5 days however, it declined after 7 
days compared to ATRA and EC23 treated cells. On the other hand, PAX6 was another 
gene responded later after NeuroD1 with over expression 10 times more in EC23 treated 
cultures more than ATRA. EC19 treated cultures did not show any significant up-
regulation of PAX6 after 5 days and only slightly increased after 7 days (Fig. 4.12b). 
Interestingly, the PAX6 gene was over-expressed 100 times more in EC23 treated 
cultures than NeuroD1 gene. It can be suggested on the basis that the promoter region of 
PAX6 gene is completely under the control of retinoic acid receptor especially RAR-β, 
and hence, can explain the difference in magnitude and time onset. EC19 methyl ester 
also came in the same lower biological order of magnitude for up-regulation of PAX6 as 
matched with previous biological assays.  
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Figure 4.12: Gene expression analysis using qPCR for; a) NeuroD1 and; b) PAX6 in TERA-2.cl.SP12 
treated with ATRA, EC19, EC23 and their methyl ester analogues. TERA2.cl.SP12 cells were exposed to 
10 μM of different synthetic derivatives for 3, 5 and 7 days. Level of NeuroD1 increased after 7 days with 
cultures treated in ATRA, EC23 compared to EC19, while the cultures of methyl ester analogues of EC19 
and EC23 showed decline in the level of NeuroD1 after 7 days. PAX6 gene level increased with ATRA, 
EC23 and EC23 methyl ester after 3, 5 and 7 days, while other analogues did not show increasing in its 
level. Gene profile quantification is relative to the level of gene expression in TERA2.cl.SP12 cultured 
with 0.1% DMSO solvent for 7 days. Data are normalized to both control 0.1% DMSO and the internal 
reference gene (GADPH). Statistical analysis was done by paired t-test followed by F-test (test of 
varience) at (P<0.05) in comparison to cultures treated with retinoids for 3 days.  Data represent mean ± 
SEM, n = 3. 
Retinoid 
compound 
Probability 
P value 
5 days 
P value 
7 days 
ATRA P < 0.05 0.5372 
NS 
0.0086 
Yes ** 
EC19 P < 0.05 0.0011 
Yes ** 
0.0233 
Yes * 
EC23 P < 0.05 0.0339 
Yes * 
0.0002 
Yes *** 
EC19 M P < 0.05 0.0001 
Yes *** 
0.0265 
Yes *** 
EC23 M P < 0.05 0.0001 
Yes *** 
0.0065 
Yes ** 
Retinoid 
compound 
Probability 
P value 
5 days 
P value 
7 days 
ATRA P < 0.05 0.0001 
Yes **** 
0.0001 
Yes *** 
EC19 P < 0.05 0.3774 
NS 
0.0364 
Yes * 
EC23 P < 0.05 0.0001 
Yes **** 
0.0001 
Yes 
**** 
EC19 M P < 0.05 0.0027 
Yes ** 
0.2180 
NS 
EC23 M P < 0.05 0.0001 
Yes **** 
0.0001 
Yes *** 
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Gene expression analysis of RAR-α, -β and –γ on the SHSY5Y neuroblastoma cell line 
treated with retinoids showed different responses over a scale time of 2 to 12 hours and 
at concentrations of 10, 1, 0.1, 0.01 and 0.001 µM. The RAR-β gene expression level 
increased over time with concentration of 10 µM for both ATRA and EC23 treated cells. 
Based on the previous information in introduction chapter, this could suggest an early 
signs of cellular differentiation in neuroblastoma cells within 2 hours and the induction 
reached to the maximal peak after 6 – 8 hours and then declined (Fig. 4.12a). Also, it 
was noticed that EC23 showed higher gene expression levels than ATRA treated cells 
all over the time scale with 3 times magnitude higher after 6 hours of treatment. EC19 
did not show any significant increase in gene expression of RAR-β at any time point of 
treatment with 10 µM concentration. By testing different concentrations of these 
retinoids within 6 hours treatment, EC23 showed the same concentration dependent 
effect on expression of RAR-β compared to ATRA while EC19 showed higher gene 
expression of RAR-β at concentrations of 0.1 and 0.01 µM (Fig. 4.13b). EC19 methyl 
ester did not show any significant over-expression of RAR-β over the different time 
scale while, EC23 methyl ester showed significant increase in RAR-β gene expression 
relative to control cells treated with DMSO within early treatment (2 hours) but this was 
declined gradually by time until 12 hours treatment (Fig. 4.13a). All these information 
can reveal that RAR- β can be a useful marker as early sign for cellular differentiaon in 
SHSY5Y neuroblastoma cells. Also, RAR- β can be used as a marker to show the 
difference in biological activity between the different synthetic retinoids such as EC19 
and EC23. 
RAR-α and RAR-γ genes showed different levels of expression in SHSY5Y cells upon 
treatment with 10 µM of different retinoids over time than in RAR-β gene expression. 
Only, ATRA increased the expression of RAR-α gene level compared to control cells 
after 4 hours and over-expressed by time within 12 hours with ATRA showed higher 
level of RAR-α compared to EC19 and EC23. While, EC23 showed an increase in 
RAR-α gene expression by 12 hours treatment, however, its level was not higher than 
ATRA (Fig. 4.14b). RAR–γ gene level increased significantly after 12 hours treatment 
in all retinoid treated cells however ATRA showed higher level than EC23 and EC19. It 
also noted that ATRA induced high level of RAR-γ gene expression compared to RAR-
α after 12 hours (5 fold higher). 
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Figure 4.13: Real time PCR analysis of RAR-β gene expression in SHSY5Y cells treated with ATRA, 
EC19, EC23 and methyl ester analogues; a) SHSY5Y cells were exposed to 10μM of different synthetic 
derivatives for up to 12 hrs. ATRA and EC23 showed higher expression level compared to EC19 and 
other analogues over time scale with maximal peak after 6 hrs; b) SHSY5Y cells were exposed to 1, 0.1, 
0.01 and 0.001μM of different synthetic derivatives for up to 8 hrs. EC23 induced higher level of RAR-β 
over different concentration scales. EC19 showed also slightly higher level of expression of RAR-β 
compared to ATRA at 0.1 and 0.01 μM concentrations. Gene profilequantification is relative to the level 
of gene expression in SHSY5Ycultured with DMSO solvent for 12 hrs. Data were normalized to both 
control  0.1% DMSO and the internal reference gene (β-actin). Data represent mean ± SEM, n = 3.  
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Figure 4.14: Real time PCR analysis of SHSY5Y cells which exposed to 10μM of ATRA, EC19, EC23 
and methyl ester analogues for up to 12 hrs  and gene expression  analysis of; a) RAR-α gene and; b) 
RAR-γ gene. ATRA and EC23 showed slight increase in expression level of RAR-α after 4 hrs which 
increased significantly after 12 hrs compared to EC19 and other synthetic analogues. ATRA treated cells 
showed higher level of RAR-α expression than EC23. Also, ATRA and EC23 showed higher expression 
level of RAR-γ after 12 hrs compared to EC19 and other analogues after 12 hrs. ATRA treated cells 
showed 5 times higher level of RAR-γ than EC23. Gene profile quantification is relative to the level of 
gene expression in SHSY5Y cultured with 0.1% DMSO solvent for 4, 8 and 12 hours. Data are 
normalized to both control 0.1% DMSO and the internal reference gene (β-actin). Statistical analysis was 
done by paired t-test followed by F-test (test of varience) at (P<0.05) in comparison to cultures treated 
with retinoids for 3 days.  Data represent mean ± SEM, n = 3. 
 
Retinoid 
compound 
Probability 
P value 
8 hours 
P value 
12 hours 
ATRA P < 0.05 0.0151 
Yes * 
0.0001 
Yes *** 
EC19 P < 0.05 0.5023 
NS 
0.0011 
Yes * 
EC23 P < 0.05 0.2905 
NS 
0.034 
Yes * 
EC19 M P < 0.05 0.9811 
NS 
0.0649 
NS 
EC23 M P < 0.05 0.9898 
NS 
0.0415 
Yes * 
Retinoid 
compound 
Probability 
P value 
8 hours 
P value 
12 hours 
ATRA P < 0.05 0.0001 
Yes **** 
0.0001 
Yes *** 
EC19 P < 0.05 0.0309 
Yes* 
0.01 
Yes ** 
EC23 P < 0.05 0.2250 
NS 
0.0001 
Yes **** 
EC19 M P < 0.05 0.6961 
NS 
0.0001 
Yes **** 
EC23 M P < 0.05 0.0271 
Yes * 
0.0001 
Yes *** 
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The stability of these molecules in SHSY5Y cells were also investigated through the 
gene expression levels of CYP26A1. It was shown that 10 µM of ATRA induced 
quickly over-expression of CYP26A1 within 2 hours of cell uptake with the same 
maximal peak of gene expression after 6 hours and then, it declined gradually compared 
to the non-significant expression of EC19, EC23 and methyl ester analogues treated 
cultures (Fig.4.15a). Additionally, CYP26A1 was highly induced by ATRA over 
different concentration scales compared to EC19 and EC23 treated cultures (Fig. 4.15b). 
It is also noted, although CYP26A1 declined after 6 hours of ATRA treated cells but it 
was still higher than control cells treated with DMSO or even EC19 and EC23 treated 
cells. This may indicate that the process of cellular metabolism for ATRA is a 
continuous process occurs parallel to the process of induction of cellular differentiation 
and responsible for decline in RAR-β gene expression after 6 hours. 
The data gene expression data was presented here for ATRA, EC19 and EC23 using 
different concentrations and time scales showed that the both TERA-2.cl.SP12 cells as 
relatively long time scale and SHSY5Y cells as early stage seems to useful for 
biological evaluation of the synthetic retinoids. Both models can demonstarte the 
difference between the biological potency between these synthetic analogues in term of 
induction of genes responsible for cellular differentiation. Moreover, ATRA was 
reliable for cellular metabolism through the induction of CYP26A1 gene while, the 
EC19 and EC23 seem to be resistant for cellular metabolism. 
The second target was to evaluate the biological potency of other synthetic analogues; 
the GZ derivatives with special focusing on GZ18 and GZ25 compared to ATRA. It was 
found that GZ18 and GZ25 was able to induce higher gene expression level of NeuroD1 
compared to ATRA with maximal peak up to 5 days of TERA-2.cl.SP12 cell treatment. 
However, this declined gradually after 7 days. Two notes are observed here, first, GZ25 
was consistently potent for induction of NeuroD1 gene expression compared to GZ18 
over 7 days. Second, the level of NeuroD1 gene expression gradually increased with 
ATRA treated cells up to 7 days, compared to the level of expression of either GZ18 or 
GZ25 treated cells (Fig. 4.16a). For PAX6 gene expression analysis, the level of PAX6 
was slightly shown to be increased after 3 days of ATRA or GZ25 treatment with a 
significant increase after 7 days. Interestingly, GZ25 treated cells showed a higher 
induction of PAX6 gene level (5 fold higher) than ATRA treated cells (Fig. 4.16b). 
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Figure 4.15: Real time PCR analysis of CYP26A1 gene expression in SHSY5Y cells treated with ATRA, 
EC19, EC23 and methyl ester analogues; a) SHSY5Y cells were exposed to 10 μM of different synthetic 
derivatives for up to 12 hours. Only ATRA showed higher expression level compared to EC23 and EC19 
and other analogues over time scale with maximal peak after 6 hrs; b) SHSY5Y cells were exposed to 1, 
0.1, 0.01 and 0.001 μM of different synthetic derivatives for up to 8 hours. Also ATRA induced higher 
level of CYP26A1 over different concentration scales. EC19 showed also slightly higher level of 
expression of CYP26A1 compared to ATRA at 0.001, 0.01 and 0.1 μM concentrations. Gene profile 
quantification is relative to the level of gene expression in SHSY5Y cultured with DMSO solvent for 12 
hrs. Data are normalized to both control 0.1% DMSO and the internal reference gene (β-actin). Data 
represent mean ± SEM, n = 3. 
Chapter IV 
 
130 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16: Gene expression analysis of; a) NeuroD1 and; b) PAX6 in TERA-2.cl.SP12 treated with 
ATRA, GZ18 and GZ25. TERA2.cl.SP12 cells were exposed to 10μM of different synthetic derivatives 
for 3, 5 and 7 days. Level of NeuroD1 increased significantly by time treatment with ATRA while GZ18 
and GZ25 showed maximal peak of induction after 5 days and then decreased gradually. GZ25 showed 
markedly higher level of expression of NeuroD1 over time scale compared to GZ18. PAX6 gene level 
increased with ATRA and GZ25 with maximal peak at late stage (after 7 days) of induction of cellular 
differentiation. GZ18 showed also increase in PAX6 gene level after 7 days however, it was lower than 
either ATRA or GZ25. Gene profile quantification is relative to the level of gene expression in 
TERA2.cl.SP12 cultured with 0.1% DMSO solvent for 3, 5 and 7 days. Data are normalized to both 
control 0.1% DMSO and the internal reference gene (GADPH). Statistical analysis was done by paired t-
test followed by F-test (test of varience) at (P<0.05) in comparison to cultures treated with retinoids for 3 
days.  Data represent mean ± SEM, n = 3. 
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For RAR-β gene expression analysis, biological screening of all the GZ derivatives 
showed that GZ25 had the higher potency for induction of RAR-β at very early stages 
(2 – 3 hours) compared to ATRA and other GZ analogues with maximum peak after 6 
hours. However, ATRA had the higher induction potency for RAR-β gene level, 
compared to GZ25 and the other GZ derivatives after 6 hours. RAR-β gene level 
decreased gradually after 6 hours but was higher for ATRA and GZ25 treated cells 
compared to other GZ analogues (Fig. 4.17a). GZ18 only showed a low variable gene 
expression level of RAR-β along the whole time scale of culture treatment and the 
RAR-β level was lower than that ATRA and GZ25, and only the significant increase 
was observed after 12 hours. This might suggest the late response of this compound due 
to lower potency and this matched with delayed onset of induction for TUJ-1 markers 
which was observed previousely. At lower concentration scales, GZ25 was still 
significantly higher than GZ18 or ATRA for the induction of RAR-β gene expression 
(Fig. 4.17b). 
For RAR-α, GZ18 and GZ25 showed a gradual increase in the level of gene expression 
with a maximal peak after 12 hours of SHSY5Y treatment. However, ATRA induced a 
higher level of RAR-α gene expression compared to GZ18 and GZ25 cultures. 
Furthermore, GZ25 and GZ18 showed comparably similar levels of gene expression 
after 12 hours, with slight enhancement with GZ18 treated cultures (Fig. 4.18a). In 
addition, ATRA showed a higher level of RAR-γ expression after 12 hours of 
neuroblastoma treated cells compared to GZ18 and GZ25. However, GZ25 showed, a 
markedly higher level of expression compared to GZ18 (Fig. 4.18b). GZ25 was shown 
to be reliable for cellular metabolism similar to ATRA as it induced high gene 
expression level of CYP26A1 significantly over different time scales compared to other 
GZ analogues. Also, the maximal peak of CYP26A1 gene induction came earlier than 
that for ATRA (3 hours compared to 6 hours for ATRA) (Fig. 4.19a). This also was 
confirmed at lower concentration levels, GZ25 was able to induce more gene expression 
levels of CYP26A1 compared to either ATRA or GZ18 at a concentration of 0.001 µM.  
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Figure 4.17: Real time PCR analysis of RAR-β gene expression in SHSY5Y cells treated with ATRA, 
and different GZ derivatives (GZ18, GZ22, GZ23, GZ24 and GZ25); a) SHSY5Y cells were exposed to 
10 μM of different synthetic derivatives for up to 12 hours. ATRA and GZ25 showed higher expression 
level compared to other analogues over time scale with maximal peak after 6 hrs however, ATRA showed 
higher level of expression at 6 hrs than GZ25; b) SHSY5Y cells were exposed to 1, 0.1, 0.01 and 0.001 
μM of ATRA, GZ18 and GZ25 for up to 8 hours. GZ25 induced higher level of RAR-β over different 
concentration scales, this was followed by ATRA as a second order of magnitude. GZ18 showed the 
lowest level of expression of RAR-β compared to GZ25 and ATRA. Data are normalized to both control 
0.1% DMSO and the internal reference gene (β-actin) Data represent mean ± SEM, n = 3. 
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Figure 4.18: Real time PCR analysis of SHSY5Y cells which exposed to 10μM of ATRA, GZ18 and 
GZ25 for up to 12 hours and gene expression analysis of; a) RAR-α gene and; b) RAR-γ gene. ATRA 
induced the expression level of RAR-α after 4 hours and over-expressed after 12 hours compared to GZ18 
and GZ25 whih only induced the over-expression level of RAR-α after 12 hours. GZ18 showed 
comparable level of expression of RAR-α to GZ25. Also, ATRA and GZ25 showed higher expression 
level of RAR-γ after 12 hours compared to GZ18 and ATRA treated cells showed 5 times higher level of 
RAR-γ than GZ25. Data are normalized to both control 0.1% DMSO and the internal reference gene (β-
actin). Data represent mean ± SEM, n = 3. 
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Figure 4.19: Real time PCR analysis of CYP26A1 gene expression in SHSY5Y cells treated with ATRA, 
GZ18 and GZ25; a) SHSY5Y cells were exposed to 10 μM of different synthetic derivatives for up to 12 
hrs. GZ25 showed higher expression level similar to ATRA with maximal peak after 3 hours which was 
earlier than ATRA (6 hours); b) SHSY5Y cells were exposed to 1, 0.1, 0.01 and 0.001 μM of different 
synthetic derivatives for up to 8 hrs. Also GZ25 induced higher level of CYP26A1 at 0.001 and 0.01 µM 
concentration scales. GZ18 showed also slightly higher level of expression of CYP26A1 compared to 
ATRA at 0.001 and 0.01 μM concentrations. Data are normalized to both control 0.1% DMSO and the 
internal reference gene (β-actin). Data represent mean ± SEM, n = 3. 
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Only GZ18 was able to slightly induce gene expression of CYP26A1 at 1 and 0.1 µM 
but not at concentrations lower than that. This may give an indication that it is not 
necessarily that environmentally stable synthetic retinoid analogues would be 
metabolically stable as well (Fig. 5.19b).  
 
4.5 X-gal assay analysis of EC19 and EC23 
This assay was done by Prof. Peter Mccaffery’s group in Aberdeen University using Sil-
15 reporter cells (also called F9-RARE-lacZ cells) in the X-Gal Assay. This cell line 
was derived from a stable transfection of F9 teratocarcinoma cells with a plasmid 
containing the LacZ gene under the control of a promoter linked to a retinoic acid 
response element (RARE). This assay can visually detect and semi-quantify the 
transcriptional activity of retinoic acid and other retinoids by monitoring β-
galactosidase activity produced by the reporter cells in response to the retinoic 
acid/retinoids in the surrounding medium. EC19 and EC23 were tested compared to 
control cells (as a blank) which are treated with DMSO solvent. The response of the Sil-
15 reporter cell line to the two retinoids, EC23 and EC19 compared to RA was assayed 
at concentrations ranging from 10-6 M to 10-14 M (Fig. 4.20). EC23 was shown to be 
effective for induction of β-galactosidase expression and hence, a high genomic activity 
through RARE, while EC19 did not show any increase in induction of β-galactosidase 
gene at any of the concentration scale. This may give another indication for the selective 
and higher potency of EC23 compared to ATRA and EC19 for induction of cellular 
differentiation through activation of the RARE promoter and consequently, RARs. 
 
4.6 Induction of neurite outgrowth in SHSY5Y using EC19 and EC23. 
This assay was done by Prof. Peter Mccaffery’s group in Aberdeen University using 
SH-SY5Y cells as a model to study neuronal differentiation phenotypes through 
measuring neurite outgrowth. The exposure time of cells with ATRA, EC19 and EC23 
was long time scale to obtain more stable neuron-like properties, such as the neurite 
outgrowth. 
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Figure 4.20: Concentration response graph of X-gal assay for evaluating ATRA, EC23 and EC19 for 
induction of genomic response of β-galactosidase in Sil-15 reporter cells. ATRA and EC23 showed 
higher absorbance level as an indication of potent induction of β-galactosidase activity through RARE at 
different concentration scales. EC19 was similar to blank control cells and did not show induction of β-
galactosidase activity. n = 3. 
The effects of EC23 and EC19 on neuronal differentiation and neurite outgrowth in SH-
SY5Y cells were evaluated after 5 days at two different concentrations of 10 µM and 
0.01 µM and compared to control cells treated with DMSO. Cells were fixed and 
stained for TUJ-1 and the mouse anti-β-III tubulin, a secondary antibody was used for 
fluorescent labelling of neurites for easy tracing the number and length in different 
fields. Fig. 4.21a and Fig. 5.22a showed that EC23 was potent enough at concentration 
of 10 µM to induce induction of cellular differentiation of SHSY5Y and produced high 
numbers of mature neurons compared to DMSO treated cells. The length of these 
neurons was not increased with the corresponding increase in concentration of EC23 
from 0.01 µM (Fig. 4.22c and Fig.4.22d) to 10 µM (Fig.4.21c and Fig.4.21d). However, 
the numbers of neurons were slightly increased with the 10 µM concentration compared 
to 0.01 µM. In a different way; EC19 was not potent in either concentration to induce 
any increase in both neurite number and length for the same time of cell exposure 
compared to control cultures (Fig.4.23a and Fig. 4.24a). This means that EC19 was not 
potent even over long times of exposure to induce cellular differentiation of the 
SHSY5Y cells (Fig.4.23c and Fig.4.24c). Interestingly, it was noted that EC19 had the 
effect on SHSY5Y cells to form clumps, which was not further studied yet to 
investigate its biological role on cell adhesion (Fig.4.25). 
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Figure 4.21: Neurite outgrowth of SHSY5Y treated with EC23 and stained for TUJ-1; A) 10 µM EC23 
as it induced the differentiation of SH-SY5Y cells. B) DMSO treated SH-SY5Y cells as a control. C) The 
length of neurites extending from SH-SY5Y cells after 5 days of 10 µM EC23 treatment was measured 
and compared with the control. The average length was expressed in the graph ± SEM, n=3. Significant 
difference was measured by t-test (P= 0.0005). D) The total number of neurites extending from SH-SY5Y 
cells after 5 days of 10 µM EC23 treatment was measured and compared with the control. The average 
number was expressed in the graph ± SEM, n = 3(3 values of average neurite length; one value per each 
cover slip of the three). Significant difference was measured by Student’s t-test (P = 0.0014). Scale bar 50 
µm. This analysis was done by Prof. Peter Mccaffery’s group in Aberdeen University, UK. 
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Figure 4.22: Neurite outgrowth of SHSY5Y treated with EC23 and stained for TUJ-1; A) 0.01 µM EC23 
as it induced the differentiation of SH-SY5Y cells. B) DMSO treated SH-SY5Y cells as a control. C) The 
length of neurites extending from SH-SY5Y cells after 5 days of 0.01 µM EC23 treatment was measured 
and compared with the control. The average length was expressed in the graph ± SEM, n = 3. No 
significant difference was measured by t-test (P = 0.1701). D) The total number of neurites extending 
from SH-SY5Y cells after 5 days of 0.01 µM EC23 treatment was measured and compared with the 
control. The average number was expressed in the graph ± SEM, n = 3(3 values of average neurite length; 
one value per each cover slip of the three). Significant difference was measured by t-test (P = 0.0147). 
Scale bar 50 µm. This analysis was done by Prof. Peter Mccaffery’s group in Aberdeen University, UK. 
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Figure 4.23: Neurite outgrowth of SHSY5Y treated with EC19 and stained for TUJ-1; A) EC19 treated 
SH-SY5Y cells at 10 µM. EC19 did not induce neurite outgrowth of SH-SY5Y cells. B) DMSO treated 
SH-SY5Y cells used as a control. C) The length of neurites extending from SH-SY5Y cells after 5 days of 
10 µM EC19 treatment was measured and compared with the control. The average length was expressed 
in the graph ± SEM, n = 3(3 values of average neurite length; one value per each cover slip of the three). 
No significant difference was measured by t-test (P = 0.3043). Scale bar 50 µm. This analysis was done 
by Prof. Peter Mccaffery’s group in Aberdeen University, UK. 
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Figure 4.24: Neurite outgrowth of SHSY5Y treated with EC19 and stained for TUJ-1; A) EC19 treated 
SH-SY5Y cells at 0.01 µM. EC19 did not induce neurite outgrowth of SH-SY5Y cells. B) DMSO treated 
SH-SY5Y cells used as a control. C) The length of neurites extending from SH-SY5Y cells after 5 days of 
0.01µM EC19 treatment was measured and compared with the control. The average length was expressed 
in the graph ± SEM, n = 3(3 values of average neurite length; one value per each cover slip of the three). 
No difference was measured by T-test (P = 0.6881). Scale bar 50 µm. This analysis was done by Prof. 
Peter Mccaffery’s group in Aberdeen University, UK. 
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Figure 5.25: SHSY5Y cells treated with 10 µM EC19 for 5 days and then, stained for TUJ-1; a) EC19 at 
either lower or higher concentrations did not show any peripheral neuronal outgrowth within the different 
colonies, scale bar 50 µm; b) higher resolution (10 µm) showed that EC19 induced cell clump formation 
within each colony (showed in white circles) which might suggest induction of cellular proliferation 
rather than differentiation. This analysis was done by Prof. Peter Mccaffery’s group in Aberdeen 
University, UK. 
4.7 Raman spectroscopy analysis of SHSY5Y cells 
There are many non-traditional preclinical tools that are accurate, high-throughput, and 
cost-effective those provide a unique fingerprint spectrum containing global 
biochemical information of the main macromolecules that compose a cell; either at the 
single-cell level or as an overall signal from a global cell population. The evidence for 
retinoids–cell interactions and hence, their efficacy can be, inferred by the acquisition of 
IR spectral data from treated cells. It is possible to detect discriminatory changes to the 
cellular IR signals even before visible morphological changes are evident, producing 
data of diagnostic significance for retinoid screening applications. Some previous FTIR 
analysis of TERA-2.cl.SP12 cells was done to investigate the biological changes 
occurred to stem cells upon cellular differentiation with EC19 and EC23. In this study, 
Raman spectroscopy, a more powerful tool with higher resolution was used to find out 
if any biological changes might happen upon treatment of SHSY5Y cells with EC19, 
EC23 and ATRA for 3 days. Prior to recording the Raman analysis of the cells, every 
spectrum was corrected for Raman scattering/fluorescence using a polynomial baseline 
fitting function.  
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After doing this optimization, every recorded cell spectrum had a flat baselines, which 
made elucidating spectral differences between the different spectra easier (gives each 
spectrum a common flat baseline).After, a polynomial fitting process, every spectrum 
was then normalised to account for the larger Raman signal intensities seen from some 
of the cell spectra recorded. When comparing the mean cell spectra from the different 
groups (retinoid treated neuroblastoma cells, ATRA and EC23 groups) and control 
neuroblastoma cells (control un-treated and DMSO treated neuroblastoma cells) there 
were few Raman band, which were different from cells that had been treated with 
retinoids (starred in the Fig. 4.26).  
 
The clear spectral differences at 1570-1640 cm-1 from ATRA treated cell spectra when 
compared against control cells could be due to the C=C vibrations of the retinoid 
molecules still present inside the treated neuroblastoma cells. To back this up, Raman 
spectra recorded before from retinal and vitamin A in liver tissue and retinoic acid in 
literature were displayed and compared to the Raman spectrum of pure ATRA, EC19 
and EC23 to confirm the region of this band. Every Raman spectra recorded for pure 
retinoid compounds had a high-intensity Raman band situated at 1570-1620 cm-1 due to 
the differences in compound chemical structures. This band has been previously 
assigned to the stretching vibrations of C=C molecules present in the molecular 
structures of retinoids. There is an interesting band for carbon – carbon triple bonds, 
which provides a strong Raman signal with frequencies typically between 2100 – 2250 
cm-1 (Fig.4.27). By looking to Fig. 4.26, if the band at ~1602 was due to the retinoid 
compounds still present in and around the cell, a strong C-C triple bond should be seen 
from EC19 or EC23 treated cell spectra; a vibration frequency at 2100-2250 cm-1, but 
this signal does not exist. To confirm this finding, Raman spectrum was recorded at the 
range of 1800-3600 cm-1 and there was no signal seen in the 2100-2250 cm-1 (fig. 4.28). 
Therefore, it is unlikely that this Raman band at ~1602 cm-1 was due to the retinoids still 
being bound, but is purely due to biological changes in the neuroblastoma occuring 
upon retinoid treatment. Furthermore, Fig.4.29a and Fig.4.29b were produced using 
principal component analysis (PCA) and show that the retinoid treated cells can be 
separated from the control cells (untreated and DMSO treated neuroblastoma cells), 
with spectral differences in the PC1 separation boundary, explaining differences 
between the retinoid treated and not treated ones.  
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The main spectral differences causing the separation along this boundary are due to a 
large increase at 1570-1640, and increases at 1220-1280, 1145 and 974-975 cm-1. As 
previously explained, the Raman band at 1570-1640 cm-1 is more than likely to derive 
from the retinoid structures present inside the cells. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.26: Mean Raman spectra of SHSY5Y neuroblastoma cells of un-differentiated, DMSO- treated, 
EC23 and ATRA treated neuroblastoma cells. Mean spectra revealed spectral differences between the 
retinoid treated neuroblastoma cells and the control cells from the Raman bands situated at 1570-1640, 
1220-1280 and 960-980 cm-1. This analysis was done by Graeme Clemens and Mathew Baker, University 
of Central Lancashire, UK. 
 
 
 
 
 
 
 
 
 
 
Figure 4.27: Raman spectra recorded from ATRA, EC19 and EC23 pure compounds using a 532 nm 
laser. The synthetic retinoids EC19 and EC23 have a strong Raman band attributed to carbon – carbon 
triple bond vibrations frequency between 2100 – 2250 cm-1. This analysis was done by Graeme Clemens 
and Mathew Baker, University of Central Lancashire, UK. 
Chapter IV 
 
144 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.28: EC23 treated neuroblastoma cell Raman spectrum; using 532nm laser 1800-3600 cm-1 
spectral range. There is no Raman signal is seen in the 2100-2250 cm-1 spectral range from the Raman 
spectrum recorded from an AH61 treated neuroblastoma cell. Therefore it can be concludedthat the 
increase in Raman signal ~1602 cm-1 from EC23 treated neuroblastoma cells is due to cellular changes as 
a result of cellular differentiation not any residual amount of the compound in the cells. This analysis was 
done by Graeme Clemens and Mathew Baker, University of Central Lancashire, UK. 
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Figure 4.29: principal component spectral loading vector of SHSY5Y neuroblastoma cells treated with 
ATRA, EC19 and EC23 compared to control cells, A) All the peaks between retinoids and control 
samples at 1570-1640, 1220-1280 and 960-980 cm-1 were statistically analysed by transforming into set of 
linearly un-correlated varriables and the graph was drawn between PC1 versus PC4 as the two major 
variables. All the retinoid treated neuroblastoma cells of ATRA and EC23 treated cells were clearly 
separated from EC19, control and DMSO treated cells along these PC1 principal component vector, B) 
the main spectral difference causing the separation along the PC1 vector for the Raman band situated at 
~1602 cm-1; EC23 and ATRA treated cells all showed a much greater intensity from when compared to 
EC19, DMSO and control cells in addition to other discrete spectral differences as a result of the retinoids 
treatment. This analysis was done by Graeme Clemens and Mathew Baker, University of Central 
Lancashire, UK. 
 
4.8 Conclusion 
Biological characterization of synthetic retinoids is the second tool used for screening 
and understanding the differences in the potency of these molecules, based on the 
differences in their chemical structures. The validation of different biological assays 
was based on analysis of two synthetic analogues; EC19 and EC23 compared to ATRA 
and control un-differentiated cells. In TERA-2.cl.SP12 stem cells, EC23 showed similar 
behaviour to ATRA with higher biological potency to induce cellular differentiation at 
different time scales.  
 
 
 
Chapter IV 
 
146 
 
 
This included down-expression of some extracellular markers using flow cytometry 
such as SSEA-3 and TRA-160, and up-regulation of neuro-specific extracellular marker 
A2B5. Also, EC23 was potent at inducing the secretion of intracellular TUJ-1; the early 
stage neuro-marker is an indication of cellular differentiation. While, EC19 was less 
potent at showing any enhancement in activity for the induction of cellular 
differentiation represented as changes in the previously mentioned markers. Gene 
expression analysis of TERA-2.cl.SP12 stem cells showed an increase in up-regulation 
of both NeuroD1 and PAX6 genes with different time patterns in the case of ATRA and 
EC23 treated cells compared to EC19. These genes are known to be over-expressed 
with early formation of neurons and at late stage of cellular differentiation. Upon 
investigation of other classes of synthetic retinoids, the GZ derivatives, GZ25 showed 
biological activity similar to ATRA, this was confirmed by the previously mentioned 
assays. 
Another biological assessment was done using the neuroblastoma cell line to investigate 
its efficacy as a model for biological screening of early signs of cellular differentiation 
of retinoids. Gene analysis was done including all RAR genes and cellular metabolic 
genes responsible for CYP26A1 activity and it was found that ATRA, EC23 and GZ25 
were biologically potent to induce up-regulation of RAR-β gene which was reported as 
the main gene for induction of cellular differentiation in SHSY5Y. EC23 was suggested 
as a metabolically stable synthetic analogue as it showed lower induction potency to the 
CYP26A1 gene compared to ATRA and GZ25 at different times and concentration 
scales. This combined biological approach is useful for the biological characterization 
of future synthetic retinoid analogues at late and early stages of cellular exposure to 
retinoids.
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Discussion 
 
Retinoids are essential for embryonic development and play important physiological 
functions, particularly in the brain and other highly developed organs.347 These activities 
occur through the actions of the six known nuclear receptors, the retinoic acid receptors 
(RAR-α, -β and –γ) and the retinoic X receptor (RXR-α, -β and –γ).348,349,350,351 Each of 
these receptors are encoded by distinct classes of genes and bind to different classes of 
other proteins. Indeed, most of retinoids that are used in the past for treating different 
diseases, in vivo and in vitro analysis are ATRA, 9-CRA and to less extend 13-
CRA.352,353 However, the reported drawbacks of using these molecules in research due 
to instability and cellular metabolism limits the effective use of these molecules.354 
Hence, there is a need to design and synthesise other modified molecules that are 
derivatives of vitamin A, with higher stability and more potency to be used in both in 
vitro and in vivo applications. 
The main aim of this thesis is to combine the calculated chemical structures, receptor 
binding assays and molecular docking tools in order to probe, and hence, understand the 
biological activity of newly synthesized retinoids with the ultimate goal of designing 
more specific synthetic retinoic acid derivatives, as well as improving our understanding 
of the downstream effects. Moreover, these was an urgent need to build up our 
knowledge about the biological activity of these molecules in different cell lines, at 
different concentrations and different time of exposures so as to understand the activity 
of these molecules in the  induction of neuronal development. 
Molecular docking was useful tool to conclude some important findings about the 
molecular interactions of retinoids in the RAR LBDs: 
1. The carboxylate moiety of ATRA forms a salt bridge with the highly conserved 
Arg residue and hydrogen bonds with the hydroxyl group of Ser. This is similar to the 
binding interactions shown for the crystal structure of ATRA bound to RAR-γ.355 
2. 9-CRA also showed interactions with all the RAR LBDs, however, it was unable 
to form the same salt bridge via the Arg-carboxylate interaction which would be 
stronger interactions.  
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Instead, Ser hydrogen bonds in all RAR binding pockets remain, together with the 
hydrophobic interactions around the tri-methyl-cyclohexene section of the molecule. It 
is because 9-CRA has a cis-double bond at C-9 that changes the geometry of the 
molecule such that the carboxylate cannot quite reach the Arg residue, consequently 
reducing the binding affinity compared to ATRA. 
3. The ligand binding pocket of RAR-α and RAR-β, ATRA exists with in a single 
s-cis conformation which is ideal for best fitting interactions with Arg and Ser residues 
compared to, the s-trans form of 9-CRA. While in the ligand binding pocket of RAR-γ, 
ATRA and 9-CRA both exist in a mostly s-trans form with much better interactions for 
ATRA. This might account for previous observations for selective binding to the LBD 
of RAR-γ to the more extended conformation of ATRA (favorable conformation with 
minimum energy) compared to non-extended form in RAR-α or RAR-β and hence, the 
difference in binding affinity of RAR-γ than RAR-α or RAR-β. 
 
Moreover, molecular docking was able to shed the light on some characterstics for 
retinoid molecules with specific activity towards one type of RARs: 
1- Am580 has an amide linker region (check the list of retinoid chemical structures) 
that is arranged in a specific way so that the carbonyl group is oriented in a 
conformation in close proximity to Ser232. This allowed Am580 to form additional 
hydrogen bonds with Ser232 which reflect the selectivity and tight binding of this 
retinoid analogue to RAR-α. This was matched with previous studies showed that the 
serine at position 232 in RAR-α gives an explanation for the observed differences in the 
affinity with ATRA in this RAR type compared with that for RAR-β and –γ. This 
hydrogen bonding would not be permitted between the hydroxyl of serine and the 
hydrophobic linker of ATRA.51,356. This acitvity makes this compound useful for 
application in fighting different cancer cell lines due to the up regulation of the mRNAs 
coding for pro-caspase-1, -7, -8, and -9, which results in the increased synthesis of only 
pro-caspase-1 and -7 proteins and hence, induction of cell apoptosis.357 
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2- The selectivity of CD437 (check the list of retinoid chemical structures) to RAR-
γ as it has adamantyl group side-chain with a strongly lipophilic effect. This group can 
form a hydrophobic network with residues in the H12 helix, such as, Phe304, Leu386, 
Leu407, Met406 and Ile403 which play a critical role for accommodating different 
ligands in this region.358 In addition, Met272 is a fairly hydrophobic amino acid and 
typically found buried within the binding pocket of RAR-γ. It adopts a conformation 
suitable to form a stacking interaction with the aromatic moiety of CD437. The 
hydroxyl group also showed a hydrogen bond interaction with Met406; however, it was 
a weak interaction (distance in the range of 4 Å). This also matches with previous 
observation for the activity of this compound to induce apoptosis in a variety of human 
cell types, including cancer cell lines. 359, 360,361 
 
The second approach was to measure EC50s of these compounds in the RAR LBDs in 
term of binding affinities of these compounds and ability to induce the co activator 
recruitment succesifully. This can help to discriminate between different RAR receptor 
types because their specificities as drivers of biological responses were poorly defined: 
1- All the three RARs bind ATRA with similarly high affinities with the highest 
affinity were found with RAR-γ.362 For 9-CRA, the natural retinoid isomer of ATRA, 
showed also similar binding to all RAR types with relatively lower binding affinity 
compared to ATRA due to the bednt structure of 9-CRA at carbon 9. All these 
differences could be explaine based on the previous observation of molecular binding 
interactions of these molecues. Many studies suggested that under physiological 
conditions, RAR-γ would selectively bind ATRA over 9-CRA.363,364 The preference for 
ATRA by RAR-γ was found to result from ATRA having a slower off-rate compared to 
9-CRA. Thus, once ATRA binds to RAR-γ, it remains bound for a longer time than 9-
CRA before dissociates. This difference in the off-rate between ATRA and 9-CRA is 
such that, at equilibrium, in the presence of a mixture of ATRA and 9-CRA, very little 
9-CRA is bound to RAR-γ, unless the concentration of 9-CRA exceeded that of ATRA 
by at least more than 2 fold. This can be explained by the difference in term of higher 
binding affinity of RAR-γ to ATRA than 9-CRA. 
2- TTNBP was shown to be a potent synthetic analogue of retinoic acid that is 
known from several studies to have pan-agonist potency to bind and transactivate all 
RAR types.365,366,367  
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This was revealed from the lowest measured EC50s for this compound compared to 
ATRA. It can be suggested from modelling study that this has a both hydrophobic side-
chain in addition to replacement for the polyene linker group which makes it anchored 
by network of hydrogen bonds identical to that formed with ATRA with one extra 
hydrogen bond with Ser residue in each RAR pocket in addition to the van der Waals 
contacts with residues lining the LBP. 
3- RAR selective Compounds such as Am580 and CD437 showed lower EC50 for 
RAR-α and RAR- γ respectively. This was correlated to the specific binding interactions 
of these compounds in the RAR LBDs as it was revealed from the molecular modeling 
study. 
 
In addition, COPASI biosimulation software was helpful in understanding the shape of 
the sigmoidal curves and the different level of higher asymptoes resulted from the 
receptor binding assay studies as it can be concluded that: 
1- There are four important parameters control the interactions of retinoids with 
RAR; k1,k2, k3 and k4. (k1/k2) ratio represented the binding affinity of the retinoid ligands 
to RAR LBDs. Also, the (k3/k4) ratio represents the binding affinity of the formed 
ligand-receptor complex to the co-activator. 
2- The nature of the ligand- receptor complex is a crucial element for further 
binding to the co-activator, and hence, the success of the transcription process. In other 
words, if the retinoid compound fits properly in the RAR LBD, this will trigger the 
succesiful binding to co-activator and hence, lower EC50 and higher upper asymptote. 
There are two possibilites for the higher upper asymptote in this case, the succesiful 
binded co-activator will be in close proximity to the conformational structure of 
retinoid-receptor complex and hence, the signal propagation in FRET assay will be high. 
The other probability that there will be high number of best fit retinoid-receptor 
complex which will consequently bind with many of co-activators availble and also this 
will also induce higher signal propagation in FRET assay. 
3- It was found that some compounds may be able to bind succesifully to the RAR 
LBDs however, they had lower upper asympotes and this might be explained as the 
retinoid-receptor complexs formed can not induce co-activator binding or co-activator 
binds in away different than the typical retinoid agonist. 
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Gathering all these information together was useful to understand the molecular and 
cellular activity of the new synthetic retinoid analogues, EC, GZ and their methyl ester 
derivatives (check the list of retinoid chemical structures) in different biological systems 
of TERA-2.cl.SP12 and SHSY5Y cells.  
EC19 and EC23 differ from each other only in the position of carboxylic acid group on 
the terminal substituted ring; EC23 was designed to mimic ATRA, and the meta-
position carboxylic acid of EC19 has the effect of changing the geometry of the 
molecule in a similar manner to the alkene geometry differences between ATRA and 9-
CRA. EC23 and EC19 docked into the different RARs with binding interactions which 
were different to those of ATRA, particularly with respect to the orientation of the 
crucial carboxylate group. The para-substitution of the carboxylate facilitated an 
excellent fit of EC23 into the binding pocket in all the RARs by forming a strong salt 
bridge with the conserved Arg residue, with the addition of two further hydrogen bonds 
with the conserved Ser residue. This binding mode is very similar to that of ATRA, and 
in contrast to that of the meta-substitution of the carboxylate in EC19. In this case, the 
different geometry of the phenyl carboxylate alters the orientation of the entire molecule 
in the LBD, such that neither a salt bridge nor, a hydrogen bond is possible in the LBDs 
of either RAR-α or –γ. This was correlated with the measured EC50, EC23 had the 
strongest binding affinity compared to EC19 that had the lowest EC50. 
 
However, for RAR-β, EC19 has both the topography and size that is more 
complementary with the binding pocket because of the additional space (extra groove 
compared with either RAR-α or -γ) in the LBD of RAR-β67 and hence, it had a relatively 
high affinity for the RAR-β LBD, and ligand binding also facilitates co-activator 
recruitment with higher upper asymptote.  
The binding pose of EC19 within the LBD of RAR-β was found to be stabilised by the 
formation of a salt bridge interaction with Arg and hydrogen bonds with Ser, but 
modelling also showed change in the orientation of EC19, resulting in the tetra-methyl-
tetra-hydronaphthalene moiety forming short contacts and clashes with some key 
residues in the LBD, i.e. with residues Ile270 and Val395 in RAR-α355,368,369 and Ala397, 
Leu416, Phe230, Ala234, Met415, Phe288 and Ser289 in RAR-γ but not with RAR-β 
residues.355,370  
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Such interactions are likely to affect the active conformation of H12, and thereby, the 
recruitment of co-activators and initiation of the transcription process. Having examined 
and compared ATRA, 9-CRA, EC23 and EC19, in order to confirm the key role of the 
carboxylate interaction with the Arg and Ser residues, the corresponding methyl esters 
of EC19 and EC23 were synthesized371 and investigated to see if the ester form reduced 
the activity of either EC19 or EC23. There was no increase in, the binding affinity of 
EC19 methyl ester to any of the RARs, except slightly to RAR-α, but the binding 
affinity was lower than for both ATRA and EC23 in their free acid forms. For the 
methyl ester of EC23, there was a massive drop in the binding affinity to all the RARs 
compared to both ATRA and EC23 in their acid forms. 
The second class of synthetic retinoids accommodates the alkoxythiazoles, i.e. the GZ 
derivatives (check the list of retinoid chemical structures). These compounds were 
synthesized372 with the aim to selectively bind to RAR-β. The idea was that the RAR-β 
binding site was larger due to the presence of an additional cavity between H5 and 
H10.67 It may be postulated, therefore, that ligands with larger side-chains are able to 
occupy the additional space within the RAR-β retinoid binding site, and hence, may 
show selectivity for this subtype. Receptor binding affinity showed that GZ25, and its 
ester derivatives, were the only ones able to bind efficiently to RAR-β binding pocket. 
Our suggestion for the enhanced binding affinity of these two derivatives matched 
previous studies claiming that the tetramethyl-1,2,3,4-tetra-hydronaphthyl side-chain 
can be accommodated by the RAR-β pocket and form favourable interactions with 
Leu407, Met406, and Ile403 to keep, the important helix-12 (AF-2) in the active 
conformation with minimal steric clashes.373 
In addition, the position of the thiazole group within these derivatives was optimal to 
allow all the GZ derivatives to form additional hydrogen bonds with the Ser232 residue 
and this was reflected also in the higher binding affinity of GZ25 to RAR-α. 
However, GZ25 was the one with higher binding affinity and best fitting in RAR LBDs, 
which can be explained in terms of the similar molecule length as ATRA, and hence, 
can produce the same binding interactions in the RAR-α binding pocket. The other GZ 
derivatives did not properly fit within the binding pocket either, due to the extended 
molecular length which (causing additional strain inside binding pocket, such as GZ23), 
or shorter molecules that could not hit all the hydrophobic contacts within lipophilic 
region in RAR-α, such as GZ18, GZ22 and GZ24. 
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Biological evaluation of these EC and GZ derivatives showed that the overall higher 
binding affinity of EC23 and GZ25 to all RARs was the sarting point for further up-
regulation of RAR-β level in SHSY5Y neuroblastoma cell line in early stage within 2 
hours of treatment. RAR-β is well known to be a major regulatory factor in the 
induction of cellular differentiation in many cell lines.374 Decreased expression of RAR-
β plays a key role in the maintenance of malignant phenotypes in many cancerous cells 
such as human pancreatic adenocarcinoma, and therefore, it represents a novel target for 
experimental strategies in the treatment of cancer and evaluation of retinoids.375 EC23 
and GZ25 were potent enough in a concentration dependent manner, with 10 µM to 1 
nM showing the higher potency compared to ATRA, EC19 and their methyl esters. Also, 
Many studies showed that PAX6 gene expression is controlled by the promoter region 
of the RARs (RARE), especially RAR-β and so, its expression is regulated by their 
activation.376,377,378 This was observed in TERA-2.cl.SP12 as EC23 and GZ25 were able 
to induce higher level of PAX6 after 7 days as indicated by the determination of neuro-
differentiation. The levels were 5 and 10 fold higher than for ATRA. Neither EC19 nor 
its ester derivatives or other GZ derivatives, showed any significant increase in the level 
of PAX6. Also, for further confirmation for the role of RARE and PAX6 for the 
difference in biological potency of these compounds, an X-gal assay was done using the 
LacZ gene under control of RARE which consequently was affected by RAR-β gene 
expression. EC23 and ATRA showed higher potency to induce β-galactosidase activity 
than EC19 over different concentration scales up to 10-14 M, and hence, this showed the 
higher induction of RAR gene levels reflected in the activity of RARE promoter 
region.379 
The effect of these compounds on RAR-α and RAR-γ was also studied and showed that 
retinoic acid induced over-expression of RAR-α and RAR-γ was more than EC23 and 
GZ25, and it was observed in previous research work that RAR-α and RAR-γ have a 
major role in formation of heterodimer complex with RXR. These complexes increase 
the retinoic acid metabolism by activation of CRABPII.380 This was confirmed as 
ATRA was highly susceptible to cellular metabolism more than EC23, EC19 and 
induced higher gene levels of CYP26A1 up to 12 hours and at lower concentration 
scales.  
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However, RAR- α and RAR- γ are still have biological roles for synergism with RAR-β 
for the induction of cellular differentiation and this is what was revealed from their 
higher levels after 12 hours in EC23 and GZ25 treated cultures compared to EC19 and 
other GZ analogues. 
The long term observation for the biological effect of these compounds on both 
SHSY5Y and TERA-2.cl.SP12 showed that EC23 and GZ25 at concentration of 10 µM, 
was able to induce neurite outgrowth in SHSY5Y while not at lower concentrations 
while, EC19 and other GZ analoges were not able to induce any of neurite outgrowth at 
any concentration scale. This might be explained in terms of over-expression of 
NeuroD1 gene and supported by many studies, in addition to the role of Nav2 gene 
under control of NeuroD1 to stimulate neuronal extensions.381 Also, literature showed 
that ATRA was able to induce neurite outgrowth at a concentration range of 1-10 
µM382,224 which coincided with what we observed for the optimum activity of 10 µM 
EC23 compared to 10 µM EC19, which only drives cells into clump formation in 
SHSY5Y. In TERA-2.cl.SP12, neurite outgrowth with EC23 and GZ25 was supported 
by up-regulation of TUJ-1, the neurofilament protein which is highly expressed in 
neural tissue as an indication for more committed neural phenotypes at different stages 
of neural development.383,384 While, EC19 was different in the way induction for 
cellular differentiation was observed and large numbers of lump cells stained for CK-8 
after 14 days as indication of epithelial cell fate. These results might explain why EC23 
can successfully induce stem cell and SHSY5Y differentiation resulting in neural cells 
similarly to ATRA, at lower concentration. However, since EC19 binds only RAR-β 
reasonably efficiently, or other GZ derivatives have lower RAR binding affinities this 
suggests that neurogenesis in response to EC23 might be driven more via a combination 
of all the RAR receptors. 
 
In summary, some new synthetic retinoids analogues, including EC23 and GZ25, were 
characterized in two different cell models. They have the potential biological activity to 
be more potent and more stable than ATRA to reduce any disadvantages of using 
ATRA for in vitro differentiation. The comparison was done for biological potency of 
these compounds in TERA-2.cl.SP12 stem cells and SHSY5Y neuroblastoma cells and 
it was shown that there are some common similarities in the mechanism of neuronal cell 
differentiation.  
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The main reasons for the higher biological activity of these compounds are the para-
position of the carboxylate group that makes the compounds best-fit in the RAR LBDs. 
Also, the optimum molecular length plays key role to hit the essential binding residues 
inside RAR pockets and minimize the possible ligand steric clashes. The higher binding 
affinitiy to all RARs and particulary RAR-β is essentail for successful up-regulation of 
other markers such as PAX6, NeuroD1 and TUJ-1 and hence, induction of neuronal cell 
differentiation. All these information can help in designing more compounds with more 
potent and selective biological activity towards one type of RAR for possible 
therapeutic use. Table 5.1 summarizes the key observations in binding data, biological 
characterizations and suggestions from molecular docking between natural and different 
synthetic retinoids. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter V 
 
156 
 
 
Table 5.1: The key observations in evaluation of new synthetic retinoids compared to ATRA.
Retinoid  RAR binding affinity Biological characterization features Molecular docking 
suggestions 
ATRA Binds to all RARs with 
relatively higher 
binding affinity to 
RAR-γ 
Induces higher level of RAR-α, RAR-γ and 
CYP26A1 genes in SHSY5Y cells. 
Induce neurite outgrowth and over-
expression of A2B5, TUJ-1 proteins and 
NeuroD1 gene in TERA-2 cells. 
In RAR-α and RAR-β, ATRA 
exists with s-cis conformation, 
While in RAR-γ, it exist in a 
mostly s-trans form. 
EC23 The strongest binding 
affinity to all RARs 
compared to ATRA. 
Induces the highest level of RAR-β followed 
by RAR-α, RAR-γ genes in SHSY5Y cells. 
Induce neurite outgrowth and over-
expression of A2B5, TUJ-1 proteins in 
TERA-2.cl.SP12 cells. 
Induce neurite outgrowth in SHSY5Y cells 
at 10 µM concentration. 
The para-position carboxylic 
acid fit the molecule in a 
similar way as ATRA. 
EC19 Lowest binding affinity 
to RAR-α and RAR-γ 
with relatively high 
affinity for the RAR-β. 
Induces the lowest RAR-α, RAR-β, RAR-γ, 
CYP26A1, NeuroD1, PAX6 genes in 
SHSY5Y and TERA-2 cells respectively. 
It Can not Induce neurite outgrowth in 
SHSY5Y cells. 
It induces epithelial cell differentiation in 
TERA-2 cells confirmed by high level of 
CK-8. 
The meta-position carboxylic 
acid has the effect of changing 
the geometry of the molecule 
in a similar manner to bent 
structure of 9-CRA. EC19 can 
fit in RAR-β due to extra 
space in binding pocket. 
GZ25 The strongest binding 
affinity to all RARs 
compared to ATRA 
and simillar to EC23. 
Induce the highest level of RAR-β followed 
by RAR-α, RAR-γ genes in SHSY5Y cells. 
Also, it is reliable for cellular metabolism by 
CYP26A1. 
Induce neurite outgrowth and over-
expression of TUJ-1 proteins in TERA-
2.cl.SP12 cells. 
It has similar molecule length 
as ATRA and form additional 
hydrogen bond with Ser232 in 
RAR-α to fit and fill in the 
RAR binding pocket. 
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Concluding remarks 
In this study, the use of calculated 3D structures of ligand chemical structures and their 
conformations, receptor binding assays and molecular docking tools have been 
combined to understand the biological activity of certain synthetic retinoids in 
comparison with natural systems. Two synthetic analogues, EC23 and GZ25 were 
highlighted to have higher binding affinities to all RAR types, confirmed by the 
molecular docking structures using GOLD docking software. COPASI bio-simulation 
models were useful to understand the kinetic parameters behind the ligand binding 
interactions and co-activator recruitment. These finding support the major aim of the 
designing more stable and potent synthetic retinoids to further understand the retinoic 
acid signalling pathway and in vitro differentiation.  
 
Molecular docking highlighted important interactions of these molecules, with the para-
position of carboxylate in EC23 being essential for the optimum fitting in the RAR 
LBDs. Arg and Ser residues played a crucial role for the formation of hydrophilic 
interaction networks with carboxylate moiety. The quality of the retinoid-receptor 
complex had an impact on the co-activator recruitment, and hence, the transcriptional 
process.  
 
Upon biological screening, the potency of EC23 and GZ25 was reflected in the ability 
of these compounds to induce cellular differentiation in stem cells and cancerous cells. 
TERA-2.cl.SP12 cells were useful model for prolonged investigations of synthetic 
retinoid effects on extracellular and intracellular marker expression. Additionally, gene 
expression profiles using NeuroD1 and PAX6 showed the difference in biological 
potency of these molecules. SHSY5Y neuroblastoma cells were developed as a model 
for early screening of synthetic retinoids using the RAR-β gene as a rapid and 
promising marker, which was induced by EC23 and GZ25 in away similar to ATRA 
with enhanced over-expression, as indicated in the difference in potency. When cellular 
metabolism was compared with chemical and environmental stability, it was found that 
the two factors were not necessirely correlated. This was shown in GZ25 which was 
sensitive for cellular metabolism by CYP26A1, though it was environmentally stable.  
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7.2 Future work 
 Molecular docking studies need to be continued by calculation of molecular binding 
interactions between retinoid ligands and the interacting residues inside the RAR 
LBDs. Many interaction factors, such as entropy and induction of molecular 
conformational changes induced during interactions, must be included in the docking 
calculations. This could help in using the overall fitness score for assessing the 
biological potency of retinoids in quicker and more precise way. 
 
 Accurate quantification of synthetic retinoids is required to measure level of these 
compounds both inside cells and in the media, so that their fate can be monitored. 
These compounds are lipophilic, and they are not easily measured by traditional 
protocols or to purify them purely in aqueous solution or cell extracts. Also, 
identification and quantification of the possible metabolites of these compounds is 
required, especially using the isolated microsome systems and accurate mass 
spectrometric analysis. 
 
 Raman spectroscopy analysis of live cells, such as neuroblastoma treated with these 
compounds, is required for the accurate assessment of the biological response of the 
cells to retinoids. 
 
 Further biological characterization of these synthetic retinoids, on neuroblastoma is 
required to understand the different mechanisms that control the process of cellular 
differentiation and neurite outgrowth. 
 
 Detailed in vitro and in vivo toxicity studies are needed for these synthetic retinoids 
in comparison to ATRA. This can help in the identification of one or more of 
compounds as potential drugs, for treatment of cancer. 
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